WO2022009991A1 - Method for evaluating mild cognitive impairment, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device - Google Patents

Method for evaluating mild cognitive impairment, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device Download PDF

Info

Publication number
WO2022009991A1
WO2022009991A1 PCT/JP2021/026034 JP2021026034W WO2022009991A1 WO 2022009991 A1 WO2022009991 A1 WO 2022009991A1 JP 2021026034 W JP2021026034 W JP 2021026034W WO 2022009991 A1 WO2022009991 A1 WO 2022009991A1
Authority
WO
WIPO (PCT)
Prior art keywords
lys
ser
evaluation
cit
trp
Prior art date
Application number
PCT/JP2021/026034
Other languages
French (fr)
Japanese (ja)
Inventor
健 池内
由紀 矢野
和 佐藤
Original Assignee
味の素株式会社
国立大学法人新潟大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 味の素株式会社, 国立大学法人新潟大学 filed Critical 味の素株式会社
Priority to JP2022535407A priority Critical patent/JPWO2022009991A1/ja
Priority to KR1020237000211A priority patent/KR20230037533A/en
Publication of WO2022009991A1 publication Critical patent/WO2022009991A1/en

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the present invention relates to an evaluation method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device for Mild Cognitive Impairment (hereinafter referred to as "MCI"). It is a thing.
  • MCI is a condition that is considered to be a pre-stage or borderline case of various dementias that has problems with cognitive function compared to normal age-appropriate aging but does not interfere with daily life and does not lead to a diagnosis of dementia. Point to.
  • AD Alzheimer's Disease
  • FTLD frontotemporal lobar degeneration
  • VaD vascular dementia
  • senile depression senile depression. In some cases, appropriate intervention may reduce the risk of developing dementia.
  • MMSE neuropsychological test Mini Mental State Examination
  • HDS-R Hasegawa simple intelligence evaluation scale
  • ADAS-cog Alzheimer's Disease Assessment Scale-Cognitive
  • Non-Patent Document 3 a technique for measuring the peptide fragment concentration in blood and discriminating MCI using it as an index is known. Further, AD determination and MCI determination techniques by quantitative analysis of amino acids and amino acid-related metabolites in blood are known (Patent Documents 1 and 2).
  • the present invention has been made in view of the above, and is an evaluation method, a calculation method, an evaluation device, a calculation device, an evaluation program, and a calculation that can provide highly reliable information that can be used as a reference for knowing the state of MCI. It is an object of the present invention to provide a program, a recording medium, an evaluation system and a terminal device.
  • the evaluation method according to the present invention comprises at least two amino acids out of five kinds of amino acids (Cit, Lys, Ser, Thr and Trp) in the blood to be evaluated.
  • the evaluation step includes an evaluation step of evaluating the state of MCI for the evaluation target by using the concentration value of the above or the expression including the variable to which the concentration value is substituted and the value of the expression calculated by using the concentration value. It is characterized by that.
  • the concentration value is the concentration value of at least three amino acids, and the at least three amino acids are Ser, Lys and Trp, Ser, Cit and Lys, Cit, Lys and Trp. It is characterized by including Ser, Thr and Lys, Thr, Lys and Trp, Thr, Cit and Lys, Ser, Thr and Cit, Ser, Thr and Trp, Thr, Cit and Trp, or Ser, Cit and Trp. do.
  • the concentration value is the concentration value of at least 6 amino acids, and the at least 6 amino acids are Ser, Thr, Ala, Cit, Lys and Trp, Ser, Thr, Cit. Met, Lys and Trp, Ser, Gln, Cit, Val, Met and Lys, Ser, Gln, Cit, Met, Lys and Leu, Ser, Thr, Cit, Tyr, Lys and Trp, Ser, Cit, Tyr, Met, It comprises Lys and Trp, or Ser, Thr, Cit, Orn, Lys and Trp.
  • the evaluation method according to the present invention is characterized in that the evaluation step is executed in the control unit of the information processing apparatus provided with the control unit.
  • the calculation method evaluates the concentration value of at least two amino acids among the five kinds of amino acids in the blood to be evaluated, and the state of MCI including the variable to which the concentration value is substituted. It is characterized by including a calculation step for calculating the value of the above formula using the formula for.
  • the calculation method according to the present invention is characterized in that the calculation step is executed in the control unit of the information processing apparatus provided with the control unit.
  • the evaluation device is an evaluation device including a control unit, wherein the control unit has a concentration value of at least two amino acids among the five types of amino acids in the blood to be evaluated, or the above-mentioned. It is characterized in that an evaluation means for evaluating the state of MCI is provided for the evaluation target by using an expression including a variable to which the concentration value is assigned and the value of the expression calculated by using the concentration value.
  • the evaluation device is communicably connected to the terminal device that provides the concentration value or the value of the above formula via a network, and the control unit controls the concentration value transmitted from the terminal device.
  • the data receiving means for receiving the value of the above formula and the result transmitting means for transmitting the evaluation result obtained by the evaluation means to the terminal device are further provided, and the evaluation means receives the data with the data receiving means. It is characterized by using the above-mentioned concentration value or the above-mentioned value of the above formula.
  • the calculation device is a calculation device including a control unit, wherein the control unit has a concentration value of at least two amino acids among the five types of amino acids in the blood to be evaluated, and the said. It is characterized by comprising a calculation means for calculating the value of the equation by using an equation for evaluating the state of MCI including a variable to which the concentration value is assigned.
  • the evaluation program according to the present invention is an evaluation program for execution in an information processing apparatus provided with a control unit, and is among the five types of amino acids in the blood to be evaluated for execution in the control unit.
  • the state of MCI is evaluated for the evaluation target using the concentration value of at least two amino acids of the above, or the expression including the variable to which the concentration value is substituted and the value of the equation calculated using the concentration value. It is characterized by including an evaluation step to be performed.
  • the calculation program according to the present invention is a calculation program to be executed in an information processing apparatus provided with a control unit, and is among the five types of amino acids in the blood to be evaluated to be executed by the control unit. It is characterized by including a calculation step of calculating the value of the formula using a formula for evaluating the concentration value of at least two amino acids of the above and the state of MCI including the variable to which the concentration value is assigned. do.
  • the recording medium according to the present invention is a computer-readable recording medium on which the evaluation program or the calculation program is recorded.
  • the recording medium according to the present invention is a non-temporary computer-readable recording medium, and includes a programmed instruction for causing an information processing apparatus to execute the evaluation method or the calculation method. , Is characterized by.
  • the evaluation system is an evaluation system configured by connecting an evaluation device including a control unit and a terminal device including a control unit so as to be communicable via a network, and is an evaluation system of the terminal device.
  • the control unit was calculated using the concentration value of at least two amino acids out of the five types of amino acids in the blood to be evaluated, or an expression including a variable to which the concentration value is substituted and the concentration value.
  • the evaluation device includes a data transmission means for transmitting the value of the above formula to the evaluation device, and a result receiving means for receiving the evaluation result regarding the state of MCI for the evaluation target transmitted from the evaluation device.
  • the control unit uses the data receiving means for receiving the concentration value or the value of the formula transmitted from the terminal device, and the concentration value or the value of the formula received by the data receiving means.
  • the evaluation target is provided with an evaluation means for evaluating the state of MCI and a result transmission means for transmitting the evaluation result obtained by the evaluation means to the terminal device.
  • the terminal device is a terminal device including a control unit, wherein the control unit includes a result acquisition means for acquiring an evaluation result regarding the state of MCI with respect to the evaluation target, and the evaluation result is.
  • the terminal device is communicably connected to an evaluation device that evaluates the state of MCI for the evaluation target via a network, and the control unit obtains the concentration value or the value of the formula.
  • the data transmission means for transmitting to the evaluation device is provided, and the result acquisition means receives the evaluation result transmitted from the evaluation device.
  • FIG. 1 is a principle configuration diagram showing the basic principle of the first embodiment.
  • FIG. 2 is a principle configuration diagram showing the basic principle of the second embodiment.
  • FIG. 3 is a diagram showing an example of the overall configuration of this system.
  • FIG. 4 is a diagram showing another example of the overall configuration of this system.
  • FIG. 5 is a block diagram showing an example of the configuration of the evaluation device 100 of this system.
  • FIG. 6 is a diagram showing an example of information stored in the blood data file 106a.
  • FIG. 7 is a diagram showing an example of information stored in the index state information file 106b.
  • FIG. 8 is a diagram showing an example of information stored in the designated index state information file 106c.
  • FIG. 9 is a diagram showing an example of information stored in the formula file 106d1.
  • FIG. 1 is a principle configuration diagram showing the basic principle of the first embodiment.
  • FIG. 2 is a principle configuration diagram showing the basic principle of the second embodiment.
  • FIG. 3 is a diagram showing an example of
  • FIG. 10 is a diagram showing an example of information stored in the evaluation result file 106e.
  • FIG. 11 is a block diagram showing the configuration of the evaluation unit 102d.
  • FIG. 12 is a block diagram showing an example of the configuration of the client device 200 of this system.
  • FIG. 13 is a block diagram showing an example of the configuration of the database device 400 of this system.
  • an embodiment (first embodiment) of the evaluation method and the calculation method according to the present invention and an evaluation device, a calculation device, an evaluation method, a calculation method, an evaluation program, a calculation program, a recording medium, an evaluation system, and the like according to the present invention.
  • An embodiment (second embodiment) of the terminal device will be described in detail with reference to the drawings. The present invention is not limited to these embodiments.
  • FIG. 1 is a principle configuration diagram showing the basic principle of the first embodiment.
  • blood data regarding the concentration values of at least two of the five amino acids in blood is obtained.
  • the blood data may be related to, for example, the concentration value of at least three amino acids in the blood collected from the evaluation target, and the at least three amino acids are, for example, "Ser, Lys and Trp”, “Ser, Cit”. And Lys ”,“ Cit, Lys and Trp ”,“ Ser, Thr and Lys ”,“ Thr, Lys and Trp ”,“ Thr, Cit and Lys ”,“ Ser, Thr and Cit and Lys ”,“ Ser, Thr and Cit ”,“ Ser, Thr and Trp ”.
  • the blood data may be related to, for example, the concentration value of at least 6 amino acids in the blood collected from the evaluation target, and the at least 6 amino acids are, for example, "Ser, Thr, Ala, Cit, Lys and Trp".
  • step S11 blood data measured by a company or the like that measures the concentration value may be acquired. Further, blood data may be acquired from the blood collected from the evaluation target by measuring the concentration value by, for example, the following measuring methods such as (A), (B), or (C).
  • the unit of the concentration value may be, for example, a molar concentration, a weight concentration, or an enzyme activity, or may be obtained by adding, subtracting, multiplying, or dividing an arbitrary constant to these concentrations.
  • A Plasma is separated from blood by centrifuging the collected blood sample. All plasma samples are cryopreserved at -80 ° C until the concentration value is measured.
  • acetonitrile is added to perform derivatization treatment, and if necessary, impurities such as phospholipids are removed by solid layer extraction, etc., and the labeling reagent (3-aminopyridyl-N-hydroxysuccinimi) is removed.
  • Pre-column derivatization is performed using zircarbamate), and concentration values are analyzed by liquid chromatography-mass spectrometry (including tandem mass spectrometry) (International Publication No. 2003/06628, International Publication No. 2005/116629). See).
  • (B) Plasma is separated from blood by centrifuging the collected blood sample. All plasma samples are cryopreserved at -80 ° C until the concentration value is measured.
  • sulfosalicylic acid is added to perform deproteinization treatment, and then the concentration value is analyzed by an amino acid analyzer based on the post-column derivatization method using a ninhydrin reagent.
  • C The collected blood sample is subjected to blood cell separation using a membrane, MEMS (Micro Electro Mechanical Systems) technology or the principle of centrifugation, and plasma or serum is separated from the blood. Plasma or serum samples that are not measured immediately after acquisition of plasma or serum are cryopreserved at -80 ° C until the time of concentration measurement.
  • a molecule that reacts with or binds to a target blood substance such as an enzyme or an aptamer is used, and the concentration value is analyzed by quantifying the substance that increases or decreases due to substrate recognition or the spectroscopic value.
  • step S12 the state of MCI is evaluated for the evaluation target using the concentration value contained in the blood data acquired in step S11 (step S12).
  • step S12 data such as missing values and outliers may be removed from the blood data acquired in step S11.
  • to evaluate the state of MCI is, for example, to inspect the current state of MCI.
  • step S11 the blood data to be evaluated is acquired, and in step S12, the concentration value included in the blood data to be evaluated acquired in step S11 is used for the evaluation target.
  • Evaluate the state of MCI in short, obtain information for evaluating the state of MCI for the evaluation target or highly reliable information that can be used as a reference for knowing the state of MCI for the evaluation target). Thereby, it is possible to provide information for evaluating the state of MCI for the evaluation target or highly reliable information that can be used as a reference for knowing the state of MCI for the evaluation target.
  • the concentration values of at least two amino acids among the five kinds of amino acids reflect the state of MCI for the evaluation target, and further, the concentration values may be determined by the methods listed below, for example. It may be determined that the converted value reflects the state of MCI with respect to the evaluation target. In other words, the concentration value or the converted value itself may be treated as an evaluation result regarding the state of MCI with respect to the evaluation target.
  • the possible range of concentration values is a predetermined range (for example, 0.0 to 1.0, 0.0 to 10.0, 0.0 to 100.0, or -10.0).
  • any value can be added, subtracted, multiplied, or divided with respect to the cardinality value, or the cardinality value can be converted into a predetermined conversion method (for example, exponential conversion, logarithmic conversion, etc.). Convert the cardinality value by converting it by (angle conversion, square root conversion, probit conversion, inverse number conversion, Box-Cox conversion, or power conversion), or by combining these calculations with the cardinality value. You may.
  • the value of an exponential function whose index is the concentration value and whose base is the number of napiers (specifically, a state in which the state of MCI exceeds a predetermined state (for example, a state in which the state exceeds the reference value and is likely to be affected by MCI).
  • Etc. may be further calculated (the value of p / (1-p)) when the natural logarithm ln (p / (1-p)) when the probability p is defined is equal to the concentration value.
  • a value obtained by dividing the calculated value of the exponential function by the sum of 1 and the value (specifically, the value of the probability p) may be further calculated.
  • the concentration value may be converted so that the converted value under a specific condition becomes a specific value.
  • the concentration value may be converted so that the converted value when the specificity is 60% is 5.0 and the converted value when the specificity is 90% is 8.0.
  • the deviation value may be converted so that the average is 50 and the standard deviation is 10. In addition, these conversions may be performed by gender or age.
  • the concentration value in the present specification may be the concentration value itself or the value after converting the concentration value.
  • the position information regarding the position of the predetermined mark on the predetermined indicator visually shown on the display device such as a monitor or the physical medium such as paper is the concentration value of at least two amino acids among the five kinds of amino acids or the concentration value of the amino acid.
  • concentration value When the concentration value is converted, it may be generated using the converted value, and it may be determined that the generated position information reflects the state of MCI for the evaluation target.
  • the predetermined ruler is for evaluating the state of MCI, and is, for example, a ruler with a scale, which is "a range in which a concentration value or a converted value can be taken, or a range thereof. At least the scales corresponding to the upper and lower limits in "part" are shown.
  • the predetermined mark corresponds to the concentration value or the converted value, and is, for example, a circle mark or a star mark.
  • the concentration value of at least two amino acids among the five kinds of amino acids is a predetermined value (mean value ⁇ 1SD, 2SD, 3SD, N quantile, N percentile, cutoff value having clinical significance, etc. ) May be lower or less than a predetermined value, or more than a predetermined value or higher than a predetermined value, the state of MCI may be evaluated for the evaluation target.
  • a concentration deviation value (a value obtained by normalizing the concentration distribution for each amino acid for each gender and then converting the concentration distribution into an average of 50 and a standard deviation of 10) may be used. ..
  • the evaluation target is the MCI.
  • the condition may be evaluated.
  • the state of MCI for the evaluation target May be evaluated.
  • the calculated value of the formula reflects the state of MCI for the evaluation target, and further, the value of the formula is converted by, for example, the method described below, and the converted value is obtained. It may be determined that it reflects the state of MCI for the evaluation target. In other words, the value of the expression or the converted value itself may be treated as an evaluation result regarding the state of MCI with respect to the evaluation target.
  • the possible range of values in the equation is a predetermined range (eg 0.0 to 1.0, 0.0 to 10.0, 0.0 to 100.0, or -10.0).
  • the value of an exponential function whose exponent is the value of the formula and whose base is the number of Napiers (specifically, it is highly possible that the state of MCI exceeds a predetermined state (for example, the reference value is exceeded, and the patient is suffering from MCI).
  • the value of p / (1-p) when the natural logarithmic value ln (p / (1-p)) when the probability p is defined is equal to the value of the equation) is further calculated.
  • the value obtained by dividing the calculated value of the exponential function by the sum of 1 and the value (specifically, the value of the probability p) may be further calculated.
  • the value of the expression may be converted so that the converted value under a specific condition becomes a specific value.
  • the value of the expression may be converted so that the converted value when the specificity is 60% is 5.0 and the converted value when the specificity is 90% is 8.0. Further, the deviation value may be set so that the average is 50 and the standard deviation is 10. In addition, these conversions may be performed by gender or age.
  • the value of the expression in the present specification may be the value of the expression itself or may be the value after converting the value of the expression.
  • the position information regarding the position of the predetermined mark on the predetermined ruler visually shown on the display device such as a monitor or the physical medium such as paper is converted into the value of the formula or the value of the formula when converted. It may be generated using the later values, and it may be determined that the generated position information reflects the state of MCI for the evaluation target.
  • the predetermined ruler is for evaluating the state of MCI, for example, a ruler with a scale, which is "a range in which the value of the formula or the value after conversion can be taken, or the range thereof.” At least the scales corresponding to the upper and lower limits in "a part of" are shown.
  • the predetermined mark corresponds to the value of the expression or the value after conversion, and is, for example, a circle mark or a star mark.
  • the degree of possibility that the evaluation target has MCI may be qualitatively evaluated. Specifically, "concentration value of at least two amino acids of the five kinds of amino acids and one or more preset threshold values” or “concentration value of at least two amino acids of the five kinds of amino acids”.
  • the evaluation target is defined with at least the degree of likelihood of suffering from MCI, using an expression containing variables to which the concentration value is assigned, as well as one or more preset thresholds. It may be classified into any one of a plurality of categories. In addition, it is possible that a plurality of categories are affected by MCI, which is a category for assigning a subject having a high possibility of suffering from MCI (for example, a subject considered to be suffering from MCI).
  • the multiple categories include a category for belonging a subject having a high possibility of having MCI and a category for belonging a subject having a low possibility of having MCI (a category for belonging to a subject having a low possibility of having MCI).
  • it may include a category for assigning an object that is likely to be healthy (for example, an object that is considered to be healthy).
  • the concentration value or the value of the formula may be converted by a predetermined method, and the evaluation target may be classified into any one of a plurality of categories using the converted value.
  • the format of the formula used for evaluation is not particularly limited, but may be, for example, the formula shown below.
  • Linear models such as multiple regression equations, linear discrimination equations, principal component analysis, canonical discrimination analysis based on the least squares method
  • Generalized linear models such as logistic regression and Cox regression based on the most probable method
  • Generalized linear mixed model considering variable effects such as individual differences and facility differences-Formulas created by cluster analysis such as K-means method and hierarchical cluster analysis-MCMC (Markov chain Monte Carlo method), Bayesian network, Formulas created based on Bayesian statistics such as the hierarchical Bayesian method, formulas created by class classification such as support vector machines and decision trees, formulas created by methods that do not belong to the above categories such as fractional formulas, and sums of formulas of different formats. Expression as shown by
  • the formula used for evaluation is described in, for example, the method described in International Publication No. 2004/052191, which is an international application by the applicant, or International Publication No. 2006/098192, which is an international application by the applicant. You may create it by the method.
  • the formulas obtained by these methods can be suitably used for evaluating the state of MCI regardless of the unit of the amino acid concentration value in the blood data as input data.
  • the coefficient and the constant term may be preferably a real number, and more preferably.
  • the coefficient and the constant term may be preferably a real number, and more preferably.
  • Any value that belongs to the range of the 95% confidence interval of the given coefficient and constant term may be used.
  • each coefficient and its confidence interval may be multiplied by a real number
  • the value of the constant term and its confidence interval may be obtained by adding, subtracting, multiplying or dividing an arbitrary real constant.
  • the numerator of the fractional expression is represented by the sum of variables A, B, C, ... And / or the denominator of the fractional expression is the sum of variables a, b, c, ... It is represented by.
  • the fractional expression also includes the sum of the fractional expressions ⁇ , ⁇ , ⁇ , ... (For example, ⁇ + ⁇ ) having such a configuration.
  • the fractional expression also includes a divided fractional expression.
  • the variables used for the numerator and denominator may have appropriate coefficients. Also, the variables used for the numerator and denominator may be duplicated. Further, an appropriate coefficient may be attached to each minute formula. Further, the coefficient value of each variable and the value of the constant term may be real numbers.
  • fractional expression and the one in which the variable of the molecule and the variable of the denominator are exchanged in the fractional expression generally reverse the positive and negative signs of the correlation with the objective variable, but the correlation between them is maintained. Since the evaluation performance can be regarded as equivalent, the fractional expression includes the variable of the molecule and the variable of the denominator interchanged.
  • values related to other biological information may be further used. No. Further, in the formula used at the time of evaluation, in addition to the variable to which the concentration value of at least two amino acids of the above five kinds of amino acids is substituted, the value related to other biological information (for example, the value listed below). May further include one or more variables to which is assigned. 1. 1. Concentration values of blood metabolites (amino acid-related metabolites, sugars, lipids, etc.), proteins, peptides, minerals, hormones, etc. other than amino acids 2.
  • Total protein triglyceride (neutral fat), HbA1c, glycated albumin, insulin resistance index, total cholesterol, LDL cholesterol, HDL cholesterol, amylases, total bilirubin, creatinine, estimated glomerular filtration rate (eGFR), uric acid, GOT (AST) ), GPT (ALT), GGTP ( ⁇ -GTP), glucose (blood glucose level), CRP (C-reactive protein), MCV, MCH, MCHC and other blood test values. 3. Values obtained from image information such as ultrasonic echo, X-ray, CT, MRI, and endoscopic image.
  • image information such as ultrasonic echo, X-ray, CT, MRI, and endoscopic image.
  • biomarkers 5 Values obtained from genetic information such as the number of possession of risk genes for Alzheimer's disease (APOE ⁇ 4 allele, etc.)
  • FIG. 2 is a principle configuration diagram showing the basic principle of the second embodiment.
  • the description overlapping with the above-mentioned first embodiment may be omitted.
  • a case where the value of the formula or the value after conversion thereof is used when evaluating the state of MCI is described as an example, but for example, at least two amino acids among the above five kinds of amino acids are described.
  • a concentration value or a value after conversion thereof (for example, a concentration deviation value) may be used.
  • the control unit has the concentration value included in the blood data of the evaluation target (for example, an individual such as an animal or a human) acquired in advance regarding the concentration value of at least two amino acids among the five kinds of amino acids, and the concentration.
  • the state of MCI is evaluated for the evaluation target by calculating the value of the formula using the formula stored in the storage unit in advance including the variable to which the value is assigned (step S21). This makes it possible to provide highly reliable information that can be used as a reference for knowing the state of MCI.
  • step S21 may be one created based on the formula creation process (steps 1 to 4) described below.
  • steps 1 to 4 an outline of the expression creation process will be described.
  • the process described here is just an example, and the method of creating an expression is not limited to this.
  • a plurality of different formula creation methods are performed from the index state information.
  • Multiple candidate formulas may be created in combination with those related to multivariate analysis such as trees.
  • index state information which is multivariate data composed of blood data and index data obtained by analyzing blood obtained from a large number of healthy groups and MCI groups. You may create multiple groups of candidate expressions in parallel.
  • discriminant analysis and logistic regression analysis may be performed simultaneously using different algorithms to create two different candidate expressions.
  • the candidate formula may be created by converting the index state information using the candidate formula created by performing the principal component analysis and performing the discriminant analysis on the converted index state information. As a result, the optimum formula for evaluation can be finally created.
  • the candidate formula created using the principal component analysis is a linear formula including each variable that maximizes the variance of all blood data.
  • the candidate formula created using discriminant analysis is a high-order formula (including exponent and logarithm) containing each variable that minimizes the ratio of the sum of the variances within each group to the variance of all blood data. be.
  • the candidate expression created using the support vector machine is a high-order expression (including the kernel function) including each variable that maximizes the boundary between the groups.
  • the candidate formula created by using the multiple regression analysis is a high-order formula including each variable that minimizes the sum of the distances from all the blood data.
  • the candidate expression created by using Cox regression analysis is a linear model including a logarithmic hazard ratio, and is a linear expression including each variable and its coefficient that maximizes the likelihood of the model.
  • the candidate expression created by using logistic regression analysis is a linear model representing the logarithmic odds of the probability, and is a linear expression including each variable that maximizes the likelihood of the probability.
  • k-means method k neighborhoods of each blood data are searched, the group to which the nearest points belong is defined as the group to which the data belongs, and the group to which the input blood data belongs. It is a method to select the variable that best matches the group defined as.
  • cluster analysis is a method of clustering (grouping) points that are closest to each other in all blood data.
  • the decision tree is a method of ordering variables and predicting a group of blood data from possible patterns of variables whose rank is higher.
  • the control unit verifies (mutually verifies) the candidate formula created in step 1 based on a predetermined verification method (step 2).
  • the verification of the candidate formula is performed for each candidate formula created in step 1.
  • the discrimination rate, sensitivity, specificity, information criterion, ROC_AUC (ROC_AUC) of the candidate formula are based on at least one of the bootstrap method, the holdout method, the N-fold method, the leave one-out method, and the like. It may be verified with respect to at least one of (the area under the curve of the receiver characteristic curve) and the like. This makes it possible to create a candidate formula with high predictability or robustness in consideration of index state information and evaluation conditions.
  • the discrimination rate is an evaluation method according to the present embodiment, in which an evaluation target whose true state is negative (for example, an evaluation target not suffering from MCI) is correctly evaluated as negative, and the true state is determined. It is the ratio that a positive evaluation target (for example, an evaluation target suffering from MCI) is correctly evaluated as positive. Further, the sensitivity is the ratio at which the evaluation target whose true state is positive is correctly evaluated as positive in the evaluation method according to the present embodiment. Further, the specificity is the ratio in which the evaluation target whose true state is negative is correctly evaluated as negative in the evaluation method according to the present embodiment.
  • the Akaike Information Criterion is a standard that indicates how well the observed data matches the statistical model in the case of regression analysis, etc., and is "-2 x (maximum log-likelihood of the statistical model) + 2 x (statistics).
  • the model with the smallest value defined in "Number of free parameters of the model)" is judged to be the best.
  • the value of is 1 in the complete discrimination, and the closer this value is to 1, the higher the discrimination.
  • the predictability is an average of the discrimination rate, sensitivity, and specificity obtained by repeating the verification of the candidate formula.
  • Robustness is a variance of discrimination rate, sensitivity, and specificity obtained by repeating the verification of candidate expressions.
  • the control unit selects the combination of blood data included in the index state information used when creating the candidate expression by selecting the variable of the candidate expression based on the predetermined variable selection method.
  • the variable may be selected for each candidate formula created in step 1. This makes it possible to appropriately select the variables of the candidate expression.
  • step 1 is executed again using the index state information including the blood data selected in step 3.
  • a variable of the candidate expression may be selected based on at least one of the stepwise method, the best path method, the neighborhood search method, and the genetic algorithm from the verification result in step 2.
  • the best path method is a method of selecting variables by sequentially reducing the variables included in the candidate expression one by one and optimizing the evaluation index given by the candidate expression.
  • the control unit repeatedly executes the above-mentioned steps 1, 2 and 3 and, based on the verification results accumulated by this, is a candidate to be used for evaluation from among a plurality of candidate formulas.
  • the formula used for the evaluation is created (step 4).
  • the candidate formula for example, there are a case where the optimum one is selected from the candidate formulas created by the same formula creation method and a case where the optimum one is selected from all the candidate formulas.
  • the process related to the creation of the candidate expression, the verification of the candidate expression, and the selection of the variable of the candidate expression is systematized (systematized) in a series of flows based on the index state information.
  • the optimum formula for evaluating MCI can be created.
  • 19 kinds of amino acids Al, Arg, Asn, Cit, Gln, Gly, His, Ile, Leu, Lys, Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val
  • At least one of the concentration values is used for multivariate statistical analysis, and variable selection methods and cross-validation are combined to select the optimal and robust set of variables to extract highly evaluated equations. ..
  • FIG. 3 is a diagram showing an example of the overall configuration of this system.
  • FIG. 4 is a diagram showing another example of the overall configuration of this system.
  • this system has an evaluation device 100 for evaluating the state of MCI for an individual to be evaluated, and the blood of an individual having a concentration value of at least two of the five kinds of amino acids in the blood. It is configured by connecting a client device 200 (corresponding to the terminal device of the present invention) that provides data so as to be communicable via a network 300.
  • the client device 200 that is the source of the data used for the evaluation and the client device 200 that is the destination of the evaluation result may be different.
  • this system is a database device that stores index state information used when creating an expression in the evaluation device 100, an expression used in the evaluation, and the like, in addition to the evaluation device 100 and the client device 200.
  • the 400 may be connected and configured so as to be communicable via the network 300.
  • information that can be used as a reference for knowing the state of MCI is provided from the evaluation device 100 to the client device 200 or the database device 400, or from the client device 200 or the database device 400 to the evaluation device 100 via the network 300. Will be done.
  • the information that can be used as a reference for knowing the state of MCI is, for example, information about values measured for a specific item regarding the state of MCI of an organism including humans.
  • information that can be used as a reference for knowing the state of the MCI is generated by the evaluation device 100, the client device 200, and other devices (for example, various measuring devices), and is mainly stored in the database device 400.
  • FIG. 5 is a block diagram showing an example of the configuration of the evaluation device 100 of the present system, and conceptually shows only the portion of the configuration related to the present invention.
  • the evaluation device 100 controls the evaluation device via a control unit 102 such as a CPU (Central Processing Unit) that collectively controls the evaluation device, a communication device such as a router, and a wired or wireless communication line such as a dedicated line. It is composed of a communication interface unit 104 that is communicably connected to the network 300, a storage unit 106 that stores various databases, tables, files, and the like, and an input / output interface unit 108 that is connected to the input device 112 and the output device 114. These parts are connected so as to be communicable via an arbitrary communication path.
  • the evaluation device 100 may be configured in the same housing as various analyzers (for example, amino acid analyzers and the like).
  • the small-sized analyzer may further include an evaluation unit 102d, which will be described later, and output the results obtained by the evaluation unit 102d using the above configuration.
  • the communication interface unit 104 mediates communication between the evaluation device 100 and the network 300 (or a communication device such as a router). That is, the communication interface unit 104 has a function of communicating data with another terminal via a communication line.
  • the input / output interface unit 108 is connected to the input device 112 and the output device 114.
  • the output device 114 a speaker or a printer can be used in addition to a monitor (including a home television) (in the following, the output device 114 may be described as a monitor 114).
  • the input device 112 can use a monitor that realizes a pointing device function in cooperation with the mouse.
  • the storage unit 106 is a storage means, and for example, a memory device such as a RAM (Random Access Memory) / ROM (Read Only Memory), a fixed disk device such as a hard disk, a flexible disk, an optical disk, or the like can be used.
  • a computer program for giving instructions to the CPU and performing various processes in cooperation with the OS (Operating System) is recorded in the storage unit 106.
  • the storage unit 106 stores a blood data file 106a, an index state information file 106b, a designated index state information file 106c, an expression-related information database 106d, and an evaluation result file 106e.
  • the blood data file 106a stores blood data relating to the concentration values of at least two of the five types of amino acids in the blood.
  • FIG. 6 is a diagram showing an example of information stored in the blood data file 106a.
  • the information stored in the blood data file 106a is configured by correlating the individual number for uniquely identifying the individual (sample) to be evaluated and the blood data.
  • the blood data is treated as a numerical value, that is, a continuous scale, but the blood data may be a nominal scale or an ordinal scale. In the case of a nominal scale or an ordinal scale, analysis may be performed by giving an arbitrary numerical value to each state. Further, the blood data may be combined with values related to other biological information (see above).
  • the index state information file 106b stores the index state information used when creating the expression.
  • FIG. 7 is a diagram showing an example of information stored in the index state information file 106b.
  • the information stored in the index state information file 106b includes an individual number, index data (T) relating to an index (index T1, index T2, index T3 ...) Representing the state of MCI, and index data (T). It is configured to correlate blood data with each other.
  • the index data and the blood data are treated as numerical values (that is, continuous scales), but the index data and the blood data may be a nominal scale or an ordinal scale. In the case of a nominal scale or an ordinal scale, analysis may be performed by giving an arbitrary numerical value to each state.
  • the index data is a known index or the like that serves as a marker of the state of MCI, and numerical data may be used.
  • the designated index status information file 106c stores the index status information designated by the designated unit 102b, which will be described later.
  • FIG. 8 is a diagram showing an example of information stored in the designated index state information file 106c. As shown in FIG. 8, the information stored in the designated index state information file 106c is configured by correlating the individual number, the designated index data, and the designated blood data with each other.
  • the formula-related information database 106d is composed of a formula file 106d1 that stores the formula created by the formula creation unit 102c described later.
  • the expression file 106d1 stores the expression used at the time of evaluation.
  • FIG. 9 is a diagram showing an example of information stored in the formula file 106d1.
  • the information stored in the expression file 106d1 includes a rank, an expression (in FIG. 9, Fp (Cit, %), Fp (Cit, Lys, Ser), Fk (Cit, Lys,). (Ser, ...), Etc.), the threshold value corresponding to each formula creation method, and the verification result of each formula (for example, the value of each formula) are configured in association with each other.
  • FIG. 10 is a diagram showing an example of information stored in the evaluation result file 106e.
  • the information stored in the evaluation result file 106e includes an individual number for uniquely identifying an individual (sample) to be evaluated, blood data of an individual acquired in advance, and an evaluation result regarding the state of MCI (for example, which will be described later).
  • the value of the formula calculated by the calculation unit 102d1 the value after converting the value of the formula by the conversion unit 102d2 described later, the position information generated by the generation unit 102d3 described later, or the classification result obtained by the classification unit 102d4 described later. , Etc.) and are configured in association with each other.
  • control unit 102 has an internal memory for storing a control program such as an OS, a program defining various processing procedures, required data, and the like, and various information processing is performed based on these programs. To execute. As shown in the figure, the control unit 102 is roughly divided into an acquisition unit 102a, a designation unit 102b, an expression creation unit 102c, an evaluation unit 102d, a result output unit 102e, and a transmission unit 102f. The control unit 102 removes data having missing values, removes data having many outliers, and data having missing values with respect to the index state information transmitted from the database device 400 and the blood data transmitted from the client device 200. It also performs data processing such as removal of variables with many.
  • a control program such as an OS, a program defining various processing procedures, required data, and the like, and various information processing is performed based on these programs.
  • the control unit 102 is roughly divided into an acquisition unit 102a, a designation unit 102b, an expression creation unit 102c, an evaluation unit
  • the acquisition unit 102a acquires information (specifically, blood data, index status information, formula, etc.). For example, the acquisition unit 102a acquires information by receiving information (specifically, blood data, index state information, formula, etc.) transmitted from the client device 200 or the database device 400 via the network 300. May be done. The acquisition unit 102a may receive data used for evaluation transmitted from a client device 200 different from the client device 200 to which the evaluation result is transmitted. Further, for example, when the evaluation device 100 includes a mechanism (including hardware and software) for reading out the information recorded on the recording medium, the acquisition unit 102a may use the information recorded on the recording medium (specifically, the information on the recording medium). Specifically, information may be acquired by reading out blood data, index state information, formulas, etc.) via the mechanism. The designation unit 102b designates index data and blood data to be targeted in creating the formula.
  • information specifically, blood data, index state information, formula, etc.
  • the formula creation unit 102c creates a formula based on the index status information acquired by the acquisition unit 102a and the index status information designated by the designation unit 102b.
  • the expression creating unit 102c may create the expression by selecting a desired expression from the storage unit 106. Further, the formula creation unit 102c may create a formula by selecting and downloading a desired formula from another computer device (for example, a database device 400) in which the formula is stored in advance.
  • the evaluation unit 102d is included in the formula obtained in advance (for example, the formula created by the formula creation unit 102c or the formula acquired by the acquisition unit 102a) and the blood data of the individual acquired by the acquisition unit 102a.
  • the state of MCI is evaluated for an individual by calculating the value of the equation using at least one of the above values.
  • the evaluation unit 102d evaluates the state of MCI for an individual using the concentration value of at least two amino acids among the five kinds of amino acids or the value after conversion of the concentration value (for example, the concentration deviation value). May be good.
  • FIG. 11 is a block diagram showing the configuration of the evaluation unit 102d, and conceptually shows only the portion of the configuration related to the present invention.
  • the evaluation unit 102d further includes a calculation unit 102d1, a conversion unit 102d2, a generation unit 102d3, and a classification unit 102d4.
  • the calculation unit 102d1 calculates the value of the formula by using the concentration value of at least two amino acids among the five kinds of amino acids and the formula including at least the variable to which the concentration value is assigned.
  • the evaluation unit 102d may store the value of the formula calculated by the calculation unit 102d1 as an evaluation result in a predetermined storage area of the evaluation result file 106e.
  • the conversion unit 102d2 converts the value of the formula calculated by the calculation unit 102d1 by, for example, the above-mentioned conversion method.
  • the evaluation unit 102d may store the value converted by the conversion unit 102d2 as an evaluation result in a predetermined storage area of the evaluation result file 106e. Further, the conversion unit 102d2 may convert the concentration value contained in the blood data by, for example, the above-mentioned conversion method.
  • the generation unit 102d3 uses the value of the formula calculated by the calculation unit 102d1 or the conversion unit 102d2 to obtain position information regarding the position of a predetermined mark on a predetermined ruler visually shown on a display device such as a monitor or a physical medium such as paper. It is generated using the value after conversion in (the concentration value or the value after conversion of the concentration value may be used).
  • the evaluation unit 102d may store the position information generated by the generation unit 102d3 as an evaluation result in a predetermined storage area of the evaluation result file 106e.
  • the classification unit 102d4 infects an individual with MCI using the value of the formula calculated by the calculation unit 102d1 or the value after conversion by the conversion unit 102d2 (may be a concentration value or a value after conversion of the concentration value). Classify into one of a plurality of categories defined with at least the degree of possibility of being present.
  • the result output unit 102e outputs the processing results (including the evaluation results obtained by the evaluation unit 102d) in each processing unit of the control unit 102 to the output device 114.
  • the transmission unit 102f transmits the evaluation result to the client device 200 that is the source of the blood data of the individual, and transmits the formula and the evaluation result created by the evaluation device 100 to the database device 400.
  • the transmission unit 102f may transmit the evaluation result to the client device 200 different from the client device 200 from which the data used for the evaluation is transmitted.
  • FIG. 12 is a block diagram showing an example of the configuration of the client device 200 of the present system, and conceptually shows only the portion of the configuration related to the present invention.
  • the client device 200 is composed of a control unit 210, a ROM 220, an HD (Hard Disk) 230, a RAM 240, an input device 250, an output device 260, an input / output IF 270, and a communication IF 280, and each of these units is via an arbitrary communication path. Is connected so that communication is possible.
  • the client device 200 is an information processing device (for example, a known personal computer, a workstation, a home-use game device, an Internet TV, a PDS (Personal Handyphone System)) to which peripheral devices such as a printer, a monitor, and an image scanner are connected as needed. It may be based on a terminal, a mobile terminal, a mobile communication terminal, an information processing terminal such as a PDA (Personal Digital Assistant), or the like).
  • PDA Personal Digital Assistant
  • the input device 250 is a keyboard, mouse, microphone, or the like.
  • the monitor 261 described later also realizes the pointing device function in cooperation with the mouse.
  • the output device 260 is an output means for outputting information received via the communication IF 280, and includes a monitor (including a home television) 261 and a printer 262. In addition, a speaker or the like may be provided in the output device 260.
  • the input / output IF 270 is connected to the input device 250 and the output device 260.
  • the communication IF280 connects the client device 200 and the network 300 (or a communication device such as a router) so as to be communicable.
  • the client device 200 is connected to the network 300 via a communication device such as a modem, a TA (Terminal Adapter), a router, and a telephone line, or via a dedicated line.
  • a communication device such as a modem, a TA (Terminal Adapter), a router, and a telephone line, or via a dedicated line.
  • the client device 200 can access the evaluation device 100 according to a predetermined communication standard.
  • the control unit 210 includes a reception unit 211 and a transmission unit 212.
  • the receiving unit 211 receives various information such as the evaluation result transmitted from the evaluation device 100 via the communication IF 280.
  • the transmission unit 212 transmits various information such as blood data of an individual to the evaluation device 100 via the communication IF 280.
  • the control unit 210 may be realized by a CPU and a program that interprets and executes all or any part of the processing performed by the control unit by the CPU and the CPU.
  • a computer program for giving instructions to the CPU in cooperation with the OS and performing various processes is recorded in the ROM 220 or HD 230.
  • the computer program is executed by being loaded into the RAM 240, and constitutes the control unit 210 in cooperation with the CPU.
  • the computer program may be recorded in an application program server connected to the client device 200 via an arbitrary network, and the client device 200 may download all or a part thereof as needed. ..
  • all or any part of the processing performed by the control unit 210 may be realized by hardware using wired logic or the like.
  • control unit 210 includes an evaluation unit 210a (calculation unit 210a1, conversion unit 210a2, generation unit 210a3, and classification unit 210a4) having the same function as that of the evaluation unit 102d provided in the evaluation device 100. ) May be provided.
  • the evaluation unit 210a uses the conversion unit 210a2 to obtain the value of the equation according to the information included in the evaluation result transmitted from the evaluation device 100.
  • the concentration value may be converted
  • the generation unit 210a3 may generate the position information corresponding to the value of the formula or the converted value (the concentration value or the converted value of the concentration value), or the classification unit 210a4.
  • Individuals may be classified into any one of a plurality of categories using the value of the formula or the converted value (which may be the concentration value or the converted value of the concentration value).
  • the network 300 has a function of connecting the evaluation device 100, the client device 200, and the database device 400 so as to be communicable with each other.
  • the Internet an intranet, a LAN (Local Area Network) (including both wired and wireless) and the like.
  • the network 300 includes VAN (Value-Added Network), personal computer communication network, public telephone network (including both analog / digital), dedicated line network (including both analog / digital), and CATV ().
  • Community Antenna TeleVision) network mobile line exchange network or mobile packet exchange network (IMT (International Mobile Telecommunication) 2000 system, GSM (registered trademark) (Global System for Mobile Communications) system or PDC.
  • wireless calling networks including methods, etc.
  • local wireless networks such as Bluetooth (registered trademark), PHS networks, satellite communication networks (CS (Communication Satellite), BS (Roadcasting Satellite), or ISDB (Integrated Services Digital Broadcast). ) Etc.
  • CS Common Satellite
  • BS Raster Base Station
  • ISDB Integrated Services Digital Broadcast
  • FIG. 13 is a block diagram showing an example of the configuration of the database device 400 of the present system, and conceptually shows only the portion of the configuration related to the present invention.
  • the database device 400 has a function of storing index state information used when creating a formula in the evaluation device 100 or the database device, a formula created in the evaluation device 100, an evaluation result in the evaluation device 100, and the like.
  • the database device 400 is connected to the database via a control unit 402 such as a CPU that collectively controls the database device, a communication device such as a router, and a wired or wireless communication circuit such as a dedicated line.
  • a communication interface unit 404 that connects the device to the network 300 so that it can communicate, a storage unit 406 that stores various databases, tables, files (for example, files for Web pages), and an input / output device 412 or an output device 414 that is connected to the input device 412 or the output device 414. It is composed of an output interface unit 408, and each of these units is connected so as to be communicable via an arbitrary communication path.
  • the storage unit 406 is a storage means, and for example, a memory device such as RAM / ROM, a fixed disk device such as a hard disk, a flexible disk, an optical disk, or the like can be used.
  • the storage unit 406 stores various programs and the like used for various processes.
  • the communication interface unit 404 mediates communication between the database device 400 and the network 300 (or a communication device such as a router). That is, the communication interface unit 404 has a function of communicating data with another terminal via a communication line.
  • the input / output interface unit 408 is connected to the input device 412 and the output device 414.
  • the output device 414 a speaker or a printer can be used in addition to a monitor (including a home television).
  • the input device 412 a monitor that realizes a pointing device function in cooperation with a mouse can be used in addition to a keyboard, a mouse, and a microphone.
  • the control unit 402 has an internal memory for storing a control program such as an OS, a program that defines various processing procedures, required data, and the like, and executes various information processing based on these programs. As shown in the figure, the control unit 402 is roughly divided into a transmission unit 402a and a reception unit 402b.
  • the transmission unit 402a transmits various information such as index state information and equations to the evaluation device 100.
  • the receiving unit 402b receives various information such as an expression and an evaluation result transmitted from the evaluation device 100.
  • the evaluation device 100 executes from acquisition of blood data, calculation of the value of the formula, classification into individual categories, and transmission of the evaluation result, and the client device 200 receives the evaluation result.
  • the evaluation device 100 executes the calculation of the value of the expression, for example, the conversion of the value of the expression and the position information.
  • the generation of the data and the classification of the individual into categories may be appropriately shared between the evaluation device 100 and the client device 200.
  • the evaluation unit 210a converts the value of the expression by the conversion unit 210a2, or the value of the expression or the value after conversion by the generation unit 210a3.
  • the position information corresponding to the above may be generated, or the individual may be classified into any one of a plurality of categories by using the value of the formula or the value after conversion in the classification unit 210a4.
  • the evaluation unit 210a When the client device 200 receives the converted value from the evaluation device 100, the evaluation unit 210a generates position information corresponding to the converted value by the generation unit 210a3, or the classification unit 210a4 converts the value. Individuals may be classified into any one of a plurality of categories using the later values.
  • the evaluation unit 210a uses the value of the formula or the converted value in the classification unit 210a4. Individuals may be classified into any one of a plurality of categories.
  • all or part of the processes described as being automatically performed can be manually performed, or the processes described as being manually performed. It is also possible to automatically perform all or part of the above by a known method.
  • processing procedures, control procedures, specific names, information including parameters such as registration data and search conditions for each processing, screen examples, and database configurations shown in the above documents and drawings are not specified unless otherwise specified. Can be changed arbitrarily.
  • each component shown in the figure is a functional concept and does not necessarily have to be physically configured as shown in the figure.
  • each processing function performed by the control unit 102 even if all or any part thereof is realized by the CPU and a program interpreted and executed by the CPU.
  • the program may be realized as hardware by wired logic.
  • the program is recorded on a non-temporary computer-readable recording medium containing programmed instructions for causing the information processing apparatus to execute the evaluation method or calculation method according to the present invention, and is evaluated as necessary. It is read mechanically by the device 100. That is, a computer program for giving instructions to the CPU in cooperation with the OS and performing various processes is recorded in a storage unit 106 such as a ROM or an HDD (Hard Disk Drive). This computer program is executed by being loaded into RAM, and cooperates with the CPU to form a control unit.
  • this computer program may be stored in the application program server connected to the evaluation device 100 via an arbitrary network, and it is also possible to download all or part of the computer program as needed.
  • the evaluation program or calculation program according to the present invention may be stored in a non-temporary computer-readable recording medium, or may be configured as a program product.
  • the "recording medium” includes a memory card, a USB (Universal Serial Bus) memory, an SD (Secure Digital) card, a flexible disk, a magneto-optical disk, a ROM, an EPROM (Erasable Programle Read Only Memory), and an EEPROM (Epil). Erasable and Program Read Only Memory (registered trademark), CD-ROM (Compact Disk Ready Memory), MO (Magnet-Optical disk), MO (Magnet-Optical disk), DVD (Digital Disk), DVD (Digital Disk) It shall include any "portable physical medium”.
  • program is a data processing method described in any language or description method, regardless of the format such as source code or binary code.
  • the "program” is not necessarily limited to a single program, but is distributed as a plurality of modules or libraries, or cooperates with a separate program represented by an OS to achieve its function. Including things. It should be noted that well-known configurations and procedures can be used for the specific configuration and reading procedure for reading the recording medium and the installation procedure after reading in each device shown in the embodiment.
  • Various databases and the like stored in the storage unit 106 are memory devices such as RAM and ROM, fixed disk devices such as hard disks, flexible disks, and storage means such as optical disks, and are used for various processes and website provision. Stores programs, tables, databases, files for web pages, etc.
  • the evaluation device 100 may be configured as an information processing device such as a known personal computer or workstation, or may be configured as the information processing device to which an arbitrary peripheral device is connected. Further, the evaluation device 100 may be realized by mounting software (including a program or data) that realizes the evaluation method or calculation method of the present invention on the information processing device.
  • the specific form of distribution / integration of the device is not limited to the one shown in the figure, and all or part of the device may be functionally or physically in any unit according to various additions or functional loads. It can be distributed and integrated. That is, the above-described embodiments may be arbitrarily combined and implemented, or the embodiments may be selectively implemented.
  • Example 1 The sample data used in Example 1 was used. A multivariate discriminant (multivariate function) for discriminating between the MCI group and the healthy group, including the variable to which the amino acid concentration value in plasma is substituted, was obtained.
  • a logistic regression equation was used as a multivariate discriminant.
  • the combination of 3 variables to be included in the logistic regression equation is searched from the plasma concentration values (nmol / ml) of 5 kinds of amino acids (Cit, Lys, Ser, Thr and Trp), and the ability to discriminate between the MCI group and the healthy group. Performed a search for a good logistic regression equation.
  • Table 1 shows a list of logistic regression equations for three variables that always include three of the five amino acids as variables. These logistic regression equations are considered useful in the above evaluation because the lower limit of the 95% confidence interval (95% CI) of the ROC_AUC value is higher than 0.5.
  • Example 1 The sample data used in Example 1 was used.
  • a logistic regression equation was used as a multivariate discriminant.
  • the combination of 4 variables included in the logistic regression equation (3 amino acid variables out of the 5 amino acids are required) is combined with 19 amino acids (Ala, Arg, Asn, Cit, Gln, Glu, Gly). , His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val), and search for a logistic regression equation with good discrimination between the MCI group and the healthy group. was carried out.
  • Table 2 shows a list of logistic regression equations in which the ROC_AUC values of the MCI group and the healthy group are 0.679 or more and the number of variables is 4 as shown in Table 1. Since these logistic regression equations have a high ROC_AUC value and the lower limit of 95% CI of the ROC_AUC value is higher than 0.5, they are considered to be useful in the above evaluation.
  • Example 1 The sample data used in Example 1 was used.
  • a logistic regression equation was used as a multivariate discriminant.
  • the combination of 5 variables to be included in the logistic regression equation (three amino acids out of the five amino acids are essential) was searched from the plasma concentration values of the 19 amino acids, and the MCI group and the healthy group were searched.
  • 684 (0.616, 0.752); Cit, Met, Lys, Leu, Trp, 0.684 (0.616, 0.752); Ser, Asn, Tyr, Lys, Trp, 0.684 (0.616, 0.752); Ser, Val, Lys, Phe, Trp , 0.684 (0.616, 0.752); Ser, Gln, Cit, Arg, Lys, 0.684 (0.616, 0.752); Ser, Thr, Ala, Val, Lys, 0.684 (0.615, 0.752); Ser, Thr, Met, Lys, Ile, 0.684 (0.615, 0.752); Ser, Gly, His, Lys, Trp, 0.684 (0.616, 0.752); Ser, Thr, Cit, Pro, Lys, 0.684 (0.615, 0.752); Ser, Thr, Lys, Ile , Phe, 0.683 (0.615, 0.752); Ser, Ala, Lys, Leu, Trp, 0.683 (0.615, 0.752);
  • Example 1 The sample data used in Example 1 (hereinafter referred to as training data) was used.
  • a logistic regression equation was used as a multivariate discriminant.
  • the combination of 6 variables to be included in the logistic regression equation (three amino acids out of the five amino acids are essential) was searched from the plasma concentration values of the 19 amino acids, and the MCI group and the healthy group were searched.
  • Plasma amino acid concentration data completely independent of the training data MCI patients aged 60 years or older (MCI group: 99) who had a definitive diagnosis of MCI, and 60 years old who are considered to have healthy cognitive function.
  • the performance of the logistic regression equation 200 obtained above was verified using the plasma samples obtained from the above healthy elderly people (healthy group: 100 persons) (hereinafter referred to as verification data).
  • the ROC_AUC values of the MCI group and the healthy group in the verification data are 0.600 or more, which is highly robust 128.
  • the street logistic regression equation was used.
  • Blood amino acid concentration data (hereinafter referred to as all data) including training data and verification data was used. That is, the 219 MCI group, which is a combination of the 120 MCI group described in Example 1 and the 99 MCI group described in Example 5, and the 120 healthy group and Example described in Example 1. Blood amino acid concentration data obtained from plasma samples of 220 healthy groups in which the 100 healthy groups described in 5 were combined was used.
  • the value of the formula when the specificity was 60% was set as the first cutoff value, and the value of the formula when the specificity was 90% was set as the second cutoff value. If the value of the formula is lower than the first cutoff value, it is ranked A (classification meaning that the possibility of MCI (probability, risk) is low), and the value of the formula is lower than the first cutoff value. If it is high and lower than the second cutoff value, it is rank B (a division that means that the probability of MCI is medium), and if the value of the expression is higher than the second cutoff value, it is rank C (MCI). It is defined as a category that means that there is a high possibility that it is.
  • Table 3 below shows seven logistic regression equations with a positive likelihood ratio of 3.0 or higher. These logistic regression equations have a high positive likelihood ratio, and it can be expected that they are more likely to lead to behavior change of the examinee than other equations.
  • logistic regression equations it has a logistic regression equation having a variable set "Ser, Thr, Ala, Cit, Lys, Trp” and a variable set "Ser, Thr, Cit, Met, Lys, Trp".
  • Logistic regression equation, logistic regression equation with variable set "Ser, Thr, Cit, Tyr, Lys, Trp” and logistic regression equation with variable set "Ser, Thr, Cit, Orn, Lys, Trp” are trained.
  • the ROC_AUC value of the MCI group and the healthy group in the data is as high as 0.70 or more, and the ROC_AUC value of the MCI group and the healthy group in the verification data is also as high as 0.65 or more. Is a high expression.
  • the present invention can be widely implemented in many industrial fields, especially in fields such as pharmaceuticals, foods, and medical treatments, and in particular, MCI status progression prediction, disease risk prediction, proteome, and metabolome analysis. It is extremely useful in the field of bioinformatics.
  • Evaluation device including calculation device
  • Control unit 102a Acquisition unit 102b Designation unit 102c Expression creation unit 102d Evaluation unit 102d1 Calculation unit 102d2 Conversion unit 102d3 Generation unit 102d4 Classification unit 102e Result output unit 102f Transmission unit 104 Communication interface unit 106 Storage unit 106a Concentration data file 106b Index status information File 106c Designated index status information file 106d Expression-related information database 106d1 Expression file 106e Evaluation result file 108 Input / output interface unit 112 Input device 114 Output device 200 Client device (terminal device (information and communication terminal device)) 300 network 400 database device

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

The present invention addresses the problem of providing an evaluation method, etc., whereby it is possible to provide highly reliable information that can aid in ascertaining a state of mild cognitive impairment. In the present embodiment, a state of mild cognitive impairment in an evaluation subject is evaluated using the concentration value of at least two amino acids from among Cit, Lys, Ser, Thr, and Trp in blood of the evaluation subject, or using a formula including a variable for which the concentration value is substituted and the value of the formula calculated using the concentration value. 

Description

軽度認知障害の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置Evaluation method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system and terminal device for mild cognitive impairment
 本発明は、軽度認知障害(Mild Cognitive Impairment)(以下、「MCI」と記す。)の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置に関するものである。 The present invention relates to an evaluation method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device for Mild Cognitive Impairment (hereinafter referred to as "MCI"). It is a thing.
 MCIは、年齢相応の正常な老化と比べて認知機能に問題があるものの日常生活に支障はなく認知症との診断には至らない、さまざまな認知症の前段階または境界例と考えられる状態を指す。MCIの診断について、現状、主に2つの診断基準が提唱され、広く受け入れられている(非特許文献1,2)。MCIの背景疾患は、AD(Alzheimer’s Disease)以外にもレビー小体型認知症(DLB)、前頭側頭葉変性症(FTLD)、血管性認知症(VaD)および老年性うつ等様々あり、原因疾患によっては、適切な介入を行うことにより認知症の発症リスクを低減できる可能性がある。そのため、MCIを判別可能な簡易スクリーニング法を提供することにより、より早期の段階での、より多くの者を対象とした専門医療機関の受診及び予防・治療機会の提供の可能性を高め、認知症発症者の増加防止に寄与することが期待される。 MCI is a condition that is considered to be a pre-stage or borderline case of various dementias that has problems with cognitive function compared to normal age-appropriate aging but does not interfere with daily life and does not lead to a diagnosis of dementia. Point to. Currently, two main diagnostic criteria have been proposed and widely accepted for the diagnosis of MCI (Non-Patent Documents 1 and 2). In addition to AD (Alzheimer's Disease), there are various background diseases of MCI such as Lewy body dementia (DLB), frontotemporal lobar degeneration (FTLD), vascular dementia (VaD) and senile depression. In some cases, appropriate intervention may reduce the risk of developing dementia. Therefore, by providing a simple screening method that can discriminate MCI, it is possible to increase the possibility of providing medical institution consultations and preventive / treatment opportunities for more people at an earlier stage, and it is recognized. It is expected to contribute to the prevention of an increase in the number of people with dementia.
 しかしながら、現在認知症のスクリーニング検査法として普及している神経心理検査Mini Mental State Examination(以下、「MMSE」と記す。)、改訂長谷川式簡易知能評価スケール(以下、「HDS-R」と記す。)およびAlzheimer’s Disease Assessment Scale-Cognitive(以下、「ADAS-cog」と記す。)等をMCIのスクリーニングに適用した場合、認知症の判定と比較して検出精度が低下することに加え、検査時間が長いためスループットが低いこと、および、検査実施者に熟練した技術を要すること、が課題である。MCIのスクリーニング検査法として従来の神経心理検査を補助する新たな簡易検査技術が求められる。 However, the neuropsychological test Mini Mental State Examination (hereinafter referred to as "MMSE"), which is currently widely used as a screening test method for dementia, and the revised Hasegawa simple intelligence evaluation scale (hereinafter referred to as "HDS-R"). ) And Alzheimer's Disease Assessment Scale-Cognitive (hereinafter referred to as "ADAS-cog"), etc. are applied to the screening of MCI, the detection accuracy is lower than the judgment of dementia, and the examination time is reduced. The problems are that the throughput is low due to the long length, and that the inspector requires skillful skills. As a screening test method for MCI, a new simple test technique that assists the conventional neuropsychological test is required.
 なお、血液検査によりMCIを判別する技術について、血液中のペプチド断片濃度を測定し、それを指標としてMCIを判別する技術が知られている(非特許文献3)。また、血液中のアミノ酸及びアミノ酸関連代謝物の定量的解析によるAD判定およびMCI判定技術が知られている(特許文献1,2)。 As a technique for discriminating MCI by a blood test, a technique for measuring the peptide fragment concentration in blood and discriminating MCI using it as an index is known (Non-Patent Document 3). Further, AD determination and MCI determination techniques by quantitative analysis of amino acids and amino acid-related metabolites in blood are known (Patent Documents 1 and 2).
国際公開第2018/008764号International Publication No. 2018/008764 国際公開第2020/067386号International Publication No. 2020/067386
 しかしながら、アミノ酸及びアミノ酸関連代謝物を含む代謝物の血中濃度を指標とした高精度なMCI判定技術に関しては、実用化を視野に入れた場合に、実臨床での要求基準を満たすための更なる精度向上が必要である、という問題点があった。 However, regarding the highly accurate MCI determination technology using the blood concentration of amino acids and metabolites including amino acid-related metabolites as an index, in order to meet the requirements in actual clinical practice when the practical application is taken into consideration. There was a problem that it was necessary to improve the accuracy.
 本発明は、上記に鑑みてなされたもので、MCIの状態を知る上で参考となり得る信頼性の高い情報を提供することができる評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置を提供することを目的とする。 The present invention has been made in view of the above, and is an evaluation method, a calculation method, an evaluation device, a calculation device, an evaluation program, and a calculation that can provide highly reliable information that can be used as a reference for knowing the state of MCI. It is an object of the present invention to provide a program, a recording medium, an evaluation system and a terminal device.
 上述した課題を解決し、目的を達成するために、本発明にかかる評価方法は、評価対象の血液中の5種類のアミノ酸(Cit、Lys、Ser、ThrおよびTrp)のうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を用いて、前記評価対象について、MCIの状態を評価する評価ステップを含むこと、を特徴とする。 In order to solve the above-mentioned problems and achieve the object, the evaluation method according to the present invention comprises at least two amino acids out of five kinds of amino acids (Cit, Lys, Ser, Thr and Trp) in the blood to be evaluated. The evaluation step includes an evaluation step of evaluating the state of MCI for the evaluation target by using the concentration value of the above or the expression including the variable to which the concentration value is substituted and the value of the expression calculated by using the concentration value. It is characterized by that.
 ここで、本明細書では各種アミノ酸を主に略称で表記するが、それらの正式名称は以下の通りである。
(略称)     (正式名称)
Ala           Alanine
Arg           Arginine
Asn           Asparagine
Cit           Citrulline
Gln           Glutamine
Gly           Glycine
His           Histidine
Ile           Isoleucine
Leu           Leucine
Lys           Lysine
Met           Methionine
Orn           Ornithine
Phe           Phenylalanine
Pro           Proline
Ser           Serine
Thr           Threonine
Trp           Tryptophan
Tyr           Tyrosine
Val           Valine
Here, various amino acids are mainly abbreviated in the present specification, but their official names are as follows.
(Abbreviation) (Official name)
Ala Alanine
Arg Arginine
Asn Asparagine
Cit Citrulline
Gln Glutamine
Gly Glycine
His Histidine
Ile Isoleucine
Leu Leucine
Lys Lysine
Met Methionine
Orn Ornithine
Phe Phenylalanine
Pro Proline
Ser Serine
Thr Threonine
Trp Tryptophan
Tyr Tyrosine
Val Valine
 また、本発明にかかる評価方法は、前記濃度値が、少なくとも3つのアミノ酸の濃度値であり、前記少なくとも3つのアミノ酸が、Ser、LysおよびTrp、Ser、CitおよびLys、Cit、LysおよびTrp、Ser、ThrおよびLys、Thr、LysおよびTrp、Thr、CitおよびLys、Ser、ThrおよびCit、Ser、ThrおよびTrp、Thr、CitおよびTrp、または、Ser、CitおよびTrpを含むこと、を特徴とする。 Further, in the evaluation method according to the present invention, the concentration value is the concentration value of at least three amino acids, and the at least three amino acids are Ser, Lys and Trp, Ser, Cit and Lys, Cit, Lys and Trp. It is characterized by including Ser, Thr and Lys, Thr, Lys and Trp, Thr, Cit and Lys, Ser, Thr and Cit, Ser, Thr and Trp, Thr, Cit and Trp, or Ser, Cit and Trp. do.
 また、本発明にかかる評価方法は、前記濃度値が、少なくとも6つのアミノ酸の濃度値であり、前記少なくとも6つのアミノ酸が、Ser、Thr、Ala、Cit、LysおよびTrp、Ser、Thr、Cit、Met、LysおよびTrp、Ser、Gln、Cit、Val、MetおよびLys、Ser、Gln、Cit、Met、LysおよびLeu、Ser、Thr、Cit、Tyr、LysおよびTrp、Ser、Cit、Tyr、Met、LysおよびTrp、または、Ser、Thr、Cit、Orn、LysおよびTrpを含むこと、を特徴とする。 Further, in the evaluation method according to the present invention, the concentration value is the concentration value of at least 6 amino acids, and the at least 6 amino acids are Ser, Thr, Ala, Cit, Lys and Trp, Ser, Thr, Cit. Met, Lys and Trp, Ser, Gln, Cit, Val, Met and Lys, Ser, Gln, Cit, Met, Lys and Leu, Ser, Thr, Cit, Tyr, Lys and Trp, Ser, Cit, Tyr, Met, It comprises Lys and Trp, or Ser, Thr, Cit, Orn, Lys and Trp.
 また、本発明にかかる評価方法は、前記評価ステップが、制御部を備えた情報処理装置の前記制御部において実行されること、を特徴とする。 Further, the evaluation method according to the present invention is characterized in that the evaluation step is executed in the control unit of the information processing apparatus provided with the control unit.
 また、本発明にかかる算出方法は、評価対象の血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、および、前記濃度値が代入される変数を含むMCIの状態を評価するための式を用いて、前記式の値を算出する算出ステップを含むこと、を特徴とする。 Further, the calculation method according to the present invention evaluates the concentration value of at least two amino acids among the five kinds of amino acids in the blood to be evaluated, and the state of MCI including the variable to which the concentration value is substituted. It is characterized by including a calculation step for calculating the value of the above formula using the formula for.
 また、本発明にかかる算出方法は、前記算出ステップが、制御部を備えた情報処理装置の前記制御部において実行されること、を特徴とする。 Further, the calculation method according to the present invention is characterized in that the calculation step is executed in the control unit of the information processing apparatus provided with the control unit.
 また、本発明にかかる評価装置は、制御部を備える評価装置であって、前記制御部が、評価対象の血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を用いて、前記評価対象について、MCIの状態を評価する評価手段を備えること、を特徴とする。 Further, the evaluation device according to the present invention is an evaluation device including a control unit, wherein the control unit has a concentration value of at least two amino acids among the five types of amino acids in the blood to be evaluated, or the above-mentioned. It is characterized in that an evaluation means for evaluating the state of MCI is provided for the evaluation target by using an expression including a variable to which the concentration value is assigned and the value of the expression calculated by using the concentration value.
 また、本発明にかかる評価装置は、前記濃度値または前記式の前記値を提供する端末装置とネットワークを介して通信可能に接続され、前記制御部が、前記端末装置から送信された前記濃度値または前記式の前記値を受信するデータ受信手段と、前記評価手段で得られた評価結果を前記端末装置へ送信する結果送信手段と、をさらに備え、前記評価手段が、前記データ受信手段で受信した前記濃度値または前記式の前記値を用いること、を特徴とする。 Further, the evaluation device according to the present invention is communicably connected to the terminal device that provides the concentration value or the value of the above formula via a network, and the control unit controls the concentration value transmitted from the terminal device. Alternatively, the data receiving means for receiving the value of the above formula and the result transmitting means for transmitting the evaluation result obtained by the evaluation means to the terminal device are further provided, and the evaluation means receives the data with the data receiving means. It is characterized by using the above-mentioned concentration value or the above-mentioned value of the above formula.
 また、本発明にかかる算出装置は、制御部を備える算出装置であって、前記制御部が、評価対象の血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、および、前記濃度値が代入される変数を含むMCIの状態を評価するための式を用いて、前記式の値を算出する算出手段を備えること、を特徴とする。 Further, the calculation device according to the present invention is a calculation device including a control unit, wherein the control unit has a concentration value of at least two amino acids among the five types of amino acids in the blood to be evaluated, and the said. It is characterized by comprising a calculation means for calculating the value of the equation by using an equation for evaluating the state of MCI including a variable to which the concentration value is assigned.
 また、本発明にかかる評価プログラムは、制御部を備える情報処理装置において実行させるための評価プログラムであって、前記制御部において実行させるための、評価対象の血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を用いて、前記評価対象について、MCIの状態を評価する評価ステップを含むこと、を特徴とする。 Further, the evaluation program according to the present invention is an evaluation program for execution in an information processing apparatus provided with a control unit, and is among the five types of amino acids in the blood to be evaluated for execution in the control unit. The state of MCI is evaluated for the evaluation target using the concentration value of at least two amino acids of the above, or the expression including the variable to which the concentration value is substituted and the value of the equation calculated using the concentration value. It is characterized by including an evaluation step to be performed.
 また、本発明にかかる算出プログラムは、制御部を備える情報処理装置において実行させるための算出プログラムであって、前記制御部において実行させるための、評価対象の血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、および、前記濃度値が代入される変数を含むMCIの状態を評価するための式を用いて、前記式の値を算出する算出ステップを含むこと、を特徴とする。 Further, the calculation program according to the present invention is a calculation program to be executed in an information processing apparatus provided with a control unit, and is among the five types of amino acids in the blood to be evaluated to be executed by the control unit. It is characterized by including a calculation step of calculating the value of the formula using a formula for evaluating the concentration value of at least two amino acids of the above and the state of MCI including the variable to which the concentration value is assigned. do.
 また、本発明にかかる記録媒体は、前記評価プログラムまたは前記算出プログラムを記録したコンピュータ読み取り可能な記録媒体である。具体的には、本発明にかかる記録媒体は、一時的でないコンピュータ読み取り可能な記録媒体であって、情報処理装置に前記評価方法または前記算出方法を実行させるためのプログラム化された命令を含むこと、を特徴とするものである。 Further, the recording medium according to the present invention is a computer-readable recording medium on which the evaluation program or the calculation program is recorded. Specifically, the recording medium according to the present invention is a non-temporary computer-readable recording medium, and includes a programmed instruction for causing an information processing apparatus to execute the evaluation method or the calculation method. , Is characterized by.
 また、本発明にかかる評価システムは、制御部を備える評価装置と、制御部を備える端末装置とを、ネットワークを介して通信可能に接続して構成される評価システムであって、前記端末装置の前記制御部が、評価対象の血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を、前記評価装置へ送信するデータ送信手段と、前記評価装置から送信された、前記評価対象についてのMCIの状態に関する評価結果を受信する結果受信手段と、を備え、前記評価装置の前記制御部が、前記端末装置から送信された前記濃度値または前記式の前記値を受信するデータ受信手段と、前記データ受信手段で受信した前記濃度値または前記式の前記値を用いて、前記評価対象について、MCIの状態を評価する評価手段と、前記評価手段で得られた前記評価結果を前記端末装置へ送信する結果送信手段と、を備えること、を特徴とする。 Further, the evaluation system according to the present invention is an evaluation system configured by connecting an evaluation device including a control unit and a terminal device including a control unit so as to be communicable via a network, and is an evaluation system of the terminal device. The control unit was calculated using the concentration value of at least two amino acids out of the five types of amino acids in the blood to be evaluated, or an expression including a variable to which the concentration value is substituted and the concentration value. The evaluation device includes a data transmission means for transmitting the value of the above formula to the evaluation device, and a result receiving means for receiving the evaluation result regarding the state of MCI for the evaluation target transmitted from the evaluation device. The control unit uses the data receiving means for receiving the concentration value or the value of the formula transmitted from the terminal device, and the concentration value or the value of the formula received by the data receiving means. The evaluation target is provided with an evaluation means for evaluating the state of MCI and a result transmission means for transmitting the evaluation result obtained by the evaluation means to the terminal device.
 また、本発明にかかる端末装置は、制御部を備えた端末装置であって、前記制御部が、評価対象についてのMCIの状態に関する評価結果を取得する結果取得手段を備え、前記評価結果が、前記評価対象の血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を用いて、前記評価対象について、MCIの状態を評価した結果であること、を特徴とする。 Further, the terminal device according to the present invention is a terminal device including a control unit, wherein the control unit includes a result acquisition means for acquiring an evaluation result regarding the state of MCI with respect to the evaluation target, and the evaluation result is. The concentration value of at least two amino acids out of the five kinds of amino acids in the blood to be evaluated, or the value of the formula including the variable to which the concentration value is substituted and the value of the formula calculated using the concentration value. It is a result of evaluating the state of MCI with respect to the evaluation target using the above.
 また、本発明にかかる端末装置は、前記評価対象についてMCIの状態を評価する評価装置とネットワークを介して通信可能に接続されており、前記制御部が、前記濃度値または前記式の前記値を前記評価装置へ送信するデータ送信手段を備え、前記結果取得手段が、前記評価装置から送信された前記評価結果を受信すること、を特徴とする。 Further, the terminal device according to the present invention is communicably connected to an evaluation device that evaluates the state of MCI for the evaluation target via a network, and the control unit obtains the concentration value or the value of the formula. The data transmission means for transmitting to the evaluation device is provided, and the result acquisition means receives the evaluation result transmitted from the evaluation device.
 本発明によれば、MCIの状態を知る上で参考となり得る信頼性の高い情報を提供することができるという効果を奏する。 According to the present invention, it is possible to provide highly reliable information that can be used as a reference for knowing the state of MCI.
図1は、第1実施形態の基本原理を示す原理構成図である。FIG. 1 is a principle configuration diagram showing the basic principle of the first embodiment. 図2は、第2実施形態の基本原理を示す原理構成図である。FIG. 2 is a principle configuration diagram showing the basic principle of the second embodiment. 図3は、本システムの全体構成の一例を示す図である。FIG. 3 is a diagram showing an example of the overall configuration of this system. 図4は、本システムの全体構成の他の一例を示す図である。FIG. 4 is a diagram showing another example of the overall configuration of this system. 図5は、本システムの評価装置100の構成の一例を示すブロック図である。FIG. 5 is a block diagram showing an example of the configuration of the evaluation device 100 of this system. 図6は、血液データファイル106aに格納される情報の一例を示す図である。FIG. 6 is a diagram showing an example of information stored in the blood data file 106a. 図7は、指標状態情報ファイル106bに格納される情報の一例を示す図である。FIG. 7 is a diagram showing an example of information stored in the index state information file 106b. 図8は、指定指標状態情報ファイル106cに格納される情報の一例を示す図である。FIG. 8 is a diagram showing an example of information stored in the designated index state information file 106c. 図9は、式ファイル106d1に格納される情報の一例を示す図である。FIG. 9 is a diagram showing an example of information stored in the formula file 106d1. 図10は、評価結果ファイル106eに格納される情報の一例を示す図である。FIG. 10 is a diagram showing an example of information stored in the evaluation result file 106e. 図11は、評価部102dの構成を示すブロック図である。FIG. 11 is a block diagram showing the configuration of the evaluation unit 102d. 図12は、本システムのクライアント装置200の構成の一例を示すブロック図である。FIG. 12 is a block diagram showing an example of the configuration of the client device 200 of this system. 図13は、本システムのデータベース装置400の構成の一例を示すブロック図である。FIG. 13 is a block diagram showing an example of the configuration of the database device 400 of this system.
 以下に、本発明にかかる評価方法および算出方法の実施形態(第1実施形態)ならびに本発明にかかる評価装置、算出装置、評価方法、算出方法、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置の実施形態(第2実施形態)を、図面に基づいて詳細に説明する。なお、本発明はこれらの実施形態により限定されるものではない。 Hereinafter, an embodiment (first embodiment) of the evaluation method and the calculation method according to the present invention, and an evaluation device, a calculation device, an evaluation method, a calculation method, an evaluation program, a calculation program, a recording medium, an evaluation system, and the like according to the present invention. An embodiment (second embodiment) of the terminal device will be described in detail with reference to the drawings. The present invention is not limited to these embodiments.
[第1実施形態]
[1-1.第1実施形態の概要]
 ここでは、第1実施形態の概要について図1を参照して説明する。図1は第1実施形態の基本原理を示す原理構成図である。
[First Embodiment]
[1-1. Outline of the first embodiment]
Here, the outline of the first embodiment will be described with reference to FIG. FIG. 1 is a principle configuration diagram showing the basic principle of the first embodiment.
 まず、評価対象(例えば動物やヒトなどの個体)から採取した血液(例えば血漿、血清、全血などを含む)中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値に関する血液データを取得する(ステップS11)。ここで、血液データは、例えば、評価対象から採取した血液中の少なくとも3つのアミノ酸の濃度値に関するものでもよく、当該少なくとも3つのアミノ酸は、例えば、「Ser、LysおよびTrp」、「Ser、CitおよびLys」、「Cit、LysおよびTrp」、「Ser、ThrおよびLys」、「Thr、LysおよびTrp」、「Thr、CitおよびLys」、「Ser、ThrおよびCit」、「Ser、ThrおよびTrp」、「Thr、CitおよびTrp」、または、「Ser、CitおよびTrp」を含んでもよい。また、血液データは、例えば、評価対象から採取した血液中の少なくとも6つのアミノ酸の濃度値に関するものでもよく、当該少なくとも6つのアミノ酸は、例えば、「Ser、Thr、Ala、Cit、LysおよびTrp」、「Ser、Thr、Cit、Met、LysおよびTrp」、「Ser、Gln、Cit、Val、MetおよびLys」、「Ser、Gln、Cit、Met、LysおよびLeu」、「Ser、Thr、Cit、Tyr、LysおよびTrp」、「Ser、Cit、Tyr、Met、LysおよびTrp」、または、「Ser、Thr、Cit、Orn、LysおよびTrp」を含んでもよい。 First, blood data regarding the concentration values of at least two of the five amino acids in blood (including plasma, serum, whole blood, etc.) collected from an evaluation target (for example, an individual such as an animal or a human) is obtained. Acquire (step S11). Here, the blood data may be related to, for example, the concentration value of at least three amino acids in the blood collected from the evaluation target, and the at least three amino acids are, for example, "Ser, Lys and Trp", "Ser, Cit". And Lys ”,“ Cit, Lys and Trp ”,“ Ser, Thr and Lys ”,“ Thr, Lys and Trp ”,“ Thr, Cit and Lys ”,“ Ser, Thr and Cit ”,“ Ser, Thr and Trp ”. , "Thr, Cit and Trp", or "Ser, Cit and Trp" may be included. Further, the blood data may be related to, for example, the concentration value of at least 6 amino acids in the blood collected from the evaluation target, and the at least 6 amino acids are, for example, "Ser, Thr, Ala, Cit, Lys and Trp". , "Ser, Thr, Cit, Met, Lys and Trp", "Ser, Gln, Cit, Val, Met and Lys", "Ser, Gln, Cit, Met, Lys and Leu", "Ser, Thr, Cit, It may include "Tyr, Lys and Trp", "Ser, Cit, Tyr, Met, Lys and Trp", or "Ser, Thr, Cit, Orn, Lys and Trp".
 なお、ステップS11では、例えば、濃度値の測定を行う企業等が測定した血液データを取得してもよい。また、評価対象から採取した血液から、例えば以下の(A)、(B)、または(C)などの測定方法により濃度値を測定することで、血液データを取得してもよい。ここで、濃度値の単位は、例えばモル濃度、重量濃度又は酵素活性であってもよく、これらの濃度に任意の定数を加減乗除することで得られるものでもよい。
(A)採取した血液サンプルを遠心することにより血液から血漿を分離する。全ての血漿サンプルは、濃度値の測定時まで-80℃で凍結保存する。濃度値測定時には、アセトニトリルを添加し除蛋白処理を行った後、必要に応じて固層抽出等によりリン脂質等の夾雑物を除去し、標識試薬(3-アミノピリジル-N-ヒドロキシスクシンイミジルカルバメート)を用いてプレカラム誘導体化を行い、そして、液体クロマトグラフィー質量分析法(タンデム質量分析法を含む)により濃度値を分析する(国際公開第2003/069328号、国際公開第2005/116629号を参照)。
(B)採取した血液サンプルを遠心することにより血液から血漿を分離する。全ての血漿サンプルは、濃度値の測定時まで-80℃で凍結保存する。濃度値測定時には、スルホサリチル酸を添加し除蛋白処理を行った後、ニンヒドリン試薬を用いたポストカラム誘導体化法を原理としたアミノ酸分析計により濃度値を分析する。
(C)採取した血液サンプルを、膜やMEMS(Micro Electro Mechanical Systems)技術または遠心分離の原理を用いて血球分離を行い、血液から血漿または血清を分離する。血漿または血清取得後すぐに濃度値の測定を行わない血漿または血清サンプルは、濃度値の測定時まで-80℃で凍結保存する。濃度値測定時には、酵素やアプタマーなど、標的とする血中物質と反応または結合する分子等を用い、基質認識によって増減する物質や分光学的値を定量等することにより濃度値を分析する。
In step S11, for example, blood data measured by a company or the like that measures the concentration value may be acquired. Further, blood data may be acquired from the blood collected from the evaluation target by measuring the concentration value by, for example, the following measuring methods such as (A), (B), or (C). Here, the unit of the concentration value may be, for example, a molar concentration, a weight concentration, or an enzyme activity, or may be obtained by adding, subtracting, multiplying, or dividing an arbitrary constant to these concentrations.
(A) Plasma is separated from blood by centrifuging the collected blood sample. All plasma samples are cryopreserved at -80 ° C until the concentration value is measured. At the time of concentration value measurement, acetonitrile is added to perform derivatization treatment, and if necessary, impurities such as phospholipids are removed by solid layer extraction, etc., and the labeling reagent (3-aminopyridyl-N-hydroxysuccinimi) is removed. Pre-column derivatization is performed using zircarbamate), and concentration values are analyzed by liquid chromatography-mass spectrometry (including tandem mass spectrometry) (International Publication No. 2003/06628, International Publication No. 2005/116629). See).
(B) Plasma is separated from blood by centrifuging the collected blood sample. All plasma samples are cryopreserved at -80 ° C until the concentration value is measured. When measuring the concentration value, sulfosalicylic acid is added to perform deproteinization treatment, and then the concentration value is analyzed by an amino acid analyzer based on the post-column derivatization method using a ninhydrin reagent.
(C) The collected blood sample is subjected to blood cell separation using a membrane, MEMS (Micro Electro Mechanical Systems) technology or the principle of centrifugation, and plasma or serum is separated from the blood. Plasma or serum samples that are not measured immediately after acquisition of plasma or serum are cryopreserved at -80 ° C until the time of concentration measurement. At the time of measuring the concentration value, a molecule that reacts with or binds to a target blood substance such as an enzyme or an aptamer is used, and the concentration value is analyzed by quantifying the substance that increases or decreases due to substrate recognition or the spectroscopic value.
 つぎに、ステップS11で取得した血液データに含まれている濃度値を用いて、評価対象についてMCIの状態を評価する(ステップS12)。なお、ステップS12を実行する前に、ステップS11で取得した血液データから欠損値や外れ値などのデータを除去してもよい。ここで、MCIの状態を評価するとは、例えば、MCIの現在の状態を検査することである。 Next, the state of MCI is evaluated for the evaluation target using the concentration value contained in the blood data acquired in step S11 (step S12). Before executing step S12, data such as missing values and outliers may be removed from the blood data acquired in step S11. Here, to evaluate the state of MCI is, for example, to inspect the current state of MCI.
 以上、第1実施形態によれば、ステップS11では評価対象の血液データを取得し、ステップS12では、ステップS11で取得した評価対象の血液データに含まれている濃度値を用いて、評価対象についてMCIの状態を評価する(要するに、評価対象についてMCIの状態を評価するための情報または評価対象についてMCIの状態を知る上で参考となり得る信頼性の高い情報を取得する)。これにより、評価対象についてMCIの状態を評価するための情報または評価対象についてMCIの状態を知る上で参考となり得る信頼性の高い情報を提供することができる。 As described above, according to the first embodiment, in step S11, the blood data to be evaluated is acquired, and in step S12, the concentration value included in the blood data to be evaluated acquired in step S11 is used for the evaluation target. Evaluate the state of MCI (in short, obtain information for evaluating the state of MCI for the evaluation target or highly reliable information that can be used as a reference for knowing the state of MCI for the evaluation target). Thereby, it is possible to provide information for evaluating the state of MCI for the evaluation target or highly reliable information that can be used as a reference for knowing the state of MCI for the evaluation target.
 また、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値が評価対象についてのMCIの状態を反映したものであると決定してもよく、さらに、当該濃度値を例えば以下に挙げた手法などで変換し、変換後の値が評価対象についてのMCIの状態を反映したものであると決定してもよい。換言すると、濃度値又は変換後の値そのものを、評価対象についてのMCIの状態に関する評価結果として扱ってもよい。
 濃度値の取り得る範囲が所定範囲(例えば0.0から1.0までの範囲、0.0から10.0までの範囲、0.0から100.0までの範囲、又は-10.0から10.0までの範囲、など)に収まるようにするためなどに、例えば、濃度値に対して任意の値を加減乗除したり、濃度値を所定の変換手法(例えば、指数変換、対数変換、角変換、平方根変換、プロビット変換、逆数変換、Box-Cox変換、又はべき乗変換など)で変換したり、また、濃度値に対してこれらの計算を組み合わせて行ったりすることで、濃度値を変換してもよい。例えば、濃度値を指数としネイピア数を底とする指数関数の値(具体的には、MCIの状態が所定の状態(例えば、基準値を超えた、MCIに罹患している可能性が高い状態、など)である確率pを定義したときの自然対数ln(p/(1-p))が濃度値と等しいとした場合におけるp/(1-p)の値)をさらに算出してもよく、また、算出した指数関数の値を1と当該値との和で割った値(具体的には、確率pの値)をさらに算出してもよい。
 また、特定の条件のときの変換後の値が特定の値となるように、濃度値を変換してもよい。例えば、特異度が60%のときの変換後の値が5.0となり且つ特異度が90%のときの変換後の値が8.0となるように濃度値を変換してもよい。
 また、各アミノ酸ごとに、濃度分布を正規分布化した後、平均50、標準偏差10となるように偏差値化してもよい。
 なお、これらの変換は、男女別や年齢別に行ってもよい。
 なお、本明細書における濃度値は、濃度値そのものであってもよく、濃度値を変換した後の値であってもよい。
Further, it may be determined that the concentration values of at least two amino acids among the five kinds of amino acids reflect the state of MCI for the evaluation target, and further, the concentration values may be determined by the methods listed below, for example. It may be determined that the converted value reflects the state of MCI with respect to the evaluation target. In other words, the concentration value or the converted value itself may be treated as an evaluation result regarding the state of MCI with respect to the evaluation target.
The possible range of concentration values is a predetermined range (for example, 0.0 to 1.0, 0.0 to 10.0, 0.0 to 100.0, or -10.0). In order to fit within the range up to 10.0, etc.), for example, any value can be added, subtracted, multiplied, or divided with respect to the cardinality value, or the cardinality value can be converted into a predetermined conversion method (for example, exponential conversion, logarithmic conversion, etc.). Convert the cardinality value by converting it by (angle conversion, square root conversion, probit conversion, inverse number conversion, Box-Cox conversion, or power conversion), or by combining these calculations with the cardinality value. You may. For example, the value of an exponential function whose index is the concentration value and whose base is the number of napiers (specifically, a state in which the state of MCI exceeds a predetermined state (for example, a state in which the state exceeds the reference value and is likely to be affected by MCI). , Etc.) may be further calculated (the value of p / (1-p)) when the natural logarithm ln (p / (1-p)) when the probability p is defined is equal to the concentration value. Further, a value obtained by dividing the calculated value of the exponential function by the sum of 1 and the value (specifically, the value of the probability p) may be further calculated.
Further, the concentration value may be converted so that the converted value under a specific condition becomes a specific value. For example, the concentration value may be converted so that the converted value when the specificity is 60% is 5.0 and the converted value when the specificity is 90% is 8.0.
Further, after the concentration distribution is normally distributed for each amino acid, the deviation value may be converted so that the average is 50 and the standard deviation is 10.
In addition, these conversions may be performed by gender or age.
The concentration value in the present specification may be the concentration value itself or the value after converting the concentration value.
 また、モニタ等の表示装置又は紙等の物理媒体に視認可能に示される所定の物差し上における所定の目印の位置に関する位置情報を、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値又は当該濃度値を変換した場合にはその変換後の値を用いて生成し、生成した位置情報が評価対象についてのMCIの状態を反映したものであると決定してもよい。なお、所定の物差しとは、MCIの状態を評価するためのものであり、例えば、目盛りが示された物差しであって、「濃度値又は変換後の値の取り得る範囲、又は、当該範囲の一部分」における上限値と下限値に対応する目盛りが少なくとも示されたもの、などである。また、所定の目印とは、濃度値又は変換後の値に対応するものであり、例えば、丸印又は星印などである。 In addition, the position information regarding the position of the predetermined mark on the predetermined indicator visually shown on the display device such as a monitor or the physical medium such as paper is the concentration value of at least two amino acids among the five kinds of amino acids or the concentration value of the amino acid. When the concentration value is converted, it may be generated using the converted value, and it may be determined that the generated position information reflects the state of MCI for the evaluation target. The predetermined ruler is for evaluating the state of MCI, and is, for example, a ruler with a scale, which is "a range in which a concentration value or a converted value can be taken, or a range thereof. At least the scales corresponding to the upper and lower limits in "part" are shown. Further, the predetermined mark corresponds to the concentration value or the converted value, and is, for example, a circle mark or a star mark.
 また、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値が、所定値(平均値±1SD、2SD、3SD、N分位点、Nパーセンタイル又は臨床的意義の認められたカットオフ値など)より低い若しくは所定値以下の場合又は所定値以上若しくは所定値より高い場合に、評価対象について、MCIの状態を評価してもよい。その際、濃度値そのものではなく、濃度偏差値(各アミノ酸ごとに、男女別に濃度分布を正規分布化した後、平均50、標準偏差10となるように偏差値化した値)を用いてもよい。例えば、濃度偏差値が平均値-2SD未満の場合(濃度偏差値<30の場合)又は濃度偏差値が平均値+2SDより高い場合(濃度偏差値>70の場合)に、評価対象について、MCIの状態を評価してもよい。 Further, the concentration value of at least two amino acids among the five kinds of amino acids is a predetermined value (mean value ± 1SD, 2SD, 3SD, N quantile, N percentile, cutoff value having clinical significance, etc. ) May be lower or less than a predetermined value, or more than a predetermined value or higher than a predetermined value, the state of MCI may be evaluated for the evaluation target. At that time, instead of the concentration value itself, a concentration deviation value (a value obtained by normalizing the concentration distribution for each amino acid for each gender and then converting the concentration distribution into an average of 50 and a standard deviation of 10) may be used. .. For example, when the concentration deviation value is less than the mean value -2SD (when the concentration deviation value <30) or when the concentration deviation value is higher than the mean value + 2SD (when the concentration deviation value> 70), the evaluation target is the MCI. The condition may be evaluated.
 また、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、および、当該濃度値が代入される変数を含む式を用いて、式の値を算出することで、評価対象についてMCIの状態を評価してもよい。 Further, by calculating the value of the formula using the concentration value of at least two amino acids among the five types of amino acids and the formula including the variable to which the concentration value is assigned, the state of MCI for the evaluation target. May be evaluated.
 また、算出した式の値が評価対象についてのMCIの状態を反映したものであると決定してもよく、さらに、式の値を例えば以下に挙げた手法などで変換し、変換後の値が評価対象についてのMCIの状態を反映したものであると決定してもよい。換言すると、式の値又は変換後の値そのものを、評価対象についてのMCIの状態に関する評価結果として扱ってもよい。
 式の値の取り得る範囲が所定範囲(例えば0.0から1.0までの範囲、0.0から10.0までの範囲、0.0から100.0までの範囲、又は-10.0から10.0までの範囲、など)に収まるようにするためなどに、例えば、式の値に対して任意の値を加減乗除したり、式の値を所定の変換手法(例えば、指数変換、対数変換、角変換、平方根変換、プロビット変換、逆数変換、Box-Cox変換、又はべき乗変換など)で変換したり、また、式の値に対してこれらの計算を組み合わせて行ったりすることで、式の値を変換してもよい。例えば、式の値を指数としネイピア数を底とする指数関数の値(具体的には、MCIの状態が所定の状態(例えば、基準値を超えた、MCIに罹患している可能性が高い状態、など)である確率pを定義したときの自然対数ln(p/(1-p))が式の値と等しいとした場合におけるp/(1-p)の値)をさらに算出してもよく、また、算出した指数関数の値を1と当該値との和で割った値(具体的には、確率pの値)をさらに算出してもよい。
 また、特定の条件のときの変換後の値が特定の値となるように、式の値を変換してもよい。例えば、特異度が60%のときの変換後の値が5.0となり且つ特異度が90%のときの変換後の値が8.0となるように式の値を変換してもよい。
 また、平均50、標準偏差10となるように偏差値化してもよい。
 なお、これらの変換は、男女別や年齢別に行ってもよい。
 なお、本明細書における式の値は、式の値そのものであってもよく、式の値を変換した後の値であってもよい。
Further, it may be determined that the calculated value of the formula reflects the state of MCI for the evaluation target, and further, the value of the formula is converted by, for example, the method described below, and the converted value is obtained. It may be determined that it reflects the state of MCI for the evaluation target. In other words, the value of the expression or the converted value itself may be treated as an evaluation result regarding the state of MCI with respect to the evaluation target.
The possible range of values in the equation is a predetermined range (eg 0.0 to 1.0, 0.0 to 10.0, 0.0 to 100.0, or -10.0). For example, to add, subtract, multiply, or divide an arbitrary value to the value of an expression, or to convert the value of an expression into a predetermined conversion method (for example, exponential conversion, etc.) so that the value falls within the range from 10.0 to 10.0, etc.). By converting by logarithmic conversion, angular conversion, square root conversion, probit conversion, reciprocal conversion, Box-Cox conversion, or power conversion, etc., or by combining these calculations with respect to the value of the expression. You may convert the value of the expression. For example, the value of an exponential function whose exponent is the value of the formula and whose base is the number of Napiers (specifically, it is highly possible that the state of MCI exceeds a predetermined state (for example, the reference value is exceeded, and the patient is suffering from MCI). The value of p / (1-p) when the natural logarithmic value ln (p / (1-p)) when the probability p is defined is equal to the value of the equation) is further calculated. Alternatively, the value obtained by dividing the calculated value of the exponential function by the sum of 1 and the value (specifically, the value of the probability p) may be further calculated.
Further, the value of the expression may be converted so that the converted value under a specific condition becomes a specific value. For example, the value of the expression may be converted so that the converted value when the specificity is 60% is 5.0 and the converted value when the specificity is 90% is 8.0.
Further, the deviation value may be set so that the average is 50 and the standard deviation is 10.
In addition, these conversions may be performed by gender or age.
The value of the expression in the present specification may be the value of the expression itself or may be the value after converting the value of the expression.
 また、モニタ等の表示装置又は紙等の物理媒体に視認可能に示される所定の物差し上における所定の目印の位置に関する位置情報を、式の値又は当該式の値を変換した場合にはその変換後の値を用いて生成し、生成した位置情報が評価対象についてのMCIの状態を反映したものであると決定してもよい。なお、所定の物差しとは、MCIの状態を評価するためのものであり、例えば、目盛りが示された物差しであって、「式の値又は変換後の値の取り得る範囲、又は、当該範囲の一部分」における上限値と下限値に対応する目盛りが少なくとも示されたもの、などである。また、所定の目印とは、式の値又は変換後の値に対応するものであり、例えば、丸印又は星印などである。 In addition, the position information regarding the position of the predetermined mark on the predetermined ruler visually shown on the display device such as a monitor or the physical medium such as paper is converted into the value of the formula or the value of the formula when converted. It may be generated using the later values, and it may be determined that the generated position information reflects the state of MCI for the evaluation target. The predetermined ruler is for evaluating the state of MCI, for example, a ruler with a scale, which is "a range in which the value of the formula or the value after conversion can be taken, or the range thereof." At least the scales corresponding to the upper and lower limits in "a part of" are shown. Further, the predetermined mark corresponds to the value of the expression or the value after conversion, and is, for example, a circle mark or a star mark.
 また、評価対象がMCIに罹患している可能性の程度を定性的に評価してもよい。具体的には、「前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値ならびに予め設定された1つまたは複数の閾値」または「前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、当該濃度値が代入される変数を含む式、ならびに予め設定された1つまたは複数の閾値」を用いて、評価対象を、MCIに罹患している可能性の程度を少なくとも考慮して定義された複数の区分のうちのどれか1つに分類してもよい。なお、複数の区分には、MCIに罹患している可能性の程度が高い対象(例えば、MCIに罹患していると見做す対象)を属させるための区分、MCIに罹患している可能性の程度が低い対象(例えば、MCIに罹患していないと見做す対象)を属させるための区分、およびMCIに罹患している可能性の程度が中程度である対象を属させるための区分が含まれていてもよい。また、複数の区分には、MCIに罹患している可能性の程度が高い対象を属させるための区分、および、MCIに罹患している可能性の程度が低い対象を属させるための区分(例えば、健常である可能性が高い対象(例えば健常であると見做す対象)を属させるための区分など)が含まれていてもよい。また、濃度値又は式の値を所定の手法で変換し、変換後の値を用いて評価対象を複数の区分のうちのどれか1つに分類してもよい。 Further, the degree of possibility that the evaluation target has MCI may be qualitatively evaluated. Specifically, "concentration value of at least two amino acids of the five kinds of amino acids and one or more preset threshold values" or "concentration value of at least two amino acids of the five kinds of amino acids". The evaluation target is defined with at least the degree of likelihood of suffering from MCI, using an expression containing variables to which the concentration value is assigned, as well as one or more preset thresholds. It may be classified into any one of a plurality of categories. In addition, it is possible that a plurality of categories are affected by MCI, which is a category for assigning a subject having a high possibility of suffering from MCI (for example, a subject considered to be suffering from MCI). Classification to belong to subjects with a low degree of sex (eg, subjects considered not to have MCI), and to belong to subjects with a moderate degree of likelihood of having MCI. The division may be included. In addition, the multiple categories include a category for belonging a subject having a high possibility of having MCI and a category for belonging a subject having a low possibility of having MCI (a category for belonging to a subject having a low possibility of having MCI). For example, it may include a category for assigning an object that is likely to be healthy (for example, an object that is considered to be healthy). Further, the concentration value or the value of the formula may be converted by a predetermined method, and the evaluation target may be classified into any one of a plurality of categories using the converted value.
 また、評価の際に用いる式について、その形式は特に問わないが、例えば、以下に示す形式のものでもよい。
・最小二乗法に基づく重回帰式、線形判別式、主成分分析、正準判別分析などの線形モデル
・最尤法に基づくロジスティック回帰、Cox回帰などの一般化線形モデル
・一般化線形モデルに加えて個体間差、施設間差などの変量効果を考慮した一般化線形混合モデル
・K-means法、階層的クラスタ解析などクラスタ解析で作成された式
・MCMC(マルコフ連鎖モンテカルロ法)、ベイジアンネットワーク、階層ベイズ法などベイズ統計に基づき作成された式
・サポートベクターマシンや決定木などクラス分類により作成された式
・分数式など上記のカテゴリに属さない手法により作成された式
・異なる形式の式の和で示されるような式
The format of the formula used for evaluation is not particularly limited, but may be, for example, the formula shown below.
・ Linear models such as multiple regression equations, linear discrimination equations, principal component analysis, canonical discrimination analysis based on the least squares method ・ Generalized linear models such as logistic regression and Cox regression based on the most probable method ・ In addition to generalized linear models Generalized linear mixed model considering variable effects such as individual differences and facility differences-Formulas created by cluster analysis such as K-means method and hierarchical cluster analysis-MCMC (Markov chain Monte Carlo method), Bayesian network, Formulas created based on Bayesian statistics such as the hierarchical Bayesian method, formulas created by class classification such as support vector machines and decision trees, formulas created by methods that do not belong to the above categories such as fractional formulas, and sums of formulas of different formats. Expression as shown by
 また、評価の際に用いる式を、例えば、本出願人による国際出願である国際公開第2004/052191号に記載の方法又は本出願人による国際出願である国際公開第2006/098192号に記載の方法で作成してもよい。なお、これらの方法で得られた式であれば、入力データとしての血液データにおけるアミノ酸の濃度値の単位に因らず、当該式をMCIの状態を評価するのに好適に用いることができる。 Further, the formula used for evaluation is described in, for example, the method described in International Publication No. 2004/052191, which is an international application by the applicant, or International Publication No. 2006/098192, which is an international application by the applicant. You may create it by the method. The formulas obtained by these methods can be suitably used for evaluating the state of MCI regardless of the unit of the amino acid concentration value in the blood data as input data.
 ここで、重回帰式、多重ロジスティック回帰式、正準判別関数などにおいては各変数に係数及び定数項が付加されるが、この係数及び定数項は、好ましくは実数であれば構わず、より好ましくは、データから前記の各種分類を行うために得られた係数及び定数項の99%信頼区間の範囲に属する値であれば構わず、さらに好ましくは、データから前記の各種分類を行うために得られた係数及び定数項の95%信頼区間の範囲に属する値であれば構わない。また、各係数の値及びその信頼区間は、それを実数倍したものでもよく、定数項の値及びその信頼区間は、それに任意の実定数を加減乗除したものでもよい。ロジスティック回帰式、線形判別式、重回帰式などを評価の際に用いる場合、線形変換(定数の加算、定数倍)及び単調増加(減少)の変換(例えばlogit変換など)は評価性能を変えるものではなく変換前と同等であるので、これらの変換が行われた後のものを用いてもよい。 Here, in the multiple regression equation, the multiple logistic regression equation, the canonical discrimination function, etc., a coefficient and a constant term are added to each variable, but the coefficient and the constant term may be preferably a real number, and more preferably. Is any value that belongs to the range of the 99% confidence interval of the coefficient and the constant term obtained for performing the above-mentioned various classifications from the data, and more preferably, the above-mentioned various classifications are obtained from the data. Any value that belongs to the range of the 95% confidence interval of the given coefficient and constant term may be used. Further, the value of each coefficient and its confidence interval may be multiplied by a real number, and the value of the constant term and its confidence interval may be obtained by adding, subtracting, multiplying or dividing an arbitrary real constant. When logistic regression equations, linear discrimination equations, multiple regression equations, etc. are used for evaluation, linear transformations (addition of constants, multiplication of constants) and transformations of monotonous increase (decrease) (for example, logit transformation) change the evaluation performance. However, since it is the same as before the conversion, the one after these conversions may be used.
 また、分数式とは、当該分数式の分子が変数A,B,C,・・・の和で表わされ及び/又は当該分数式の分母が変数a,b,c,・・・の和で表わされるものである。また、分数式には、このような構成の分数式α,β,γ,・・・の和(例えばα+βのようなもの)も含まれる。また、分数式には、分割された分数式も含まれる。なお、分子や分母に用いられる変数にはそれぞれ適当な係数がついても構わない。また、分子や分母に用いられる変数は重複しても構わない。また、各分数式に適当な係数がついても構わない。また、各変数の係数の値や定数項の値は、実数であれば構わない。ある分数式と、当該分数式において分子の変数と分母の変数が入れ替えられたものとでは、目的変数との相関の正負の符号が概して逆転するものの、それらの相関性は保たれるが故に、評価性能も同等と見做せるので、分数式には、分子の変数と分母の変数が入れ替えられたものも含まれる。 In the fractional expression, the numerator of the fractional expression is represented by the sum of variables A, B, C, ... And / or the denominator of the fractional expression is the sum of variables a, b, c, ... It is represented by. The fractional expression also includes the sum of the fractional expressions α, β, γ, ... (For example, α + β) having such a configuration. The fractional expression also includes a divided fractional expression. The variables used for the numerator and denominator may have appropriate coefficients. Also, the variables used for the numerator and denominator may be duplicated. Further, an appropriate coefficient may be attached to each minute formula. Further, the coefficient value of each variable and the value of the constant term may be real numbers. A certain fractional expression and the one in which the variable of the molecule and the variable of the denominator are exchanged in the fractional expression generally reverse the positive and negative signs of the correlation with the objective variable, but the correlation between them is maintained. Since the evaluation performance can be regarded as equivalent, the fractional expression includes the variable of the molecule and the variable of the denominator interchanged.
 そして、MCIの状態を評価する際、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値以外に、他の生体情報に関する値(例えば、以下に挙げた値など)をさらに用いても構わない。また、評価の際に用いる式には、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値が代入される変数以外に、他の生体情報に関する値(例えば、以下に挙げた値など)が代入される1つ又は複数の変数がさらに含まれていてもよい。
1.アミノ酸以外の他の血中の代謝物(アミノ酸関連代謝物・糖類・脂質等)、タンパク質、ペプチド、ミネラル、ホルモン等の濃度値
2.総蛋白、トリグリセリド(中性脂肪)、HbA1c、糖化アルブミン、インスリン抵抗性指数、総コレステロール、LDLコレステロール、HDLコレステロール、アミラーゼ、総ビリルビン、クレアチニン、推算糸球体濾過量(eGFR)、尿酸、GOT(AST)、GPT(ALT),GGTP(γ-GTP)、グルコース(血糖値)、CRP(C反応性蛋白)、MCV、MCH,MCHC等の血液検査値
3.超音波エコー、X線、CT、MRI、内視鏡像等の画像情報から得られる値
4.年齢、身長、体重、BMI、腹囲、収縮期血圧、拡張期血圧、性別、喫煙情報、食事情報、飲酒情報、運動情報、ストレス情報、睡眠情報、家族の既往歴情報、疾患歴情報(糖尿病等)等の生体指標に関する値
5.アルツハイマー型認知症のリスク遺伝子(APOEε4アリル等)の保有数等の遺伝子情報から得られる値
Then, when evaluating the state of MCI, in addition to the concentration values of at least two amino acids among the five kinds of amino acids, values related to other biological information (for example, values listed below) may be further used. No. Further, in the formula used at the time of evaluation, in addition to the variable to which the concentration value of at least two amino acids of the above five kinds of amino acids is substituted, the value related to other biological information (for example, the value listed below). May further include one or more variables to which is assigned.
1. 1. Concentration values of blood metabolites (amino acid-related metabolites, sugars, lipids, etc.), proteins, peptides, minerals, hormones, etc. other than amino acids 2. Total protein, triglyceride (neutral fat), HbA1c, glycated albumin, insulin resistance index, total cholesterol, LDL cholesterol, HDL cholesterol, amylases, total bilirubin, creatinine, estimated glomerular filtration rate (eGFR), uric acid, GOT (AST) ), GPT (ALT), GGTP (γ-GTP), glucose (blood glucose level), CRP (C-reactive protein), MCV, MCH, MCHC and other blood test values. 3. Values obtained from image information such as ultrasonic echo, X-ray, CT, MRI, and endoscopic image. Age, height, weight, BMI, abdominal circumference, systolic blood pressure, diastolic blood pressure, gender, smoking information, diet information, drinking information, exercise information, stress information, sleep information, family history information, disease history information (diabetes, etc.) ) And other biomarkers 5. Values obtained from genetic information such as the number of possession of risk genes for Alzheimer's disease (APOEε4 allele, etc.)
[第2実施形態]
[2-1.第2実施形態の概要]
 ここでは、第2実施形態の概要について図2を参照して説明する。図2は第2実施形態の基本原理を示す原理構成図である。なお、本第2実施形態の説明では、上述した第1実施形態と重複する説明を省略する場合がある。特に、ここでは、MCIの状態を評価する際に、式の値又はその変換後の値を用いるケースを一例として記載しているが、例えば、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値又はその変換後の値(例えば濃度偏差値など)を用いてもよい。
[Second Embodiment]
[2-1. Outline of the second embodiment]
Here, the outline of the second embodiment will be described with reference to FIG. FIG. 2 is a principle configuration diagram showing the basic principle of the second embodiment. In the description of the second embodiment, the description overlapping with the above-mentioned first embodiment may be omitted. In particular, here, a case where the value of the formula or the value after conversion thereof is used when evaluating the state of MCI is described as an example, but for example, at least two amino acids among the above five kinds of amino acids are described. A concentration value or a value after conversion thereof (for example, a concentration deviation value) may be used.
 制御部は、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値に関する予め取得した評価対象(例えば動物やヒトなどの個体)の血液データに含まれている当該濃度値、および、当該濃度値が代入される変数を含む予め記憶部に記憶された式を用いて、式の値を算出することで、評価対象についてMCIの状態を評価する(ステップS21)。これにより、MCIの状態を知る上で参考となり得る信頼性の高い情報を提供することができる。 The control unit has the concentration value included in the blood data of the evaluation target (for example, an individual such as an animal or a human) acquired in advance regarding the concentration value of at least two amino acids among the five kinds of amino acids, and the concentration. The state of MCI is evaluated for the evaluation target by calculating the value of the formula using the formula stored in the storage unit in advance including the variable to which the value is assigned (step S21). This makes it possible to provide highly reliable information that can be used as a reference for knowing the state of MCI.
 なお、ステップS21で用いられる式は、以下に説明する式作成処理(工程1~工程4)に基づいて作成されたものでもよい。ここで、式作成処理の概要について説明する。なお、ここで説明する処理はあくまでも一例であり、式の作成方法はこれに限定されない。 The formula used in step S21 may be one created based on the formula creation process (steps 1 to 4) described below. Here, an outline of the expression creation process will be described. The process described here is just an example, and the method of creating an expression is not limited to this.
 まず、制御部は、血液データとMCIの状態を表す指標に関する指標データとを含む予め記憶部に記憶された指標状態情報(欠損値や外れ値などを持つデータが事前に除去されているものでもよい)から所定の式作成手法に基づいて、候補式(例えば、y=a1x1+a2x2+・・・+anxn、y:指標データ、xi:血液データ、ai:定数、i=1,2,・・・,n)を作成する(工程1)。 First, the control unit may have previously removed index status information (data having missing values, outliers, etc.) stored in the storage unit in advance, including blood data and index data relating to an index representing the MCI status. From (good) to a candidate formula (for example, y = a1x1 + a2x2 + ... + anxn, y: index data, xi: blood data, ai: constant, i = 1, 2, ..., N) based on a predetermined formula creation method. ) Is created (step 1).
 なお、工程1において、指標状態情報から、複数の異なる式作成手法(主成分分析や判別分析、サポートベクターマシン、重回帰分析、Cox回帰分析、ロジスティック回帰分析、k-means法、クラスター解析、決定木などの多変量解析に関するものを含む。)を併用して複数の候補式を作成してもよい。具体的には、多数の健常群およびMCI群から得た血液を分析して得た血液データおよび指標データから構成される多変量データである指標状態情報に対して、複数の異なるアルゴリズムを利用して複数群の候補式を同時並行的に作成してもよい。例えば、異なるアルゴリズムを利用して判別分析およびロジスティック回帰分析を同時に行い、2つの異なる候補式を作成してもよい。また、主成分分析を行って作成した候補式を利用して指標状態情報を変換し、変換した指標状態情報に対して判別分析を行うことで候補式を作成してもよい。これにより、最終的に、評価に最適な式を作成することができる。 In step 1, a plurality of different formula creation methods (principal component analysis, discriminant analysis, support vector machine, multiple regression analysis, Cox regression analysis, logistic regression analysis, k-means method, cluster analysis, determination) are performed from the index state information. Multiple candidate formulas may be created in combination with those related to multivariate analysis such as trees. Specifically, a plurality of different algorithms are used for index state information, which is multivariate data composed of blood data and index data obtained by analyzing blood obtained from a large number of healthy groups and MCI groups. You may create multiple groups of candidate expressions in parallel. For example, discriminant analysis and logistic regression analysis may be performed simultaneously using different algorithms to create two different candidate expressions. Further, the candidate formula may be created by converting the index state information using the candidate formula created by performing the principal component analysis and performing the discriminant analysis on the converted index state information. As a result, the optimum formula for evaluation can be finally created.
 ここで、主成分分析を用いて作成した候補式は、全ての血液データの分散を最大にするような各変数を含む一次式である。また、判別分析を用いて作成した候補式は、各群内の分散の和の全ての血液データの分散に対する比を最小にするような各変数を含む高次式(指数や対数を含む)である。また、サポートベクターマシンを用いて作成した候補式は、群間の境界を最大にするような各変数を含む高次式(カーネル関数を含む)である。また、重回帰分析を用いて作成した候補式は、全ての血液データからの距離の和を最小にするような各変数を含む高次式である。また、Cox回帰分析を用いて作成した候補式は、対数ハザード比を含む線形モデルで、そのモデルの尤度を最大とするような各変数とその係数を含む1次式であるである。また、ロジスティック回帰分析を用いて作成した候補式は、確率の対数オッズを表す線形モデルであり、その確率の尤度を最大にするような各変数を含む一次式である。また、k-means法とは、各血液データのk個近傍を探索し、近傍点の属する群の中で一番多いものをそのデータの所属群と定義し、入力された血液データの属する群と定義された群とが最も合致するような変数を選択する手法である。また、クラスター解析とは、全ての血液データの中で最も近い距離にある点同士をクラスタリング(群化)する手法である。また、決定木とは、変数に序列をつけて、序列が上位である変数の取りうるパターンから血液データの群を予測する手法である。 Here, the candidate formula created using the principal component analysis is a linear formula including each variable that maximizes the variance of all blood data. In addition, the candidate formula created using discriminant analysis is a high-order formula (including exponent and logarithm) containing each variable that minimizes the ratio of the sum of the variances within each group to the variance of all blood data. be. In addition, the candidate expression created using the support vector machine is a high-order expression (including the kernel function) including each variable that maximizes the boundary between the groups. Further, the candidate formula created by using the multiple regression analysis is a high-order formula including each variable that minimizes the sum of the distances from all the blood data. Further, the candidate expression created by using Cox regression analysis is a linear model including a logarithmic hazard ratio, and is a linear expression including each variable and its coefficient that maximizes the likelihood of the model. The candidate expression created by using logistic regression analysis is a linear model representing the logarithmic odds of the probability, and is a linear expression including each variable that maximizes the likelihood of the probability. In the k-means method, k neighborhoods of each blood data are searched, the group to which the nearest points belong is defined as the group to which the data belongs, and the group to which the input blood data belongs. It is a method to select the variable that best matches the group defined as. In addition, cluster analysis is a method of clustering (grouping) points that are closest to each other in all blood data. The decision tree is a method of ordering variables and predicting a group of blood data from possible patterns of variables whose rank is higher.
 式作成処理の説明に戻り、制御部は、工程1で作成した候補式を、所定の検証手法に基づいて検証(相互検証)する(工程2)。候補式の検証は、工程1で作成した各候補式に対して行う。なお、工程2において、ブートストラップ法やホールドアウト法、N-フォールド法、リーブワンアウト法などのうち少なくとも1つに基づいて、候補式の判別率や感度、特異度、情報量基準、ROC_AUC(受信者特性曲線の曲線下面積)などのうち少なくとも1つに関して検証してもよい。これにより、指標状態情報や評価条件を考慮した予測性または頑健性の高い候補式を作成することができる。 Returning to the explanation of the formula creation process, the control unit verifies (mutually verifies) the candidate formula created in step 1 based on a predetermined verification method (step 2). The verification of the candidate formula is performed for each candidate formula created in step 1. In step 2, the discrimination rate, sensitivity, specificity, information criterion, ROC_AUC (ROC_AUC) of the candidate formula are based on at least one of the bootstrap method, the holdout method, the N-fold method, the leave one-out method, and the like. It may be verified with respect to at least one of (the area under the curve of the receiver characteristic curve) and the like. This makes it possible to create a candidate formula with high predictability or robustness in consideration of index state information and evaluation conditions.
 ここで、判別率とは、本実施形態にかかる評価手法で、真の状態が陰性である評価対象(例えば、MCIに罹患していない評価対象など)を正しく陰性と評価し、真の状態が陽性である評価対象(例えば、MCIに罹患している評価対象など)を正しく陽性と評価している割合である。また、感度とは、本実施形態にかかる評価手法で、真の状態が陽性である評価対象を正しく陽性と評価している割合である。また、特異度とは、本実施形態にかかる評価手法で、真の状態が陰性である評価対象を正しく陰性と評価している割合である。また、赤池情報量規準とは、回帰分析などの場合に、観測データが統計モデルにどの程度一致するかを表す基準であり、「-2×(統計モデルの最大対数尤度)+2×(統計モデルの自由パラメータ数)」で定義される値が最小となるモデルを最もよいと判断する。また、ROC_AUCは、2次元座標上に(x,y)=(1-特異度,感度)をプロットして作成される曲線である受信者特性曲線(ROC)の曲線下面積として定義され、ROC_AUCの値は完全な判別では1となり、この値が1に近いほど判別性が高いことを示す。また、予測性とは、候補式の検証を繰り返すことで得られた判別率や感度、特異性を平均したものである。また、頑健性とは、候補式の検証を繰り返すことで得られた判別率や感度、特異性の分散である。 Here, the discrimination rate is an evaluation method according to the present embodiment, in which an evaluation target whose true state is negative (for example, an evaluation target not suffering from MCI) is correctly evaluated as negative, and the true state is determined. It is the ratio that a positive evaluation target (for example, an evaluation target suffering from MCI) is correctly evaluated as positive. Further, the sensitivity is the ratio at which the evaluation target whose true state is positive is correctly evaluated as positive in the evaluation method according to the present embodiment. Further, the specificity is the ratio in which the evaluation target whose true state is negative is correctly evaluated as negative in the evaluation method according to the present embodiment. The Akaike Information Criterion is a standard that indicates how well the observed data matches the statistical model in the case of regression analysis, etc., and is "-2 x (maximum log-likelihood of the statistical model) + 2 x (statistics). The model with the smallest value defined in "Number of free parameters of the model)" is judged to be the best. Further, ROC_AUC is defined as the area under the curve of the receiver characteristic curve (ROC), which is a curve created by plotting (x, y) = (1-specificity, sensitivity) on two-dimensional coordinates, and is defined as ROC_AUC. The value of is 1 in the complete discrimination, and the closer this value is to 1, the higher the discrimination. Further, the predictability is an average of the discrimination rate, sensitivity, and specificity obtained by repeating the verification of the candidate formula. Robustness is a variance of discrimination rate, sensitivity, and specificity obtained by repeating the verification of candidate expressions.
 式作成処理の説明に戻り、制御部は、所定の変数選択手法に基づいて候補式の変数を選択することで、候補式を作成する際に用いる指標状態情報に含まれる血液データの組み合わせを選択する(工程3)。なお、工程3において、変数の選択は、工程1で作成した各候補式に対して行ってもよい。これにより、候補式の変数を適切に選択することができる。そして、工程3で選択した血液データを含む指標状態情報を用いて再び工程1を実行する。また、工程3において、工程2での検証結果からステップワイズ法、ベストパス法、近傍探索法、遺伝的アルゴリズムのうち少なくとも1つに基づいて候補式の変数を選択してもよい。なお、ベストパス法とは、候補式に含まれる変数を1つずつ順次減らしていき、候補式が与える評価指標を最適化することで変数を選択する方法である。 Returning to the explanation of the expression creation process, the control unit selects the combination of blood data included in the index state information used when creating the candidate expression by selecting the variable of the candidate expression based on the predetermined variable selection method. (Step 3). In step 3, the variable may be selected for each candidate formula created in step 1. This makes it possible to appropriately select the variables of the candidate expression. Then, step 1 is executed again using the index state information including the blood data selected in step 3. Further, in step 3, a variable of the candidate expression may be selected based on at least one of the stepwise method, the best path method, the neighborhood search method, and the genetic algorithm from the verification result in step 2. The best path method is a method of selecting variables by sequentially reducing the variables included in the candidate expression one by one and optimizing the evaluation index given by the candidate expression.
 式作成処理の説明に戻り、制御部は、上述した工程1、工程2および工程3を繰り返し実行し、これにより蓄積した検証結果に基づいて、複数の候補式の中から評価の際に用いる候補式を選出することで、評価の際に用いる式を作成する(工程4)。なお、候補式の選出には、例えば、同じ式作成手法で作成した候補式の中から最適なものを選出する場合と、すべての候補式の中から最適なものを選出する場合とがある。 Returning to the explanation of the formula creation process, the control unit repeatedly executes the above-mentioned steps 1, 2 and 3 and, based on the verification results accumulated by this, is a candidate to be used for evaluation from among a plurality of candidate formulas. By selecting the formula, the formula used for the evaluation is created (step 4). In addition, in the selection of the candidate formula, for example, there are a case where the optimum one is selected from the candidate formulas created by the same formula creation method and a case where the optimum one is selected from all the candidate formulas.
 以上、説明したように、式作成処理では、指標状態情報に基づいて、候補式の作成、候補式の検証および候補式の変数の選択に関する処理を一連の流れで体系化(システム化)して実行することにより、MCIの評価に最適な式を作成することができる。換言すると、式作成処理では、19種類のアミノ酸(Ala、Arg、Asn、Cit、Gln、Gly、His、Ile、Leu、Lys、Met、Orn、Phe、Pro、Ser、Thr、Trp、Tyr、Val)の濃度値のうちの少なくとも1つを多変量の統計解析に用い、最適でロバストな変数の組を選択するために変数選択法とクロスバリデーションとを組み合わせて、評価性能の高い式を抽出する。 As described above, in the expression creation process, the process related to the creation of the candidate expression, the verification of the candidate expression, and the selection of the variable of the candidate expression is systematized (systematized) in a series of flows based on the index state information. By executing this, the optimum formula for evaluating MCI can be created. In other words, in the formula creation process, 19 kinds of amino acids (Ala, Arg, Asn, Cit, Gln, Gly, His, Ile, Leu, Lys, Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val ), At least one of the concentration values is used for multivariate statistical analysis, and variable selection methods and cross-validation are combined to select the optimal and robust set of variables to extract highly evaluated equations. ..
[2-2.第2実施形態の構成]
 ここでは、第2実施形態にかかる評価システム(以下では本システムと記す場合がある。)の構成について、図3から図13を参照して説明する。なお、本システムはあくまでも一例であり、本発明はこれに限定されない。特に、ここでは、MCIの状態を評価する際に、式の値又はその変換後の値を用いるケースを一例として記載しているが、例えば、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値又はその変換後の値(例えば濃度偏差値など)を用いてもよい。
[2-2. Configuration of the second embodiment]
Here, the configuration of the evaluation system (hereinafter, may be referred to as this system) according to the second embodiment will be described with reference to FIGS. 3 to 13. The present system is merely an example, and the present invention is not limited thereto. In particular, here, a case where the value of the formula or the value after conversion thereof is used when evaluating the state of MCI is described as an example, but for example, at least two amino acids among the above five kinds of amino acids are described. A concentration value or a value after conversion thereof (for example, a concentration deviation value) may be used.
 まず、本システムの全体構成について図3および図4を参照して説明する。図3は本システムの全体構成の一例を示す図である。また、図4は本システムの全体構成の他の一例を示す図である。本システムは、図3に示すように、評価対象である個体についてMCIの状態を評価する評価装置100と、血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値に関する個体の血液データを提供するクライアント装置200(本発明の端末装置に相当)とを、ネットワーク300を介して通信可能に接続して構成されている。 First, the overall configuration of this system will be described with reference to FIGS. 3 and 4. FIG. 3 is a diagram showing an example of the overall configuration of this system. Further, FIG. 4 is a diagram showing another example of the overall configuration of this system. As shown in FIG. 3, this system has an evaluation device 100 for evaluating the state of MCI for an individual to be evaluated, and the blood of an individual having a concentration value of at least two of the five kinds of amino acids in the blood. It is configured by connecting a client device 200 (corresponding to the terminal device of the present invention) that provides data so as to be communicable via a network 300.
 なお、本システムにおいて、評価に用いられるデータの提供元となるクライアント装置200と評価結果の提供先となるクライアント装置200は別々のものであってもよい。本システムは、図4に示すように、評価装置100やクライアント装置200の他に、評価装置100で式を作成する際に用いる指標状態情報や、評価の際に用いる式などを格納したデータベース装置400を、ネットワーク300を介して通信可能に接続して構成されてもよい。これにより、ネットワーク300を介して、評価装置100からクライアント装置200やデータベース装置400へ、あるいはクライアント装置200やデータベース装置400から評価装置100へ、MCIの状態を知る上で参考となる情報などが提供される。ここで、MCIの状態を知る上で参考となる情報とは、例えば、ヒトを含む生物のMCIの状態に関する特定の項目について測定した値に関する情報などである。また、MCIの状態を知る上で参考となる情報は、評価装置100やクライアント装置200や他の装置(例えば各種の計測装置等)で生成され、主にデータベース装置400に蓄積される。 In this system, the client device 200 that is the source of the data used for the evaluation and the client device 200 that is the destination of the evaluation result may be different. As shown in FIG. 4, this system is a database device that stores index state information used when creating an expression in the evaluation device 100, an expression used in the evaluation, and the like, in addition to the evaluation device 100 and the client device 200. The 400 may be connected and configured so as to be communicable via the network 300. As a result, information that can be used as a reference for knowing the state of MCI is provided from the evaluation device 100 to the client device 200 or the database device 400, or from the client device 200 or the database device 400 to the evaluation device 100 via the network 300. Will be done. Here, the information that can be used as a reference for knowing the state of MCI is, for example, information about values measured for a specific item regarding the state of MCI of an organism including humans. In addition, information that can be used as a reference for knowing the state of the MCI is generated by the evaluation device 100, the client device 200, and other devices (for example, various measuring devices), and is mainly stored in the database device 400.
 つぎに、本システムの評価装置100の構成について図5から図11を参照して説明する。図5は、本システムの評価装置100の構成の一例を示すブロック図であり、該構成のうち本発明に関係する部分のみを概念的に示している。 Next, the configuration of the evaluation device 100 of this system will be described with reference to FIGS. 5 to 11. FIG. 5 is a block diagram showing an example of the configuration of the evaluation device 100 of the present system, and conceptually shows only the portion of the configuration related to the present invention.
 評価装置100は、当該評価装置を統括的に制御するCPU(Central Processing Unit)等の制御部102と、ルータ等の通信装置および専用線等の有線または無線の通信回線を介して当該評価装置をネットワーク300に通信可能に接続する通信インターフェース部104と、各種のデータベースやテーブルやファイルなどを格納する記憶部106と、入力装置112や出力装置114に接続する入出力インターフェース部108と、で構成されており、これら各部は任意の通信路を介して通信可能に接続されている。ここで、評価装置100は、各種の分析装置(例えばアミノ酸分析装置等)と同一筐体で構成されてもよい。例えば、血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値を算出(測定)し、算出した値を出力(印刷やモニタ表示など)する構成(ハードウェアおよびソフトウェア)を備えた小型分析装置において、後述する評価部102dをさらに備え、当該評価部102dで得られた結果を前記構成を用いて出力すること、を特徴とするものでもよい。 The evaluation device 100 controls the evaluation device via a control unit 102 such as a CPU (Central Processing Unit) that collectively controls the evaluation device, a communication device such as a router, and a wired or wireless communication line such as a dedicated line. It is composed of a communication interface unit 104 that is communicably connected to the network 300, a storage unit 106 that stores various databases, tables, files, and the like, and an input / output interface unit 108 that is connected to the input device 112 and the output device 114. These parts are connected so as to be communicable via an arbitrary communication path. Here, the evaluation device 100 may be configured in the same housing as various analyzers (for example, amino acid analyzers and the like). For example, it is provided with a configuration (hardware and software) that calculates (measures) the concentration values of at least two of the five types of amino acids in blood and outputs the calculated values (printing, monitor display, etc.). The small-sized analyzer may further include an evaluation unit 102d, which will be described later, and output the results obtained by the evaluation unit 102d using the above configuration.
 通信インターフェース部104は、評価装置100とネットワーク300(またはルータ等の通信装置)との間における通信を媒介する。すなわち、通信インターフェース部104は、他の端末と通信回線を介してデータを通信する機能を有する。 The communication interface unit 104 mediates communication between the evaluation device 100 and the network 300 (or a communication device such as a router). That is, the communication interface unit 104 has a function of communicating data with another terminal via a communication line.
 入出力インターフェース部108は、入力装置112や出力装置114に接続する。ここで、出力装置114には、モニタ(家庭用テレビを含む)の他、スピーカやプリンタを用いることができる(なお、以下では、出力装置114をモニタ114として記載する場合がある。)。入力装置112には、キーボードやマウスやマイクの他、マウスと協働してポインティングデバイス機能を実現するモニタを用いることができる。 The input / output interface unit 108 is connected to the input device 112 and the output device 114. Here, as the output device 114, a speaker or a printer can be used in addition to a monitor (including a home television) (in the following, the output device 114 may be described as a monitor 114). In addition to the keyboard, mouse, and microphone, the input device 112 can use a monitor that realizes a pointing device function in cooperation with the mouse.
 記憶部106は、ストレージ手段であり、例えば、RAM(Random Access Memory)・ROM(Read Only Memory)等のメモリ装置や、ハードディスクのような固定ディスク装置、フレキシブルディスク、光ディスク等を用いることができる。記憶部106には、OS(Operating System)と協働してCPUに命令を与え各種処理を行うためのコンピュータプログラムが記録されている。記憶部106は、図示の如く、血液データファイル106aと、指標状態情報ファイル106bと、指定指標状態情報ファイル106cと、式関連情報データベース106dと、評価結果ファイル106eと、を格納する。 The storage unit 106 is a storage means, and for example, a memory device such as a RAM (Random Access Memory) / ROM (Read Only Memory), a fixed disk device such as a hard disk, a flexible disk, an optical disk, or the like can be used. A computer program for giving instructions to the CPU and performing various processes in cooperation with the OS (Operating System) is recorded in the storage unit 106. As shown in the figure, the storage unit 106 stores a blood data file 106a, an index state information file 106b, a designated index state information file 106c, an expression-related information database 106d, and an evaluation result file 106e.
 血液データファイル106aは、血液中の前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値に関する血液データを格納する。図6は、血液データファイル106aに格納される情報の一例を示す図である。血液データファイル106aに格納される情報は、図6に示すように、評価対象である個体(サンプル)を一意に識別するための個体番号と、血液データとを相互に関連付けて構成されている。ここで、図6では、血液データを数値、すなわち連続尺度として扱っているが、血液データは名義尺度や順序尺度でもよい。なお、名義尺度や順序尺度の場合は、それぞれの状態に対して任意の数値を与えることで解析してもよい。また、血液データに、他の生体情報に関する値(上記参照)を組み合わせてもよい。 The blood data file 106a stores blood data relating to the concentration values of at least two of the five types of amino acids in the blood. FIG. 6 is a diagram showing an example of information stored in the blood data file 106a. As shown in FIG. 6, the information stored in the blood data file 106a is configured by correlating the individual number for uniquely identifying the individual (sample) to be evaluated and the blood data. Here, in FIG. 6, the blood data is treated as a numerical value, that is, a continuous scale, but the blood data may be a nominal scale or an ordinal scale. In the case of a nominal scale or an ordinal scale, analysis may be performed by giving an arbitrary numerical value to each state. Further, the blood data may be combined with values related to other biological information (see above).
 図5に戻り、指標状態情報ファイル106bは、式を作成する際に用いる指標状態情報を格納する。図7は、指標状態情報ファイル106bに格納される情報の一例を示す図である。指標状態情報ファイル106bに格納される情報は、図7に示すように、個体番号と、MCIの状態を表す指標(指標T1、指標T2、指標T3・・・)に関する指標データ(T)と、血液データと、を相互に関連付けて構成されている。ここで、図7では、指標データおよび血液データを数値(すなわち連続尺度)として扱っているが、指標データおよび血液データは名義尺度や順序尺度でもよい。なお、名義尺度や順序尺度の場合は、それぞれの状態に対して任意の数値を与えることで解析してもよい。また、指標データは、MCIの状態のマーカーとなる既知の指標などであり、数値データを用いてもよい。 Returning to FIG. 5, the index state information file 106b stores the index state information used when creating the expression. FIG. 7 is a diagram showing an example of information stored in the index state information file 106b. As shown in FIG. 7, the information stored in the index state information file 106b includes an individual number, index data (T) relating to an index (index T1, index T2, index T3 ...) Representing the state of MCI, and index data (T). It is configured to correlate blood data with each other. Here, in FIG. 7, the index data and the blood data are treated as numerical values (that is, continuous scales), but the index data and the blood data may be a nominal scale or an ordinal scale. In the case of a nominal scale or an ordinal scale, analysis may be performed by giving an arbitrary numerical value to each state. Further, the index data is a known index or the like that serves as a marker of the state of MCI, and numerical data may be used.
 図5に戻り、指定指標状態情報ファイル106cは、後述する指定部102bで指定した指標状態情報を格納する。図8は、指定指標状態情報ファイル106cに格納される情報の一例を示す図である。指定指標状態情報ファイル106cに格納される情報は、図8に示すように、個体番号と、指定した指標データと、指定した血液データと、を相互に関連付けて構成されている。 Returning to FIG. 5, the designated index status information file 106c stores the index status information designated by the designated unit 102b, which will be described later. FIG. 8 is a diagram showing an example of information stored in the designated index state information file 106c. As shown in FIG. 8, the information stored in the designated index state information file 106c is configured by correlating the individual number, the designated index data, and the designated blood data with each other.
 図5に戻り、式関連情報データベース106dは、後述する式作成部102cで作成した式を格納する式ファイル106d1で構成される。式ファイル106d1は、評価の際に用いる式を格納する。図9は、式ファイル106d1に格納される情報の一例を示す図である。式ファイル106d1に格納される情報は、図9に示すように、ランクと、式(図9では、Fp(Cit,・・・)やFp(Cit,Lys,Ser)、Fk(Cit,Lys,Ser,・・・)など)と、各式作成手法に対応する閾値と、各式の検証結果(例えば各式の値)と、を相互に関連付けて構成されている。 Returning to FIG. 5, the formula-related information database 106d is composed of a formula file 106d1 that stores the formula created by the formula creation unit 102c described later. The expression file 106d1 stores the expression used at the time of evaluation. FIG. 9 is a diagram showing an example of information stored in the formula file 106d1. As shown in FIG. 9, the information stored in the expression file 106d1 includes a rank, an expression (in FIG. 9, Fp (Cit, ...), Fp (Cit, Lys, Ser), Fk (Cit, Lys,). (Ser, ...), Etc.), the threshold value corresponding to each formula creation method, and the verification result of each formula (for example, the value of each formula) are configured in association with each other.
 図5に戻り、評価結果ファイル106eは、後述する評価部102dで得られた評価結果を格納する。図10は、評価結果ファイル106eに格納される情報の一例を示す図である。評価結果ファイル106eに格納される情報は、評価対象である個体(サンプル)を一意に識別するための個体番号と、予め取得した個体の血液データと、MCIの状態に関する評価結果(例えば、後述する算出部102d1で算出した式の値、後述する変換部102d2で式の値を変換した後の値、後述する生成部102d3で生成した位置情報、又は、後述する分類部102d4で得られた分類結果、など)と、を相互に関連付けて構成されている。 Returning to FIG. 5, the evaluation result file 106e stores the evaluation results obtained by the evaluation unit 102d, which will be described later. FIG. 10 is a diagram showing an example of information stored in the evaluation result file 106e. The information stored in the evaluation result file 106e includes an individual number for uniquely identifying an individual (sample) to be evaluated, blood data of an individual acquired in advance, and an evaluation result regarding the state of MCI (for example, which will be described later). The value of the formula calculated by the calculation unit 102d1, the value after converting the value of the formula by the conversion unit 102d2 described later, the position information generated by the generation unit 102d3 described later, or the classification result obtained by the classification unit 102d4 described later. , Etc.) and are configured in association with each other.
 図5に戻り、制御部102は、OS等の制御プログラム・各種の処理手順等を規定したプログラム・所要データなどを格納するための内部メモリを有し、これらのプログラムに基づいて種々の情報処理を実行する。制御部102は、図示の如く、大別して、取得部102aと指定部102bと式作成部102cと評価部102dと結果出力部102eと送信部102fとを備えている。制御部102は、データベース装置400から送信された指標状態情報やクライアント装置200から送信された血液データに対して、欠損値のあるデータの除去・外れ値の多いデータの除去・欠損値のあるデータの多い変数の除去などのデータ処理も行う。 Returning to FIG. 5, the control unit 102 has an internal memory for storing a control program such as an OS, a program defining various processing procedures, required data, and the like, and various information processing is performed based on these programs. To execute. As shown in the figure, the control unit 102 is roughly divided into an acquisition unit 102a, a designation unit 102b, an expression creation unit 102c, an evaluation unit 102d, a result output unit 102e, and a transmission unit 102f. The control unit 102 removes data having missing values, removes data having many outliers, and data having missing values with respect to the index state information transmitted from the database device 400 and the blood data transmitted from the client device 200. It also performs data processing such as removal of variables with many.
 取得部102aは、情報(具体的には、血液データや指標状態情報、式など)を取得する。例えば、取得部102aは、クライアント装置200やデータベース装置400から送信された情報(具体的には、血液データや指標状態情報、式など)を、ネットワーク300を介して受信することで、情報の取得を行ってもよい。なお、取得部102aは、評価結果の送信先のクライアント装置200とは異なるクライアント装置200から送信された評価に用いられるデータを受信してもよい。また、例えば、記録媒体に記録されている情報の読み出しを行うための機構(ハードウェアおよびソフトウェアを含む)を評価装置100が備える場合、取得部102aは、記録媒体に記録されている情報(具体的には、血液データや指標状態情報、式など)を当該機構を介して読み出すことで、情報の取得を行ってもよい。指定部102bは、式を作成するにあたり対象とする指標データおよび血液データを指定する。 The acquisition unit 102a acquires information (specifically, blood data, index status information, formula, etc.). For example, the acquisition unit 102a acquires information by receiving information (specifically, blood data, index state information, formula, etc.) transmitted from the client device 200 or the database device 400 via the network 300. May be done. The acquisition unit 102a may receive data used for evaluation transmitted from a client device 200 different from the client device 200 to which the evaluation result is transmitted. Further, for example, when the evaluation device 100 includes a mechanism (including hardware and software) for reading out the information recorded on the recording medium, the acquisition unit 102a may use the information recorded on the recording medium (specifically, the information on the recording medium). Specifically, information may be acquired by reading out blood data, index state information, formulas, etc.) via the mechanism. The designation unit 102b designates index data and blood data to be targeted in creating the formula.
 式作成部102cは、取得部102aで取得した指標状態情報や指定部102bで指定した指標状態情報に基づいて式を作成する。なお、式が予め記憶部106の所定の記憶領域に格納されている場合には、式作成部102cは、記憶部106から所望の式を選択することで、式を作成してもよい。また、式作成部102cは、式を予め格納した他のコンピュータ装置(例えばデータベース装置400)から所望の式を選択しダウンロードすることで、式を作成してもよい。 The formula creation unit 102c creates a formula based on the index status information acquired by the acquisition unit 102a and the index status information designated by the designation unit 102b. When the expression is stored in a predetermined storage area of the storage unit 106 in advance, the expression creating unit 102c may create the expression by selecting a desired expression from the storage unit 106. Further, the formula creation unit 102c may create a formula by selecting and downloading a desired formula from another computer device (for example, a database device 400) in which the formula is stored in advance.
 評価部102dは、事前に得られた式(例えば、式作成部102cで作成した式、又は、取得部102aで取得した式など)、及び、取得部102aで取得した個体の血液データに含まれる前記少なくとも1つの値を用いて、式の値を算出することで、個体についてMCIの状態を評価する。なお、評価部102dは、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値又は当該濃度値の変換後の値(例えば濃度偏差値)を用いて、個体についてMCIの状態を評価してもよい。 The evaluation unit 102d is included in the formula obtained in advance (for example, the formula created by the formula creation unit 102c or the formula acquired by the acquisition unit 102a) and the blood data of the individual acquired by the acquisition unit 102a. The state of MCI is evaluated for an individual by calculating the value of the equation using at least one of the above values. In addition, the evaluation unit 102d evaluates the state of MCI for an individual using the concentration value of at least two amino acids among the five kinds of amino acids or the value after conversion of the concentration value (for example, the concentration deviation value). May be good.
 ここで、評価部102dの構成について図11を参照して説明する。図11は、評価部102dの構成を示すブロック図であり、該構成のうち本発明に関係する部分のみを概念的に示している。評価部102dは、算出部102d1と、変換部102d2と、生成部102d3と、分類部102d4と、をさらに備えている。 Here, the configuration of the evaluation unit 102d will be described with reference to FIG. FIG. 11 is a block diagram showing the configuration of the evaluation unit 102d, and conceptually shows only the portion of the configuration related to the present invention. The evaluation unit 102d further includes a calculation unit 102d1, a conversion unit 102d2, a generation unit 102d3, and a classification unit 102d4.
 算出部102d1は、前記5種類のアミノ酸のうちの少なくとも2つのアミノ酸の濃度値、および、当該濃度値が代入される変数を少なくとも含む式を用いて、式の値を算出する。なお、評価部102dは、算出部102d1で算出した式の値を評価結果として評価結果ファイル106eの所定の記憶領域に格納してもよい。 The calculation unit 102d1 calculates the value of the formula by using the concentration value of at least two amino acids among the five kinds of amino acids and the formula including at least the variable to which the concentration value is assigned. The evaluation unit 102d may store the value of the formula calculated by the calculation unit 102d1 as an evaluation result in a predetermined storage area of the evaluation result file 106e.
 変換部102d2は、算出部102d1で算出した式の値を例えば上述した変換手法などで変換する。なお、評価部102dは、変換部102d2で変換した後の値を評価結果として評価結果ファイル106eの所定の記憶領域に格納してもよい。また、変換部102d2は、血液データに含まれている濃度値を、例えば上述した変換手法などで変換してもよい。 The conversion unit 102d2 converts the value of the formula calculated by the calculation unit 102d1 by, for example, the above-mentioned conversion method. The evaluation unit 102d may store the value converted by the conversion unit 102d2 as an evaluation result in a predetermined storage area of the evaluation result file 106e. Further, the conversion unit 102d2 may convert the concentration value contained in the blood data by, for example, the above-mentioned conversion method.
 生成部102d3は、モニタ等の表示装置又は紙等の物理媒体に視認可能に示される所定の物差し上における所定の目印の位置に関する位置情報を、算出部102d1で算出した式の値又は変換部102d2で変換した後の値(濃度値又は当該濃度値の変換後の値でもよい)を用いて生成する。なお、評価部102dは、生成部102d3で生成した位置情報を評価結果として評価結果ファイル106eの所定の記憶領域に格納してもよい。 The generation unit 102d3 uses the value of the formula calculated by the calculation unit 102d1 or the conversion unit 102d2 to obtain position information regarding the position of a predetermined mark on a predetermined ruler visually shown on a display device such as a monitor or a physical medium such as paper. It is generated using the value after conversion in (the concentration value or the value after conversion of the concentration value may be used). The evaluation unit 102d may store the position information generated by the generation unit 102d3 as an evaluation result in a predetermined storage area of the evaluation result file 106e.
 分類部102d4は、算出部102d1で算出した式の値又は変換部102d2で変換した後の値(濃度値又は当該濃度値の変換後の値でもよい)を用いて、個体を、MCIに罹患している可能性の程度を少なくとも考慮して定義された複数の区分のうちのどれか1つに分類する。 The classification unit 102d4 infects an individual with MCI using the value of the formula calculated by the calculation unit 102d1 or the value after conversion by the conversion unit 102d2 (may be a concentration value or a value after conversion of the concentration value). Classify into one of a plurality of categories defined with at least the degree of possibility of being present.
 結果出力部102eは、制御部102の各処理部での処理結果(評価部102dで得られた評価結果を含む)等を出力装置114に出力する。 The result output unit 102e outputs the processing results (including the evaluation results obtained by the evaluation unit 102d) in each processing unit of the control unit 102 to the output device 114.
 送信部102fは、個体の血液データの送信元のクライアント装置200に対して評価結果を送信したり、データベース装置400に対して、評価装置100で作成した式や評価結果を送信したりする。なお、送信部102fは、評価に用いられるデータの送信元のクライアント装置200とは異なるクライアント装置200に対して評価結果を送信してもよい。 The transmission unit 102f transmits the evaluation result to the client device 200 that is the source of the blood data of the individual, and transmits the formula and the evaluation result created by the evaluation device 100 to the database device 400. The transmission unit 102f may transmit the evaluation result to the client device 200 different from the client device 200 from which the data used for the evaluation is transmitted.
 つぎに、本システムのクライアント装置200の構成について図12を参照して説明する。図12は、本システムのクライアント装置200の構成の一例を示すブロック図であり、該構成のうち本発明に関係する部分のみを概念的に示している。 Next, the configuration of the client device 200 of this system will be described with reference to FIG. FIG. 12 is a block diagram showing an example of the configuration of the client device 200 of the present system, and conceptually shows only the portion of the configuration related to the present invention.
 クライアント装置200は、制御部210とROM220とHD(Hard Disk)230とRAM240と入力装置250と出力装置260と入出力IF270と通信IF280とで構成されており、これら各部は任意の通信路を介して通信可能に接続されている。クライアント装置200は、プリンタ・モニタ・イメージスキャナ等の周辺装置を必要に応じて接続した情報処理装置(例えば、既知のパーソナルコンピュータ・ワークステーション・家庭用ゲーム装置・インターネットTV・PHS(Personal Handyphone System)端末・携帯端末・移動体通信端末・PDA(Personal Digital Assistant)等の情報処理端末など)を基にしたものであってもよい。 The client device 200 is composed of a control unit 210, a ROM 220, an HD (Hard Disk) 230, a RAM 240, an input device 250, an output device 260, an input / output IF 270, and a communication IF 280, and each of these units is via an arbitrary communication path. Is connected so that communication is possible. The client device 200 is an information processing device (for example, a known personal computer, a workstation, a home-use game device, an Internet TV, a PDS (Personal Handyphone System)) to which peripheral devices such as a printer, a monitor, and an image scanner are connected as needed. It may be based on a terminal, a mobile terminal, a mobile communication terminal, an information processing terminal such as a PDA (Personal Digital Assistant), or the like).
 入力装置250はキーボードやマウスやマイク等である。なお、後述するモニタ261もマウスと協働してポインティングデバイス機能を実現する。出力装置260は、通信IF280を介して受信した情報を出力する出力手段であり、モニタ(家庭用テレビを含む)261およびプリンタ262を含む。この他、出力装置260にスピーカ等を設けてもよい。入出力IF270は入力装置250や出力装置260に接続する。 The input device 250 is a keyboard, mouse, microphone, or the like. The monitor 261 described later also realizes the pointing device function in cooperation with the mouse. The output device 260 is an output means for outputting information received via the communication IF 280, and includes a monitor (including a home television) 261 and a printer 262. In addition, a speaker or the like may be provided in the output device 260. The input / output IF 270 is connected to the input device 250 and the output device 260.
 通信IF280は、クライアント装置200とネットワーク300(またはルータ等の通信装置)とを通信可能に接続する。換言すると、クライアント装置200は、モデムやTA(Terminal Adapter)やルータなどの通信装置および電話回線を介して、または専用線を介してネットワーク300に接続される。これにより、クライアント装置200は、所定の通信規約に従って評価装置100にアクセスすることができる。 The communication IF280 connects the client device 200 and the network 300 (or a communication device such as a router) so as to be communicable. In other words, the client device 200 is connected to the network 300 via a communication device such as a modem, a TA (Terminal Adapter), a router, and a telephone line, or via a dedicated line. As a result, the client device 200 can access the evaluation device 100 according to a predetermined communication standard.
 制御部210は、受信部211および送信部212を備えている。受信部211は、通信IF280を介して、評価装置100から送信された評価結果などの各種情報を受信する。送信部212は、通信IF280を介して、個体の血液データなどの各種情報を評価装置100へ送信する。 The control unit 210 includes a reception unit 211 and a transmission unit 212. The receiving unit 211 receives various information such as the evaluation result transmitted from the evaluation device 100 via the communication IF 280. The transmission unit 212 transmits various information such as blood data of an individual to the evaluation device 100 via the communication IF 280.
 制御部210は、当該制御部で行う処理の全部または任意の一部を、CPUおよび当該CPUにて解釈して実行するプログラムで実現してもよい。ROM220またはHD230には、OSと協働してCPUに命令を与え、各種処理を行うためのコンピュータプログラムが記録されている。当該コンピュータプログラムは、RAM240にロードされることで実行され、CPUと協働して制御部210を構成する。また、当該コンピュータプログラムは、クライアント装置200と任意のネットワークを介して接続されるアプリケーションプログラムサーバに記録されてもよく、クライアント装置200は、必要に応じてその全部または一部をダウンロードしてもよい。また、制御部210で行う処理の全部または任意の一部を、ワイヤードロジック等によるハードウェアで実現してもよい。 The control unit 210 may be realized by a CPU and a program that interprets and executes all or any part of the processing performed by the control unit by the CPU and the CPU. A computer program for giving instructions to the CPU in cooperation with the OS and performing various processes is recorded in the ROM 220 or HD 230. The computer program is executed by being loaded into the RAM 240, and constitutes the control unit 210 in cooperation with the CPU. Further, the computer program may be recorded in an application program server connected to the client device 200 via an arbitrary network, and the client device 200 may download all or a part thereof as needed. .. Further, all or any part of the processing performed by the control unit 210 may be realized by hardware using wired logic or the like.
 ここで、制御部210は、評価装置100に備えられている評価部102dが有する機能と同様の機能を有する評価部210a(算出部210a1、変換部210a2、生成部210a3、及び分類部210a4を含む)を備えていてもよい。そして、制御部210に評価部210aが備えられている場合には、評価部210aは、評価装置100から送信された評価結果に含まれている情報に応じて、変換部210a2で式の値(濃度値でもよい)を変換したり、生成部210a3で式の値又は変換後の値(濃度値又は当該濃度値の変換後の値でもよい)に対応する位置情報を生成したり、分類部210a4で式の値又は変換後の値(濃度値又は当該濃度値の変換後の値でもよい)を用いて個体を複数の区分のうちのどれか1つに分類したりしてもよい。 Here, the control unit 210 includes an evaluation unit 210a (calculation unit 210a1, conversion unit 210a2, generation unit 210a3, and classification unit 210a4) having the same function as that of the evaluation unit 102d provided in the evaluation device 100. ) May be provided. When the control unit 210 is provided with the evaluation unit 210a, the evaluation unit 210a uses the conversion unit 210a2 to obtain the value of the equation according to the information included in the evaluation result transmitted from the evaluation device 100. The concentration value may be converted), the generation unit 210a3 may generate the position information corresponding to the value of the formula or the converted value (the concentration value or the converted value of the concentration value), or the classification unit 210a4. Individuals may be classified into any one of a plurality of categories using the value of the formula or the converted value (which may be the concentration value or the converted value of the concentration value).
 つぎに、本システムのネットワーク300について図3、図4を参照して説明する。ネットワーク300は、評価装置100とクライアント装置200とデータベース装置400とを相互に通信可能に接続する機能を有し、例えばインターネットやイントラネットやLAN(Local Area Network)(有線/無線の双方を含む)等である。なお、ネットワーク300は、VAN(Value-Added Network)や、パソコン通信網や、公衆電話網(アナログ/デジタルの双方を含む)や、専用回線網(アナログ/デジタルの双方を含む)や、CATV(Community Antenna TeleVision)網や、携帯回線交換網または携帯パケット交換網(IMT(International Mobile Telecommunication)2000方式、GSM(登録商標)(Global System for Mobile Communications)方式またはPDC(Personal Digital Cellular)/PDC-P方式等を含む)や、無線呼出網や、Bluetooth(登録商標)等の局所無線網や、PHS網や、衛星通信網(CS(Communication Satellite)、BS(Broadcasting Satellite)またはISDB(Integrated Services Digital Broadcasting)等を含む)等でもよい。 Next, the network 300 of this system will be described with reference to FIGS. 3 and 4. The network 300 has a function of connecting the evaluation device 100, the client device 200, and the database device 400 so as to be communicable with each other. For example, the Internet, an intranet, a LAN (Local Area Network) (including both wired and wireless) and the like. Is. The network 300 includes VAN (Value-Added Network), personal computer communication network, public telephone network (including both analog / digital), dedicated line network (including both analog / digital), and CATV (). Community Antenna TeleVision) network, mobile line exchange network or mobile packet exchange network (IMT (International Mobile Telecommunication) 2000 system, GSM (registered trademark) (Global System for Mobile Communications) system or PDC. (Including methods, etc.), wireless calling networks, local wireless networks such as Bluetooth (registered trademark), PHS networks, satellite communication networks (CS (Communication Satellite), BS (Roadcasting Satellite), or ISDB (Integrated Services Digital Broadcast). ) Etc.) may be used.
 つぎに、本システムのデータベース装置400の構成について図13を参照して説明する。図13は、本システムのデータベース装置400の構成の一例を示すブロック図であり、該構成のうち本発明に関係する部分のみを概念的に示している。 Next, the configuration of the database device 400 of this system will be described with reference to FIG. FIG. 13 is a block diagram showing an example of the configuration of the database device 400 of the present system, and conceptually shows only the portion of the configuration related to the present invention.
 データベース装置400は、評価装置100または当該データベース装置で式を作成する際に用いる指標状態情報や、評価装置100で作成した式、評価装置100での評価結果などを格納する機能を有する。図13に示すように、データベース装置400は、当該データベース装置を統括的に制御するCPU等の制御部402と、ルータ等の通信装置および専用線等の有線または無線の通信回路を介して当該データベース装置をネットワーク300に通信可能に接続する通信インターフェース部404と、各種のデータベースやテーブルやファイル(例えばWebページ用ファイル)などを格納する記憶部406と、入力装置412や出力装置414に接続する入出力インターフェース部408と、で構成されており、これら各部は任意の通信路を介して通信可能に接続されている。 The database device 400 has a function of storing index state information used when creating a formula in the evaluation device 100 or the database device, a formula created in the evaluation device 100, an evaluation result in the evaluation device 100, and the like. As shown in FIG. 13, the database device 400 is connected to the database via a control unit 402 such as a CPU that collectively controls the database device, a communication device such as a router, and a wired or wireless communication circuit such as a dedicated line. A communication interface unit 404 that connects the device to the network 300 so that it can communicate, a storage unit 406 that stores various databases, tables, files (for example, files for Web pages), and an input / output device 412 or an output device 414 that is connected to the input device 412 or the output device 414. It is composed of an output interface unit 408, and each of these units is connected so as to be communicable via an arbitrary communication path.
 記憶部406は、ストレージ手段であり、例えば、RAM・ROM等のメモリ装置や、ハードディスクのような固定ディスク装置や、フレキシブルディスクや、光ディスク等を用いることができる。記憶部406には、各種処理に用いる各種プログラム等を格納する。通信インターフェース部404は、データベース装置400とネットワーク300(またはルータ等の通信装置)との間における通信を媒介する。すなわち、通信インターフェース部404は、他の端末と通信回線を介してデータを通信する機能を有する。入出力インターフェース部408は、入力装置412や出力装置414に接続する。ここで、出力装置414には、モニタ(家庭用テレビを含む)の他、スピーカやプリンタを用いることができる。また、入力装置412には、キーボードやマウスやマイクの他、マウスと協働してポインティングデバイス機能を実現するモニタを用いることができる。 The storage unit 406 is a storage means, and for example, a memory device such as RAM / ROM, a fixed disk device such as a hard disk, a flexible disk, an optical disk, or the like can be used. The storage unit 406 stores various programs and the like used for various processes. The communication interface unit 404 mediates communication between the database device 400 and the network 300 (or a communication device such as a router). That is, the communication interface unit 404 has a function of communicating data with another terminal via a communication line. The input / output interface unit 408 is connected to the input device 412 and the output device 414. Here, as the output device 414, a speaker or a printer can be used in addition to a monitor (including a home television). Further, as the input device 412, a monitor that realizes a pointing device function in cooperation with a mouse can be used in addition to a keyboard, a mouse, and a microphone.
 制御部402は、OS等の制御プログラム・各種の処理手順等を規定したプログラム・所要データなどを格納するための内部メモリを有し、これらのプログラムに基づいて種々の情報処理を実行する。制御部402は、図示の如く、大別して、送信部402aと受信部402bを備えている。送信部402aは、指標状態情報や式などの各種情報を、評価装置100へ送信する。受信部402bは、評価装置100から送信された、式や評価結果などの各種情報を受信する。 The control unit 402 has an internal memory for storing a control program such as an OS, a program that defines various processing procedures, required data, and the like, and executes various information processing based on these programs. As shown in the figure, the control unit 402 is roughly divided into a transmission unit 402a and a reception unit 402b. The transmission unit 402a transmits various information such as index state information and equations to the evaluation device 100. The receiving unit 402b receives various information such as an expression and an evaluation result transmitted from the evaluation device 100.
 なお、本説明では、評価装置100が、血液データの取得から、式の値の算出、個体の区分への分類、そして評価結果の送信までを実行し、クライアント装置200が評価結果の受信を実行するケースを例として挙げたが、クライアント装置200に評価部210aが備えられている場合は、評価装置100は式の値の算出を実行すれば十分であり、例えば式の値の変換、位置情報の生成、及び、個体の区分への分類などは、評価装置100とクライアント装置200とで適宜分担して実行してもよい。
 例えば、クライアント装置200は、評価装置100から式の値を受信した場合には、評価部210aは、変換部210a2で式の値を変換したり、生成部210a3で式の値又は変換後の値に対応する位置情報を生成したり、分類部210a4で式の値又は変換後の値を用いて個体を複数の区分のうちのどれか1つに分類したりしてもよい。
 また、クライアント装置200は、評価装置100から変換後の値を受信した場合には、評価部210aは、生成部210a3で変換後の値に対応する位置情報を生成したり、分類部210a4で変換後の値を用いて個体を複数の区分のうちのどれか1つに分類したりしてもよい。
 また、クライアント装置200は、評価装置100から式の値又は変換後の値と位置情報とを受信した場合には、評価部210aは、分類部210a4で式の値又は変換後の値を用いて個体を複数の区分のうちのどれか1つに分類してもよい。
In this description, the evaluation device 100 executes from acquisition of blood data, calculation of the value of the formula, classification into individual categories, and transmission of the evaluation result, and the client device 200 receives the evaluation result. However, when the client device 200 is provided with the evaluation unit 210a, it is sufficient for the evaluation device 100 to execute the calculation of the value of the expression, for example, the conversion of the value of the expression and the position information. The generation of the data and the classification of the individual into categories may be appropriately shared between the evaluation device 100 and the client device 200.
For example, when the client device 200 receives the value of the expression from the evaluation device 100, the evaluation unit 210a converts the value of the expression by the conversion unit 210a2, or the value of the expression or the value after conversion by the generation unit 210a3. The position information corresponding to the above may be generated, or the individual may be classified into any one of a plurality of categories by using the value of the formula or the value after conversion in the classification unit 210a4.
When the client device 200 receives the converted value from the evaluation device 100, the evaluation unit 210a generates position information corresponding to the converted value by the generation unit 210a3, or the classification unit 210a4 converts the value. Individuals may be classified into any one of a plurality of categories using the later values.
When the client device 200 receives the value of the formula or the converted value and the position information from the evaluation device 100, the evaluation unit 210a uses the value of the formula or the converted value in the classification unit 210a4. Individuals may be classified into any one of a plurality of categories.
[2-3.他の実施形態]
 本発明にかかる評価装置、算出装置、評価方法、算出方法、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置は、上述した第2実施形態以外にも、請求の範囲に記載した技術的思想の範囲内において種々の異なる実施形態にて実施されてよいものである。
[2-3. Other embodiments]
The evaluation device, calculation device, evaluation method, calculation method, evaluation program, calculation program, recording medium, evaluation system, and terminal device according to the present invention are technically described in the scope of claims in addition to the above-mentioned second embodiment. It may be implemented in a variety of different embodiments within the scope of the idea.
 また、第2実施形態において説明した各処理のうち、自動的に行われるものとして説明した処理の全部または一部を手動的に行うこともでき、あるいは、手動的に行われるものとして説明した処理の全部または一部を公知の方法で自動的に行うこともできる。 Further, among the processes described in the second embodiment, all or part of the processes described as being automatically performed can be manually performed, or the processes described as being manually performed. It is also possible to automatically perform all or part of the above by a known method.
 このほか、上記文献中や図面中で示した処理手順、制御手順、具体的名称、各処理の登録データや検索条件等のパラメータを含む情報、画面例、データベース構成については、特記する場合を除いて任意に変更することができる。 In addition, processing procedures, control procedures, specific names, information including parameters such as registration data and search conditions for each processing, screen examples, and database configurations shown in the above documents and drawings are not specified unless otherwise specified. Can be changed arbitrarily.
 また、評価装置100に関して、図示の各構成要素は機能概念的なものであり、必ずしも物理的に図示の如く構成されていることを要しない。 Further, with respect to the evaluation device 100, each component shown in the figure is a functional concept and does not necessarily have to be physically configured as shown in the figure.
 例えば、評価装置100が備える処理機能、特に制御部102にて行われる各処理機能については、その全部または任意の一部を、CPUおよび当該CPUにて解釈実行されるプログラムにて実現してもよく、また、ワイヤードロジックによるハードウェアとして実現してもよい。尚、プログラムは、情報処理装置に本発明にかかる評価方法または算出方法を実行させるためのプログラム化された命令を含む一時的でないコンピュータ読み取り可能な記録媒体に記録されており、必要に応じて評価装置100に機械的に読み取られる。すなわち、ROMまたはHDD(Hard Disk Drive)などの記憶部106などには、OSと協働してCPUに命令を与え、各種処理を行うためのコンピュータプログラムが記録されている。このコンピュータプログラムは、RAMにロードされることによって実行され、CPUと協働して制御部を構成する。 For example, with respect to the processing functions included in the evaluation device 100, particularly each processing function performed by the control unit 102, even if all or any part thereof is realized by the CPU and a program interpreted and executed by the CPU. Well, it may be realized as hardware by wired logic. The program is recorded on a non-temporary computer-readable recording medium containing programmed instructions for causing the information processing apparatus to execute the evaluation method or calculation method according to the present invention, and is evaluated as necessary. It is read mechanically by the device 100. That is, a computer program for giving instructions to the CPU in cooperation with the OS and performing various processes is recorded in a storage unit 106 such as a ROM or an HDD (Hard Disk Drive). This computer program is executed by being loaded into RAM, and cooperates with the CPU to form a control unit.
 また、このコンピュータプログラムは評価装置100に対して任意のネットワークを介して接続されたアプリケーションプログラムサーバに記憶されていてもよく、必要に応じてその全部または一部をダウンロードすることも可能である。 Further, this computer program may be stored in the application program server connected to the evaluation device 100 via an arbitrary network, and it is also possible to download all or part of the computer program as needed.
 また、本発明にかかる評価プログラムまたは算出プログラムを、一時的でないコンピュータ読み取り可能な記録媒体に格納してもよく、また、プログラム製品として構成することもできる。ここで、この「記録媒体」とは、メモリーカード、USB(Universal Serial Bus)メモリ、SD(Secure Digital)カード、フレキシブルディスク、光磁気ディスク、ROM、EPROM(Erasable Programmable Read Only Memory)、EEPROM(Electrically Erasable and Programmable Read Only Memory)(登録商標)、CD-ROM(Compact Disc Read Only Memory)、MO(Magneto-Optical disk)、DVD(Digital Versatile Disk)、および、Blu-ray(登録商標) Disc等の任意の「可搬用の物理媒体」を含むものとする。 Further, the evaluation program or calculation program according to the present invention may be stored in a non-temporary computer-readable recording medium, or may be configured as a program product. Here, the "recording medium" includes a memory card, a USB (Universal Serial Bus) memory, an SD (Secure Digital) card, a flexible disk, a magneto-optical disk, a ROM, an EPROM (Erasable Programle Read Only Memory), and an EEPROM (Epil). Erasable and Program Read Only Memory (registered trademark), CD-ROM (Compact Disk Ready Memory), MO (Magnet-Optical disk), MO (Magnet-Optical disk), DVD (Digital Disk), DVD (Digital Disk) It shall include any "portable physical medium".
 また、「プログラム」とは、任意の言語または記述方法にて記述されたデータ処理方法であり、ソースコードまたはバイナリコード等の形式を問わない。なお、「プログラム」は必ずしも単一的に構成されるものに限られず、複数のモジュールやライブラリとして分散構成されるものや、OSに代表される別個のプログラムと協働してその機能を達成するものをも含む。なお、実施形態に示した各装置において記録媒体を読み取るための具体的な構成および読み取り手順ならびに読み取り後のインストール手順等については、周知の構成や手順を用いることができる。 The "program" is a data processing method described in any language or description method, regardless of the format such as source code or binary code. The "program" is not necessarily limited to a single program, but is distributed as a plurality of modules or libraries, or cooperates with a separate program represented by an OS to achieve its function. Including things. It should be noted that well-known configurations and procedures can be used for the specific configuration and reading procedure for reading the recording medium and the installation procedure after reading in each device shown in the embodiment.
 記憶部106に格納される各種のデータベース等は、RAM、ROM等のメモリ装置、ハードディスク等の固定ディスク装置、フレキシブルディスク、および、光ディスク等のストレージ手段であり、各種処理やウェブサイト提供に用いる各種のプログラム、テーブル、データベース、および、ウェブページ用ファイル等を格納する。 Various databases and the like stored in the storage unit 106 are memory devices such as RAM and ROM, fixed disk devices such as hard disks, flexible disks, and storage means such as optical disks, and are used for various processes and website provision. Stores programs, tables, databases, files for web pages, etc.
 また、評価装置100は、既知のパーソナルコンピュータまたはワークステーション等の情報処理装置として構成してもよく、また、任意の周辺装置が接続された当該情報処理装置として構成してもよい。また、評価装置100は、当該情報処理装置に本発明の評価方法または算出方法を実現させるソフトウェア(プログラムまたはデータ等を含む)を実装することにより実現してもよい。 Further, the evaluation device 100 may be configured as an information processing device such as a known personal computer or workstation, or may be configured as the information processing device to which an arbitrary peripheral device is connected. Further, the evaluation device 100 may be realized by mounting software (including a program or data) that realizes the evaluation method or calculation method of the present invention on the information processing device.
 更に、装置の分散・統合の具体的形態は図示するものに限られず、その全部または一部を、各種の付加等に応じてまたは機能負荷に応じて、任意の単位で機能的または物理的に分散・統合して構成することができる。すなわち、上述した実施形態を任意に組み合わせて実施してもよく、実施形態を選択的に実施してもよい。 Furthermore, the specific form of distribution / integration of the device is not limited to the one shown in the figure, and all or part of the device may be functionally or physically in any unit according to various additions or functional loads. It can be distributed and integrated. That is, the above-described embodiments may be arbitrarily combined and implemented, or the embodiments may be selectively implemented.
 MCIの確定診断が行われた60歳以上のMCI患者(MCI群:120名)、及び、認知機能が健常と考えられる60歳以上の健常高齢者(健常群:120名)の血漿サンプルから、前述のアミノ酸分析法(A)により血中アミノ酸濃度を測定した。 From plasma samples of MCI patients aged 60 years or older (MCI group: 120) who had a definitive diagnosis of MCI, and healthy elderly people aged 60 years or older (healthy group: 120) who are considered to have healthy cognitive function. The blood amino acid concentration was measured by the above-mentioned amino acid analysis method (A).
 SerとTrpの血漿中濃度値(nmol/ml)を用いて、MCI群と健常群を判別する2変数のロジスティック回帰式を求めた。このロジスティック回帰式によるMCI群と健常群の判別能をROC_AUCで評価したところ、0.540を示した。ROC_AUCが0.5を超えることから、このロジスティック回帰式は、MCIの状態の評価において有用なものであると考えられる。 Using the plasma concentration values of Ser and Trp (nmol / ml), a two-variable logistic regression equation for discriminating between the MCI group and the healthy group was obtained. When the ability to discriminate between the MCI group and the healthy group by this logistic regression equation was evaluated by ROC_AUC, it showed 0.540. Since ROC_AUC exceeds 0.5, this logistic regression equation is considered to be useful in assessing the state of MCI.
 実施例1で用いたサンプルデータを用いた。血漿中のアミノ酸濃度値が代入される変数を含む、MCI群と健常群の2群を判別するための多変量判別式(多変量関数)を求めた。 The sample data used in Example 1 was used. A multivariate discriminant (multivariate function) for discriminating between the MCI group and the healthy group, including the variable to which the amino acid concentration value in plasma is substituted, was obtained.
 多変量判別式としてロジスティック回帰式を用いた。ロジスティック回帰式に含める3個の変数の組み合わせを、5種類のアミノ酸(Cit、Lys、Ser、ThrおよびTrp)の血漿中濃度値(nmol/ml)から探索し、MCI群と健常群の判別能が良好なロジスティック回帰式の探索を実施した。 A logistic regression equation was used as a multivariate discriminant. The combination of 3 variables to be included in the logistic regression equation is searched from the plasma concentration values (nmol / ml) of 5 kinds of amino acids (Cit, Lys, Ser, Thr and Trp), and the ability to discriminate between the MCI group and the healthy group. Performed a search for a good logistic regression equation.
 前記5種類のアミノ酸のうちの3つのアミノ酸を変数として必ず含む3変数のロジスティック回帰式の一覧を、以下の表1に示した。これらのロジスティック回帰式は、ROC_AUC値の95%信頼区間(95%CI)の下限が0.5よりも高いことから、前記の評価において有用なものであると考えられる。 Table 1 below shows a list of logistic regression equations for three variables that always include three of the five amino acids as variables. These logistic regression equations are considered useful in the above evaluation because the lower limit of the 95% confidence interval (95% CI) of the ROC_AUC value is higher than 0.5.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
 実施例1で用いたサンプルデータを用いた。血漿中のアミノ酸濃度値が代入される変数を含む、MCI群と健常群との2群を判別するための多変量判別式(多変量関数)を求めた。 The sample data used in Example 1 was used. A multivariate discriminant (multivariate function) for discriminating between the MCI group and the healthy group, which includes a variable to which the amino acid concentration value in plasma is substituted, was obtained.
 多変量判別式としてロジスティック回帰式を用いた。ロジスティック回帰式に含める4個の変数の組み合わせ(前記5種類のアミノ酸のうちの3つのアミノ酸の変数を必須とする)を、19種類のアミノ酸(Ala、Arg、Asn、Cit、Gln、Glu、Gly、His、Ile、Leu、Lys、Met、Phe、Pro、Ser、Thr、Trp、Tyr、Val)の血漿中濃度値から探索し、MCI群と健常群の判別能が良好なロジスティック回帰式の探索を実施した。 A logistic regression equation was used as a multivariate discriminant. The combination of 4 variables included in the logistic regression equation (3 amino acid variables out of the 5 amino acids are required) is combined with 19 amino acids (Ala, Arg, Asn, Cit, Gln, Glu, Gly). , His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val), and search for a logistic regression equation with good discrimination between the MCI group and the healthy group. Was carried out.
 MCI群と健常群のROC_AUC値が表1に示した0.679以上で、変数の個数が4個のロジスティック回帰式の一覧を、以下の表2に示した。これらのロジスティック回帰式は、ROC_AUC値が高く、さらにROC_AUC値の95%CIの下限が0.5よりも高いことから、前記の評価において有用なものであると考えられる。 Table 2 below shows a list of logistic regression equations in which the ROC_AUC values of the MCI group and the healthy group are 0.679 or more and the number of variables is 4 as shown in Table 1. Since these logistic regression equations have a high ROC_AUC value and the lower limit of 95% CI of the ROC_AUC value is higher than 0.5, they are considered to be useful in the above evaluation.
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
 実施例1で用いたサンプルデータを用いた。血漿中のアミノ酸濃度値が代入される変数を含む、MCI群と健常群との2群を判別するための多変量判別式(多変量関数)を求めた。 The sample data used in Example 1 was used. A multivariate discriminant (multivariate function) for discriminating between the MCI group and the healthy group, which includes a variable to which the amino acid concentration value in plasma is substituted, was obtained.
 多変量判別式としてロジスティック回帰式を用いた。ロジスティック回帰式に含める5個の変数の組み合わせ(前記5種類のアミノ酸のうちの3つのアミノ酸を必須とする)を、前記19種類のアミノ酸の血漿中濃度値から探索し、MCI群と健常群の判別能が良好なロジスティック回帰式の探索を実施した。 A logistic regression equation was used as a multivariate discriminant. The combination of 5 variables to be included in the logistic regression equation (three amino acids out of the five amino acids are essential) was searched from the plasma concentration values of the 19 amino acids, and the MCI group and the healthy group were searched. We searched for a logistic regression equation with good discriminant ability.
 上記で得られた981通りのロジスティック回帰式うち、MCI群と健常群のROC_AUC値が0.679以上の270通りの式を、以下の[5変数の式]に示した。これらのロジスティック回帰式は、ROC_AUC値が高く、さらにROC_AUC値の95%CIの下限が0.5よりも高いことから、前記の評価において有用なものであると考えられる。なお、以下の[5変数の式]には、式に含まれる5つのアミノ酸に対応する、ROC_AUC値と、ROC_AUC値の95%CIの下限の値と、ROC_AUC値の95%CIの上限の値とが示されている。 Of the 981 logistic regression equations obtained above, 270 equations with ROC_AUC values of 0.679 or more in the MCI group and the healthy group are shown in the following [5-variable equations]. Since these logistic regression equations have a high ROC_AUC value and the lower limit of 95% CI of the ROC_AUC value is higher than 0.5, they are considered to be useful in the above evaluation. In the following [5-variable expression], the ROC_AUC value corresponding to the five amino acids included in the expression, the lower limit value of 95% CI of the ROC_AUC value, and the upper limit value of 95% CI of the ROC_AUC value are shown. Is shown.
[5変数の式]
Ser, Asn, Cit, Lys, Leu, 0.701 (0.635 , 0.768); Ser, Thr, Cit, Lys, Trp, 0.7 (0.633 , 0.767); Ser, Thr, Cit, Val, Lys, 0.7 (0.633 , 0.767); Ser, Cit, Met, Lys, Leu, 0.7 (0.633 , 0.767); Ser, Thr, Cit, Lys, Leu, 0.699 (0.632 , 0.767); Ser, Cit, Val, Met, Lys, 0.699 (0.632 , 0.766); Ser, Thr, Arg, Lys, Trp, 0.699 (0.632 , 0.766); Ser, Thr, Arg, Lys, Leu, 0.699 (0.631 , 0.767); Ser, Gln, Cit, Lys, Leu, 0.698 (0.631 , 0.766); Ser, Cit, Val, Lys, Phe, 0.698 (0.631 , 0.766); Ser, Gly, Cit, Lys, Leu, 0.698 (0.631 , 0.766); Ser, Asn, Cit, Val, Lys, 0.698 (0.631 , 0.765); Ser, Cit, Pro, Val, Lys, 0.698 (0.631 , 0.765); Ser, Cit, Val, Orn, Lys, 0.698 (0.631 , 0.765); Ser, Gly, Cit, Val, Lys, 0.698 (0.63 , 0.765); Ser, Thr, Arg, Val, Lys, 0.698 (0.63 , 0.765); Ser, Cit, Lys, Leu, Phe, 0.697 (0.63 , 0.764); Ser, Cit, Met, Lys, Trp, 0.697 (0.629 , 0.764); Ser, Ala, Cit, Val, Lys, 0.696 (0.629 , 0.763); Ser, Cit, Val, Lys, Ile, 0.696 (0.628 , 0.763); Ser, Cit, Met, Lys, Ile, 0.696 (0.628 , 0.763); Ser, Gly, Thr, Lys, Trp, 0.696 (0.628 , 0.763); Ser, Cit, Arg, Lys, Leu, 0.696 (0.628 , 0.763); Ser, Cit, Val, Lys, Leu, 0.695 (0.628 , 0.763); Ser, Cit, Orn, Lys, Leu, 0.695 (0.628 , 0.763); Ser, Cit, Lys, Ile, Leu, 0.695 (0.628 , 0.763); Ser, Cit, Arg, Val, Lys, 0.695 (0.628 , 0.763); Ser, Gly, Thr, Cit, Lys, 0.695 (0.628 , 0.762); Ser, Cit, Pro, Lys, Leu, 0.695 (0.628 , 0.762); Ser, Cit, Tyr, Val, Lys, 0.695 (0.627 , 0.762); Ser, Asn, Cit, Lys, Trp, 0.695 (0.628 , 0.761); Ser, Gln, Cit, Val, Lys, 0.695 (0.627 , 0.762); Ser, Asn, Cit, Lys, Ile, 0.694 (0.627 , 0.762); Ser, Cit, Tyr, Lys, Leu, 0.694 (0.627 , 0.762); Ser, Gly, Cit, Lys, Trp, 0.694 (0.627 , 0.762); Ser, Ala, Cit, Lys, Leu, 0.694 (0.627 , 0.762); Ser, Arg, Lys, Leu, Trp, 0.694 (0.627 , 0.761); Ser, Gly, Cit, Lys, Ile, 0.694 (0.626 , 0.761); Ser, Cit, Lys, Leu, Trp, 0.694 (0.626 , 0.761); Ser, Thr, Lys, Leu, Trp, 0.693 (0.626 , 0.761); Ser, Thr, Cit, Lys, Ile, 0.693 (0.625 , 0.76); Ser, His, Cit, Lys, Leu, 0.693 (0.625 , 0.76); Ser, Cit, Val, Lys, Trp, 0.692 (0.625 , 0.76); Ser, Thr, Lys, Ile, Trp, 0.692 (0.625 , 0.76); Ser, His, Cit, Val, Lys, 0.692 (0.625 , 0.759); Ser, Gly, Thr, Lys, Ile, 0.692 (0.624 , 0.759); Ser, Gln, Cit, Lys, Trp, 0.692 (0.624 , 0.759); Ser, Arg, Met, Lys, Trp, 0.692 (0.624 , 0.759); Ser, Gly, Arg, Lys, Trp, 0.691 (0.624 , 0.758); Ser, Thr, Pro, Lys, Trp, 0.691 (0.624 , 0.759); Ser, Thr, Val, Lys, Trp, 0.691 (0.623 , 0.759); Ser, Asn, Gly, Lys, Trp, 0.691 (0.624 , 0.758); Ser, Arg, Val, Lys, Trp, 0.691 (0.624 , 0.758); Ser, Gly, Thr, Lys, Leu, 0.691 (0.623 , 0.759); Ser, Thr, Arg, Lys, Ile, 0.691 (0.623 , 0.759); Ser, Cit, Orn, Lys, Ile, 0.69 (0.622 , 0.759); Ser, Gly, Thr, Val, Lys, 0.69 (0.623 , 0.758); Ser, Cit, Arg, Lys, Ile, 0.69 (0.622 , 0.758); Ser, Asn, Arg, Lys, Trp, 0.69 (0.623 , 0.757); Ser, Asn, Lys, Leu, Trp, 0.69 (0.623 , 0.757); Ser, His, Cit, Lys, Trp, 0.689 (0.622 , 0.757); Ser, Cit, Lys, Ile, Phe, 0.689 (0.621 , 0.757); Ser, Asn, Thr, Lys, Trp, 0.689 (0.622 , 0.757); Ser, Thr, Lys, Ile, Leu, 0.689 (0.621 , 0.757); Ser, Cit, Arg, Lys, Trp, 0.689 (0.622 , 0.756); Ser, Gly, Thr, Pro, Lys, 0.689 (0.622 , 0.756); Ser, Cit, Lys, Ile, Trp, 0.689 (0.622 , 0.756); Ser, Gly, Pro, Lys, Trp, 0.689 (0.621 , 0.756); Ser, Ala, Cit, Lys, Ile, 0.689 (0.621 , 0.757); Ser, Asn, Gly, Cit, Lys, 0.689 (0.621 , 0.756); Ser, Gly, Lys, Phe, Trp, 0.688 (0.621 , 0.756); Ser, His, Thr, Lys, Trp, 0.688 (0.621 , 0.756); Ser, Cit, Orn, Lys, Trp, 0.688 (0.621 , 0.756); Ser, Cit, Pro, Lys, Ile, 0.688 (0.62 , 0.757); Ser, Cit, Tyr, Lys, Ile, 0.688 (0.62 , 0.756); Ser, Gly, Val, Lys, Trp, 0.688 (0.621 , 0.756); Ser, Arg, Lys, Ile, Trp, 0.688 (0.621 , 0.755); Ser, Gln, Thr, Lys, Trp, 0.688 (0.62 , 0.756); Ser, Lys, Leu, Phe, Trp, 0.688 (0.62 , 0.755); Ser, Gly, Tyr, Lys, Trp, 0.688 (0.62 , 0.756); Ser, His, Cit, Lys, Ile, 0.688 (0.62 , 0.756); Ser, Thr, Tyr, Lys, Trp, 0.688 (0.62 , 0.756); Ser, Thr, Met, Lys, Trp, 0.688 (0.62 , 0.756); Ser, Gly, Met, Lys, Trp, 0.688 (0.62 , 0.756); Ser, Thr, Pro, Lys, Leu, 0.688 (0.62 , 0.756); Ser, Gly, Gln, Lys, Trp, 0.688 (0.62 , 0.755); Ser, Gly, Cit, Tyr, Lys, 0.688 (0.62 , 0.755); Ser, Gln, Cit, Lys, Ile, 0.688 (0.62 , 0.756); Ser, Met, Lys, Leu, Trp, 0.687 (0.62 , 0.755); Ser, Gly, Cit, Pro, Lys, 0.687 (0.619 , 0.755); Ser, Ala, Cit, Lys, Trp, 0.687 (0.62 , 0.755); Ser, Gly, Gln, Cit, Lys, 0.687 (0.619 , 0.755); Ser, Thr, Lys, Leu, Phe, 0.687 (0.619 , 0.755); Ser, Gly, Lys, Ile, Trp, 0.687 (0.619 , 0.755); Ser, Gln, Lys, Leu, Trp, 0.687 (0.62 , 0.755); Ser, Cit, Pro, Lys, Trp, 0.687 (0.62 , 0.754); Ser, Gly, Ala, Lys, Trp, 0.687 (0.619 , 0.755); Ser, Gly, Cit, Lys, Phe, 0.687 (0.619 , 0.755); Ser, Gly, Ala, Cit, Lys, 0.687 (0.619 , 0.755); Ser, Thr, Ala, Lys, Trp, 0.687 (0.619 , 0.755); Ser, Gly, Lys, Leu, Trp, 0.687 (0.619 , 0.754); Ser, Thr, Lys, Phe, Trp, 0.687 (0.619 , 0.755); Ser, Thr, Ala, Lys, Leu, 0.687 (0.618 , 0.755); Ser, Thr, Val, Lys, Leu, 0.687 (0.618 , 0.755); Ser, Gly, Cit, Met, Lys, 0.687 (0.619 , 0.754); Ser, Val, Lys, Leu, Trp, 0.687 (0.619 , 0.754); Ser, Cit, Tyr, Lys, Trp, 0.686 (0.619 , 0.754); Ser, Thr, Tyr, Lys, Leu, 0.686 (0.618 , 0.754); Ser, Asn, Thr, Lys, Leu, 0.686 (0.618 , 0.754); Ser, Asn, Val, Lys, Trp, 0.686 (0.619 , 0.754); Ser, Thr, Orn, Lys, Trp, 0.686 (0.618 , 0.754); Ser, Gly, Thr, Arg, Lys, 0.686 (0.619 , 0.754); Ser, Pro, Lys, Leu, Trp, 0.686 (0.619 , 0.754); Ser, Thr, Met, Lys, Leu, 0.686 (0.618 , 0.754); Ser, Asn, Lys, Ile, Trp, 0.686 (0.619 , 0.754); Ser, Tyr, Lys, Leu, Trp, 0.686 (0.619 , 0.754); Ser, Asn, Pro, Lys, Trp, 0.686 (0.619 , 0.754); His, Cit, Lys, Leu, Trp, 0.686 (0.618 , 0.754); Ser, Asn, Cit, Tyr, Lys, 0.686 (0.618 , 0.754); Ser, Gly, Cit, Orn, Lys, 0.686 (0.618 , 0.754); Ser, Val, Met, Lys, Trp, 0.686 (0.618 , 0.754); Ser, Met, Lys, Ile, Trp, 0.686 (0.618 , 0.754); Ser, Gln, Arg, Lys, Trp, 0.686 (0.618 , 0.753); Ser, Ala, Arg, Lys, Trp, 0.686 (0.618 , 0.753); Ser, Gly, Orn, Lys, Trp, 0.686 (0.618 , 0.753); Ser, Asn, Gln, Cit, Lys, 0.686 (0.617 , 0.754); Ser, Gly, Thr, Ala, Lys, 0.685 (0.617 , 0.754); Ser, Cit, Lys, Phe, Trp, 0.685 (0.618 , 0.753); Ser, Asn, Gln, Lys, Trp, 0.685 (0.618 , 0.753); Ser, Lys, Ile, Leu, Trp, 0.685 (0.618 , 0.753); Ser, Pro, Met, Lys, Trp, 0.685 (0.617 , 0.753); Ser, Gly, His, Cit, Lys, 0.685 (0.618 , 0.753); Ser, Gly, Cit, Arg, Lys, 0.685 (0.618 , 0.753); Ser, Gln, Thr, Val, Lys, 0.685 (0.617 , 0.753); Ser, Gln, Cit, Tyr, Lys, 0.685 (0.617 , 0.753); Ser, Gln, Thr, Lys, Leu, 0.685 (0.617 , 0.753); Ser, Gln, Lys, Ile, Trp, 0.685 (0.617 , 0.753); Ser, Asn, Thr, Val, Lys, 0.685 (0.616 , 0.753); Ser, His, Arg, Lys, Trp, 0.685 (0.617 , 0.752); Ser, Gly, Thr, Lys, Phe, 0.685 (0.616 , 0.753); Ser, Thr, Val, Lys, Ile, 0.684 (0.616 , 0.753); Ser, His, Thr, Lys, Leu, 0.684 (0.616 , 0.752); Ser, Asn, Ala, Lys, Trp, 0.684 (0.616 , 0.752); Ser, Thr, Cit, Arg, Lys, 0.684 (0.616 , 0.752); Ser, Gln, Cit, Pro, Lys, 0.684 (0.616 , 0.752); Ser, Thr, Pro, Val, Lys, 0.684 (0.616 , 0.752); Ser, Thr, Val, Met, Lys, 0.684 (0.616 , 0.752); Cit, Met, Lys, Leu, Trp, 0.684 (0.616 , 0.752); Ser, Asn, Tyr, Lys, Trp, 0.684 (0.616 , 0.752); Ser, Val, Lys, Phe, Trp, 0.684 (0.616 , 0.752); Ser, Gln, Cit, Arg, Lys, 0.684 (0.616 , 0.752); Ser, Thr, Ala, Val, Lys, 0.684 (0.615 , 0.752); Ser, Thr, Met, Lys, Ile, 0.684 (0.615 , 0.752); Ser, Gly, His, Lys, Trp, 0.684 (0.616 , 0.752); Ser, Thr, Cit, Pro, Lys, 0.684 (0.615 , 0.752); Ser, Thr, Lys, Ile, Phe, 0.683 (0.615 , 0.752); Ser, Ala, Lys, Leu, Trp, 0.683 (0.616 , 0.751); Ser, Asn, Lys, Phe, Trp, 0.683 (0.616 , 0.751); Ser, Thr, Ala, Lys, Ile, 0.683 (0.615 , 0.751); Ser, Asn, Met, Lys, Trp, 0.683 (0.615 , 0.751); Ser, Arg, Pro, Lys, Trp, 0.683 (0.616 , 0.751); Ser, Thr, Val, Lys, Phe, 0.683 (0.615 , 0.752); His, Cit, Orn, Lys, Trp, 0.683 (0.615 , 0.751); Ser, Arg, Lys, Phe, Trp, 0.683 (0.616 , 0.751); Ser, Gly, Thr, Met, Lys, 0.683 (0.615 , 0.751); Ser, Thr, Orn, Lys, Leu, 0.683 (0.615 , 0.751); His, Cit, Lys, Phe, Trp, 0.683 (0.615 , 0.751); Ser, Gly, Thr, Tyr, Lys, 0.683 (0.615 , 0.751); His, Ala, Cit, Lys, Trp, 0.683 (0.615 , 0.751); Ser, His, Lys, Leu, Trp, 0.683 (0.615 , 0.751); Ser, Arg, Tyr, Lys, Trp, 0.683 (0.615 , 0.75); Ser, Arg, Orn, Lys, Trp, 0.683 (0.615 , 0.75); Ser, Asn, Cit, Lys, Phe, 0.683 (0.615 , 0.751); Ser, Asn, Thr, Cit, Lys, 0.683 (0.615 , 0.751); Ser, Gln, Val, Lys, Trp, 0.683 (0.615 , 0.751); Ser, Gln, Thr, Cit, Lys, 0.683 (0.614 , 0.751); Ser, His, Thr, Val, Lys, 0.683 (0.614 , 0.751); Ser, Tyr, Lys, Ile, Trp, 0.683 (0.615 , 0.75); Ser, Asn, Cit, Pro, Lys, 0.683 (0.615 , 0.751); Ser, Thr, Cit, Tyr, Lys, 0.683 (0.615 , 0.751); Ser, Thr, Tyr, Val, Lys, 0.683 (0.614 , 0.751); Ser, Lys, Ile, Phe, Trp, 0.683 (0.615 , 0.751); Ser, Gln, Cit, Lys, Phe, 0.683 (0.614 , 0.751); Ser, Asn, Thr, Lys, Ile, 0.682 (0.614 , 0.751); Asn, His, Cit, Lys, Trp, 0.682 (0.615 , 0.75); His, Cit, Val, Lys, Trp, 0.682 (0.614 , 0.75); Cit, Met, Lys, Ile, Trp, 0.682 (0.614 , 0.75); Ser, Val, Lys, Ile, Trp, 0.682 (0.615 , 0.75); Ser, Cit, Tyr, Met, Lys, 0.682 (0.614 , 0.751); Ser, Orn, Lys, Leu, Trp, 0.682 (0.615 , 0.75); Ser, Gln, Cit, Met, Lys, 0.682 (0.614 , 0.751); His, Cit, Lys, Ile, Trp, 0.682 (0.614 , 0.75); Ser, Met, Lys, Phe, Trp, 0.682 (0.614 , 0.75); Ser, Asn, Gly, Thr, Lys, 0.682 (0.614 , 0.75); Ser, Asn, Ala, Cit, Lys, 0.682 (0.614 , 0.75); Ser, Thr, Pro, Lys, Ile, 0.682 (0.614 , 0.75); Ser, Gln, Pro, Lys, Trp, 0.682 (0.614 , 0.75); Ser, His, Val, Lys, Trp, 0.682 (0.614 , 0.75); Ser, Thr, Tyr, Lys, Ile, 0.682 (0.614 , 0.75); His, Thr, Cit, Lys, Trp, 0.682 (0.614 , 0.75); Ser, Asn, Orn, Lys, Trp, 0.682 (0.614 , 0.749); Ser, Gln, Cit, Orn, Lys, 0.682 (0.614 , 0.75); Ser, Thr, Orn, Lys, Ile, 0.682 (0.614 , 0.75); Ser, Asn, His, Lys, Trp, 0.682 (0.614 , 0.75); Ser, Thr, Cit, Lys, Phe, 0.682 (0.613 , 0.75); Gln, His, Cit, Lys, Trp, 0.682 (0.614 , 0.75); Cit, Tyr, Met, Lys, Trp, 0.682 (0.613 , 0.75); Ser, Tyr, Val, Lys, Trp, 0.682 (0.614 , 0.75); Ser, Cit, Pro, Met, Lys, 0.682 (0.613 , 0.75); Ser, Cit, Met, Lys, Phe, 0.682 (0.613 , 0.75); Ser, His, Lys, Ile, Trp, 0.682 (0.614 , 0.75); Ser, Gln, Ala, Cit, Lys, 0.682 (0.613 , 0.75); Ser, His, Thr, Lys, Ile, 0.681 (0.613 , 0.75); Cit, Val, Met, Lys, Trp, 0.681 (0.613 , 0.75); Ser, Pro, Val, Lys, Trp, 0.681 (0.

613 , 0.749); His, Cit, Met, Lys, Trp, 0.681 (0.613 , 0.75); Cit, Arg, Lys, Leu, Trp, 0.681 (0.613 , 0.749); Gln, Cit, Lys, Leu, Trp, 0.681 (0.613 , 0.75); Cit, Lys, Leu, Phe, Trp, 0.681 (0.613 , 0.749); Ser, Asn, Cit, Orn, Lys, 0.681 (0.613 , 0.749); His, Cit, Tyr, Lys, Trp, 0.681 (0.613 , 0.749); Ser, Gln, Thr, Lys, Ile, 0.681 (0.612 , 0.749); Ser, Gln, Met, Lys, Trp, 0.681 (0.613 , 0.749); Ser, Tyr, Met, Lys, Trp, 0.681 (0.613 , 0.749); Thr, Cit, Met, Lys, Trp, 0.681 (0.613 , 0.749); Ser, Pro, Lys, Ile, Trp, 0.681 (0.613 , 0.749); Ser, Thr, Ala, Cit, Lys, 0.681 (0.612 , 0.749); Cit, Pro, Met, Lys, Trp, 0.681 (0.612 , 0.749); Asn, Cit, Met, Lys, Trp, 0.681 (0.612 , 0.749); Ala, Cit, Met, Lys, Trp, 0.681 (0.612 , 0.749); Ser, Asn, Cit, Met, Lys, 0.681 (0.612 , 0.749); Cit, Met, Lys, Phe, Trp, 0.681 (0.612 , 0.749); Ser, Ala, Met, Lys, Trp, 0.681 (0.612 , 0.749); Ser, Asn, Cit, Arg, Lys, 0.681 (0.613 , 0.748); Ser, Gly, His, Thr, Lys, 0.68 (0.612 , 0.749); Ser, Cit, Tyr, Lys, Phe, 0.68 (0.612 , 0.749); Cit, Arg, Met, Lys, Trp, 0.68 (0.612 , 0.748); Ser, Ala, Val, Lys, Trp, 0.68 (0.612 , 0.748); Gly, His, Cit, Lys, Trp, 0.68 (0.612 , 0.749); Ser, Cit, Tyr, Orn, Lys, 0.68 (0.612 , 0.749); Cit, Met, Orn, Lys, Trp, 0.68 (0.612 , 0.749); Ser, Gln, Tyr, Lys, Trp, 0.68 (0.612 , 0.748); Ser, Orn, Lys, Ile, Trp, 0.68 (0.612 , 0.748); Ser, Cit, Pro, Tyr, Lys, 0.68 (0.612 , 0.749); Ser, Gly, Gln, Thr, Lys, 0.68 (0.612 , 0.749); His, Cit, Arg, Lys, Trp, 0.68 (0.612 , 0.748); Ser, His, Met, Lys, Trp, 0.68 (0.612 , 0.748); Ser, Gln, His, Cit, Lys, 0.68 (0.612 , 0.749); Ser, Thr, Val, Orn, Lys, 0.68 (0.612 , 0.748); Thr, Cit, Arg, Lys, Trp, 0.68 (0.612 , 0.748); Ser, Gln, Ala, Lys, Trp, 0.68 (0.612 , 0.748); Ser, Gln, Lys, Phe, Trp, 0.68 (0.612 , 0.748); Ser, Gln, Orn, Lys, Trp, 0.68 (0.612 , 0.748); Ser, Val, Orn, Lys, Trp, 0.68 (0.612 , 0.748); Gln, Cit, Arg, Lys, Trp, 0.68 (0.612 , 0.748); Gln, Cit, Val, Lys, Trp, 0.68 (0.611 , 0.748); Ser, Ala, Lys, Ile, Trp, 0.68 (0.612 , 0.748); Thr, Arg, Met, Lys, Trp, 0.68 (0.611 , 0.748); Ser, Cit, Pro, Orn, Lys, 0.68 (0.611 , 0.748); Ser, His, Thr, Cit, Lys, 0.679 (0.611 , 0.748); Gln, Cit, Lys, Ile, Trp, 0.679 (0.611 , 0.748); Gln, Cit, Lys, Phe, Trp, 0.679 (0.611 , 0.748); Gln, Ala, Cit, Lys, Trp, 0.679 (0.611 , 0.748); Gln, Cit, Pro, Lys, Trp, 0.679 (0.611 , 0.748); Gln, Cit, Met, Lys, Trp, 0.679 (0.611 , 0.748); Ser, Pro, Lys, Phe, Trp, 0.679 (0.611 , 0.748); Ser, Met, Orn, Lys, Trp, 0.679 (0.611 , 0.747); Ser, Ala, Cit, Tyr, Lys, 0.679 (0.611 , 0.748); Gly, Cit, Met, Lys, Trp, 0.679 (0.611 , 0.748); Ser, Thr, Cit, Met, Lys, 0.679 (0.611 , 0.748); Ser, Cit, Arg, Met, Lys, 0.679 (0.611 , 0.748)
[Expression of 5 variables]
Ser, Asn, Cit, Lys, Leu, 0.701 (0.635, 0.768); Ser, Thr, Cit, Lys, Trp, 0.7 (0.633, 0.767); Ser, Thr, Cit, Val, Lys, 0.7 (0.633, 0.767) Ser, Cit, Met, Lys, Leu, 0.7 (0.633, 0.767); Ser, Thr, Cit, Lys, Leu, 0.699 (0.632, 0.767); Ser, Cit, Val, Met, Lys, 0.699 (0.632, 0.766) ); Ser, Thr, Arg, Lys, Trp, 0.699 (0.632, 0.766); Ser, Thr, Arg, Lys, Leu, 0.699 (0.631, 0.767); Ser, Gln, Cit, Lys, Leu, 0.698 (0.631, 0.766); Ser, Cit, Val, Lys, Phe, 0.698 (0.631, 0.766); Ser, Gly, Cit, Lys, Leu, 0.698 (0.631, 0.766); Ser, Asn, Cit, Val, Lys, 0.698 (0.631) , 0.765); Ser, Cit, Pro, Val, Lys, 0.698 (0.631, 0.765); Ser, Cit, Val, Orn, Lys, 0.698 (0.631, 0.765); Ser, Gly, Cit, Val, Lys, 0.698 ( 0.63, 0.765); Ser, Thr, Arg, Val, Lys, 0.698 (0.63, 0.765); Ser, Cit, Lys, Leu, Phe, 0.697 (0.63, 0.764); Ser, Cit, Met, Lys, Trp, 0.697 (0.629, 0.764); Ser, Ala, Cit, Val, Lys, 0.696 (0.629, 0.763); Ser, Cit, Val, Lys, Ile, 0.696 (0.628, 0.763); Ser, Cit, Met, Lys, Ile, 0.696 (0.628, 0.763); S er, Gly, Thr, Lys, Trp, 0.696 (0.628, 0.763); Ser, Cit, Arg, Lys, Leu, 0.696 (0.628, 0.763); Ser, Cit, Val, Lys, Leu, 0.695 (0.628, 0.763) Ser, Cit, Orn, Lys, Leu, 0.695 (0.628, 0.763); Ser, Cit, Lys, Ile, Leu, 0.695 (0.628, 0.763); Ser, Cit, Arg, Val, Lys, 0.695 (0.628, 0.763) ); Ser, Gly, Thr, Cit, Lys, 0.695 (0.628, 0.762); Ser, Cit, Pro, Lys, Leu, 0.695 (0.628, 0.762); Ser, Cit, Tyr, Val, Lys, 0.695 (0.627, 0.762); Ser, Asn, Cit, Lys, Trp, 0.695 (0.628, 0.761); Ser, Gln, Cit, Val, Lys, 0.695 (0.627, 0.762); Ser, Asn, Cit, Lys, Ile, 0.694 (0.627) , 0.762); Ser, Cit, Tyr, Lys, Leu, 0.694 (0.627, 0.762); Ser, Gly, Cit, Lys, Trp, 0.694 (0.627, 0.762); Ser, Ala, Cit, Lys, Leu, 0.694 ( 0.627, 0.762); Ser, Arg, Lys, Leu, Trp, 0.694 (0.627, 0.761); Ser, Gly, Cit, Lys, Ile, 0.694 (0.626, 0.761); Ser, Cit, Lys, Leu, Trp, 0.694 (0.626, 0.761); Ser, Thr, Lys, Leu, Trp, 0.693 (0.626, 0.761); Ser, Thr, Cit, Lys, Ile, 0.693 (0.625, 0.76); Ser, His, Cit, Lys, Leu, 0.693 (0.625, 0. 76); Ser, Cit, Val, Lys, Trp, 0.692 (0.625, 0.76); Ser, Thr, Lys, Ile, Trp, 0.692 (0.625, 0.76); Ser, His, Cit, Val, Lys, 0.692 (0.625) , 0.759); Ser, Gly, Thr, Lys, Ile, 0.692 (0.624, 0.759); Ser, Gln, Cit, Lys, Trp, 0.692 (0.624, 0.759); Ser, Arg, Met, Lys, Trp, 0.692 ( 0.624, 0.759); Ser, Gly, Arg, Lys, Trp, 0.691 (0.624, 0.758); Ser, Thr, Pro, Lys, Trp, 0.691 (0.624, 0.759); Ser, Thr, Val, Lys, Trp, 0.691 (0.623, 0.759); Ser, Asn, Gly, Lys, Trp, 0.691 (0.624, 0.758); Ser, Arg, Val, Lys, Trp, 0.691 (0.624, 0.758); Ser, Gly, Thr, Lys, Leu, 0.691 (0.623, 0.759); Ser, Thr, Arg, Lys, Ile, 0.691 (0.623, 0.759); Ser, Cit, Orn, Lys, Ile, 0.69 (0.622, 0.759); Ser, Gly, Thr, Val, Lys , 0.69 (0.623, 0.758); Ser, Cit, Arg, Lys, Ile, 0.69 (0.622, 0.758); Ser, Asn, Arg, Lys, Trp, 0.69 (0.623, 0.757); Ser, Asn, Lys, Leu, Trp, 0.69 (0.623, 0.757); Ser, His, Cit, Lys, Trp, 0.689 (0.622, 0.757); Ser, Cit, Lys, Ile, Phe, 0.689 (0.621, 0.757); Ser, Asn, Thr, Lys , Trp, 0.689 (0.622, 0. 757); Ser, Thr, Lys, Ile, Leu, 0.689 (0.621, 0.757); Ser, Cit, Arg, Lys, Trp, 0.689 (0.622, 0.756); Ser, Gly, Thr, Pro, Lys, 0.689 (0.622) , 0.756); Ser, Cit, Lys, Ile, Trp, 0.689 (0.622, 0.756); Ser, Gly, Pro, Lys, Trp, 0.689 (0.621, 0.756); Ser, Ala, Cit, Lys, Ile, 0.689 ( 0.621, 0.757); Ser, Asn, Gly, Cit, Lys, 0.689 (0.621, 0.756); Ser, Gly, Lys, Phe, Trp, 0.688 (0.621, 0.756); Ser, His, Thr, Lys, Trp, 0.688 (0.621, 0.756); Ser, Cit, Orn, Lys, Trp, 0.688 (0.621, 0.756); Ser, Cit, Pro, Lys, Ile, 0.688 (0.62, 0.757); Ser, Cit, Tyr, Lys, Ile, 0.688 (0.62, 0.756); Ser, Gly, Val, Lys, Trp, 0.688 (0.621, 0.756); Ser, Arg, Lys, Ile, Trp, 0.688 (0.621, 0.755); Ser, Gln, Thr, Lys, Trp , 0.688 (0.62, 0.756); Ser, Lys, Leu, Phe, Trp, 0.688 (0.62, 0.755); Ser, Gly, Tyr, Lys, Trp, 0.688 (0.62, 0.756); Ser, His, Cit, Lys, Ile, 0.688 (0.62, 0.756); Ser, Thr, Tyr, Lys, Trp, 0.688 (0.62, 0.756); Ser, Thr, Met, Lys, Trp, 0.688 (0.62, 0.756); Ser, Gly, Met, Lys , Trp, 0.688 (0.62, 0.7 56); Ser, Thr, Pro, Lys, Leu, 0.688 (0.62, 0.756); Ser, Gly, Gln, Lys, Trp, 0.688 (0.62, 0.755); Ser, Gly, Cit, Tyr, Lys, 0.688 (0.62) , 0.755); Ser, Gln, Cit, Lys, Ile, 0.688 (0.62, 0.756); Ser, Met, Lys, Leu, Trp, 0.687 (0.62, 0.755); Ser, Gly, Cit, Pro, Lys, 0.687 ( 0.619, 0.755); Ser, Ala, Cit, Lys, Trp, 0.687 (0.62, 0.755); Ser, Gly, Gln, Cit, Lys, 0.687 (0.619, 0.755); Ser, Thr, Lys, Leu, Phe, 0.687 (0.619, 0.755); Ser, Gly, Lys, Ile, Trp, 0.687 (0.619, 0.755); Ser, Gln, Lys, Leu, Trp, 0.687 (0.62, 0.755); Ser, Cit, Pro, Lys, Trp, 0.687 (0.62, 0.754); Ser, Gly, Ala, Lys, Trp, 0.687 (0.619, 0.755); Ser, Gly, Cit, Lys, Phe, 0.687 (0.619, 0.755); Ser, Gly, Ala, Cit, Lys , 0.687 (0.619, 0.755); Ser, Thr, Ala, Lys, Trp, 0.687 (0.619, 0.755); Ser, Gly, Lys, Leu, Trp, 0.687 (0.619, 0.754); Ser, Thr, Lys, Phe, Trp, 0.687 (0.619, 0.755); Ser, Thr, Ala, Lys, Leu, 0.687 (0.618, 0.755); Ser, Thr, Val, Lys, Leu, 0.687 (0.618, 0.755); Ser, Gly, Cit, Met , Lys, 0.687 (0.619, 0.7 54); Ser, Val, Lys, Leu, Trp, 0.687 (0.619, 0.754); Ser, Cit, Tyr, Lys, Trp, 0.686 (0.619, 0.754); Ser, Thr, Tyr, Lys, Leu, 0.686 (0.618) , 0.754); Ser, Asn, Thr, Lys, Leu, 0.686 (0.618, 0.754); Ser, Asn, Val, Lys, Trp, 0.686 (0.619, 0.754); Ser, Thr, Orn, Lys, Trp, 0.686 ( 0.618, 0.754); Ser, Gly, Thr, Arg, Lys, 0.686 (0.619, 0.754); Ser, Pro, Lys, Leu, Trp, 0.686 (0.619, 0.754); Ser, Thr, Met, Lys, Leu, 0.686 (0.618, 0.754); Ser, Asn, Lys, Ile, Trp, 0.686 (0.619, 0.754); Ser, Tyr, Lys, Leu, Trp, 0.686 (0.619, 0.754); Ser, Asn, Pro, Lys, Trp, 0.686 (0.619, 0.754); His, Cit, Lys, Leu, Trp, 0.686 (0.618, 0.754); Ser, Asn, Cit, Tyr, Lys, 0.686 (0.618, 0.754); Ser, Gly, Cit, Orn, Lys , 0.686 (0.618, 0.754); Ser, Val, Met, Lys, Trp, 0.686 (0.618, 0.754); Ser, Met, Lys, Ile, Trp, 0.686 (0.618, 0.754); Ser, Gln, Arg, Lys, Trp, 0.686 (0.618, 0.753); Ser, Ala, Arg, Lys, Trp, 0.686 (0.618, 0.753); Ser, Gly, Orn, Lys, Trp, 0.686 (0.618, 0.753); Ser, Asn, Gln, Cit , Lys, 0.686 (0.6) 17, 0.754); Ser, Gly, Thr, Ala, Lys, 0.685 (0.617, 0.754); Ser, Cit, Lys, Phe, Trp, 0.685 (0.618, 0.753); Ser, Asn, Gln, Lys, Trp, 0.685 (0.618, 0.753); Ser, Lys, Ile, Leu, Trp, 0.685 (0.618, 0.753); Ser, Pro, Met, Lys, Trp, 0.685 (0.617, 0.753); Ser, Gly, His, Cit, Lys, 0.685 (0.618, 0.753); Ser, Gly, Cit, Arg, Lys, 0.685 (0.618, 0.753); Ser, Gln, Thr, Val, Lys, 0.685 (0.617, 0.753); Ser, Gln, Cit, Tyr, Lys , 0.685 (0.617, 0.753); Ser, Gln, Thr, Lys, Leu, 0.685 (0.617, 0.753); Ser, Gln, Lys, Ile, Trp, 0.685 (0.617, 0.753); Ser, Asn, Thr, Val, Lys, 0.685 (0.616, 0.753); Ser, His, Arg, Lys, Trp, 0.685 (0.617, 0.752); Ser, Gly, Thr, Lys, Phe, 0.685 (0.616, 0.753); Ser, Thr, Val, Lys , Ile, 0.684 (0.616, 0.753); Ser, His, Thr, Lys, Leu, 0.684 (0.616, 0.752); Ser, Asn, Ala, Lys, Trp, 0.684 (0.616, 0.752); Ser, Thr, Cit, Arg, Lys, 0.684 (0.616, 0.752); Ser, Gln, Cit, Pro, Lys, 0.684 (0.616, 0.752); Ser, Thr, Pro, Val, Lys, 0.684 (0.616, 0.752); Ser, Thr, Val , Met, Lys, 0. 684 (0.616, 0.752); Cit, Met, Lys, Leu, Trp, 0.684 (0.616, 0.752); Ser, Asn, Tyr, Lys, Trp, 0.684 (0.616, 0.752); Ser, Val, Lys, Phe, Trp , 0.684 (0.616, 0.752); Ser, Gln, Cit, Arg, Lys, 0.684 (0.616, 0.752); Ser, Thr, Ala, Val, Lys, 0.684 (0.615, 0.752); Ser, Thr, Met, Lys, Ile, 0.684 (0.615, 0.752); Ser, Gly, His, Lys, Trp, 0.684 (0.616, 0.752); Ser, Thr, Cit, Pro, Lys, 0.684 (0.615, 0.752); Ser, Thr, Lys, Ile , Phe, 0.683 (0.615, 0.752); Ser, Ala, Lys, Leu, Trp, 0.683 (0.616, 0.751); Ser, Asn, Lys, Phe, Trp, 0.683 (0.616, 0.751); Ser, Thr, Ala, Lys, Ile, 0.683 (0.615, 0.751); Ser, Asn, Met, Lys, Trp, 0.683 (0.615, 0.751); Ser, Arg, Pro, Lys, Trp, 0.683 (0.616, 0.751); Ser, Thr, Val , Lys, Phe, 0.683 (0.615, 0.752); His, Cit, Orn, Lys, Trp, 0.683 (0.615, 0.751); Ser, Arg, Lys, Phe, Trp, 0.683 (0.616, 0.751); Ser, Gly, Thr, Met, Lys, 0.683 (0.615, 0.751); Ser, Thr, Orn, Lys, Leu, 0.683 (0.615, 0.751); His, Cit, Lys, Phe, Trp, 0.683 (0.615, 0.751); Ser, Gly , Thr, Tyr, Lys, 0.683 (0.615, 0.751); His, Ala, Cit, Lys, Trp, 0.683 (0.615, 0.751); Ser, His, Lys, Leu, Trp, 0.683 (0.615, 0.751); Ser, Arg, Tyr, Lys , Trp, 0.683 (0.615, 0.75); Ser, Arg, Orn, Lys, Trp, 0.683 (0.615, 0.75); Ser, Asn, Cit, Lys, Phe, 0.683 (0.615, 0.751); Ser, Asn, Thr, Cit, Lys, 0.683 (0.615, 0.751); Ser, Gln, Val, Lys, Trp, 0.683 (0.615, 0.751); Ser, Gln, Thr, Cit, Lys, 0.683 (0.614, 0.751); Ser, His, Thr , Val, Lys, 0.683 (0.614, 0.751); Ser, Tyr, Lys, Ile, Trp, 0.683 (0.615, 0.75); Ser, Asn, Cit, Pro, Lys, 0.683 (0.615, 0.751); Ser, Thr, Cit, Tyr, Lys, 0.683 (0.615, 0.751); Ser, Thr, Tyr, Val, Lys, 0.683 (0.614, 0.751); Ser, Lys, Ile, Phe, Trp, 0.683 (0.615, 0.751); Ser, Gln , Cit, Lys, Phe, 0.683 (0.614, 0.751); Ser, Asn, Thr, Lys, Ile, 0.682 (0.614, 0.751); Asn, His, Cit, Lys, Trp, 0.682 (0.615, 0.75); His, Cit, Val, Lys, Trp, 0.682 (0.614, 0.75); Cit, Met, Lys, Ile, Trp, 0.682 (0.614, 0.75); Ser, Val, Lys, Ile, Trp, 0.682 (0.615, 0.75); Ser , Cit, Tyr, Met , Lys, 0.682 (0.614, 0.751); Ser, Orn, Lys, Leu, Trp, 0.682 (0.615, 0.75); Ser, Gln, Cit, Met, Lys, 0.682 (0.614, 0.751); His, Cit, Lys, Ile, Trp, 0.682 (0.614, 0.75); Ser, Met, Lys, Phe, Trp, 0.682 (0.614, 0.75); Ser, Asn, Gly, Thr, Lys, 0.682 (0.614, 0.75); Ser, Asn, Ala , Cit, Lys, 0.682 (0.614, 0.75); Ser, Thr, Pro, Lys, Ile, 0.682 (0.614, 0.75); Ser, Gln, Pro, Lys, Trp, 0.682 (0.614, 0.75); Ser, His, Val, Lys, Trp, 0.682 (0.614, 0.75); Ser, Thr, Tyr, Lys, Ile, 0.682 (0.614, 0.75); His, Thr, Cit, Lys, Trp, 0.682 (0.614, 0.75); Ser, Asn , Orn, Lys, Trp, 0.682 (0.614, 0.749); Ser, Gln, Cit, Orn, Lys, 0.682 (0.614, 0.75); Ser, Thr, Orn, Lys, Ile, 0.682 (0.614, 0.75); Ser, Asn, His, Lys, Trp, 0.682 (0.614, 0.75); Ser, Thr, Cit, Lys, Phe, 0.682 (0.613, 0.75); Gln, His, Cit, Lys, Trp, 0.682 (0.614, 0.75); Cit , Tyr, Met, Lys, Trp, 0.682 (0.613, 0.75); Ser, Tyr, Val, Lys, Trp, 0.682 (0.614, 0.75); Ser, Cit, Pro, Met, Lys, 0.682 (0.613, 0.75); Ser, Cit, Met, Lys, Phe, 0.6 82 (0.613, 0.75); Ser, His, Lys, Ile, Trp, 0.682 (0.614, 0.75); Ser, Gln, Ala, Cit, Lys, 0.682 (0.613, 0.75); Ser, His, Thr, Lys, Ile , 0.681 (0.613, 0.75); Cit, Val, Met, Lys, Trp, 0.681 (0.613, 0.75); Ser, Pro, Val, Lys, Trp, 0.681 (0.

613, 0.749); His, Cit, Met, Lys, Trp, 0.681 (0.613, 0.75); Cit, Arg, Lys, Leu, Trp, 0.681 (0.613, 0.749); Gln, Cit, Lys, Leu, Trp, 0.681 (0.613, 0.75); Cit, Lys, Leu, Phe, Trp, 0.681 (0.613, 0.749); Ser, Asn, Cit, Orn, Lys, 0.681 (0.613, 0.749); His, Cit, Tyr, Lys, Trp, 0.681 (0.613, 0.749); Ser, Gln, Thr, Lys, Ile, 0.681 (0.612, 0.749); Ser, Gln, Met, Lys, Trp, 0.681 (0.613, 0.749); Ser, Tyr, Met, Lys, Trp , 0.681 (0.613, 0.749); Thr, Cit, Met, Lys, Trp, 0.681 (0.613, 0.749); Ser, Pro, Lys, Ile, Trp, 0.681 (0.613, 0.749); Ser, Thr, Ala, Cit, Lys, 0.681 (0.612, 0.749); Cit, Pro, Met, Lys, Trp, 0.681 (0.612, 0.749); Asn, Cit, Met, Lys, Trp, 0.681 (0.612, 0.749); Ala, Cit, Met, Lys , Trp, 0.681 (0.612, 0.749); Ser, Asn, Cit, Met, Lys, 0.681 (0.612, 0.749); Cit, Met, Lys, Phe, Trp, 0.681 (0.612, 0.749); Ser, Ala, Met, Lys, Trp, 0.681 (0.612, 0.749); Ser, Asn, Cit, Arg, Lys, 0.681 (0.613, 0.748); Ser, Gly, His, Thr, Lys, 0.68 (0.612, 0.749); Ser, Cit, Tyr , Lys, Phe, 0.68 (0.612, 0.749); Cit, Arg, Met, Lys, Trp, 0.68 (0.612, 0.748); Ser, Ala, Val, Lys, Trp, 0.68 (0.612, 0.748); Gly, His, Cit, Lys, Trp, 0.68 (0.612, 0.749); Ser, Cit, Tyr, Orn, Lys, 0.68 (0.612, 0.749); Cit, Met, Orn, Lys, Trp, 0.68 (0.612, 0.749); Ser, Gln, Tyr, Lys, Trp , 0.68 (0.612, 0.748); Ser, Orn, Lys, Ile, Trp, 0.68 (0.612, 0.748); Ser, Cit, Pro, Tyr, Lys, 0.68 (0.612, 0.749); Ser, Gly, Gln, Thr, Lys, 0.68 (0.612, 0.749); His, Cit, Arg, Lys, Trp, 0.68 (0.612, 0.748); Ser, His, Met, Lys, Trp, 0.68 (0.612, 0.748); Ser, Gln, His, Cit , Lys, 0.68 (0.612, 0.749); Ser, Thr, Val, Orn, Lys, 0.68 (0.612, 0.748); Thr, Cit, Arg, Lys, Trp, 0.68 (0.612, 0.748); Ser, Gln, Ala, Lys, Trp, 0.68 (0.612, 0.748); Ser, Gln, Lys, Phe, Trp, 0.68 (0.612, 0.748); Ser, Gln, Orn, Lys, Trp, 0.68 (0.612, 0.748); Ser, Val, Orn , Lys, Trp, 0.68 (0.612, 0.748); Gln, Cit, Arg, Lys, Trp, 0.68 (0.612, 0.748); Gln, Cit, Val, Lys, Trp, 0.68 (0.611, 0.748); Ser, Ala, Lys, Ile, Trp, 0.68 (0.612, 0.7 48); Thr, Arg, Met, Lys, Trp, 0.68 (0.611, 0.748); Ser, Cit, Pro, Orn, Lys, 0.68 (0.611, 0.748); Ser, His, Thr, Cit, Lys, 0.679 (0.611) , 0.748); Gln, Cit, Lys, Ile, Trp, 0.679 (0.611, 0.748); Gln, Cit, Lys, Phe, Trp, 0.679 (0.611, 0.748); Gln, Ala, Cit, Lys, Trp, 0.679 ( 0.611, 0.748); Gln, Cit, Pro, Lys, Trp, 0.679 (0.611, 0.748); Gln, Cit, Met, Lys, Trp, 0.679 (0.611, 0.748); Ser, Pro, Lys, Phe, Trp, 0.679 (0.611, 0.748); Ser, Met, Orn, Lys, Trp, 0.679 (0.611, 0.747); Ser, Ala, Cit, Tyr, Lys, 0.679 (0.611, 0.748); Gly, Cit, Met, Lys, Trp, 0.679 (0.611, 0.748); Ser, Thr, Cit, Met, Lys, 0.679 (0.611, 0.748); Ser, Cit, Arg, Met, Lys, 0.679 (0.611, 0.748)
 実施例1で用いたサンプルデータ(以下、訓練データと記す)を用いた。血漿中のアミノ酸濃度値が代入される変数を含む、MCI群と健常群との2群を判別するための多変量判別式(多変量関数)を求めた。 The sample data used in Example 1 (hereinafter referred to as training data) was used. A multivariate discriminant (multivariate function) for discriminating between the MCI group and the healthy group, including the variable to which the amino acid concentration value in plasma is substituted, was obtained.
 多変量判別式としてロジスティック回帰式を用いた。ロジスティック回帰式に含める6個の変数の組み合わせ(前記5種類のアミノ酸のうちの3つのアミノ酸を必須とする)を、前記19種類のアミノ酸の血漿中濃度値から探索し、MCI群と健常群の判別能が良好なロジスティック回帰式の探索を実施した。 A logistic regression equation was used as a multivariate discriminant. The combination of 6 variables to be included in the logistic regression equation (three amino acids out of the five amino acids are essential) was searched from the plasma concentration values of the 19 amino acids, and the MCI group and the healthy group were searched. We searched for a logistic regression equation with good discriminant ability.
 上記で得られた4,109通りのロジスティック回帰式から、MCI群と健常群のROC_AUC値が0.679以上の1,490通りの式を選択し、さらに、選択した1,490通りの式から、ROC_AUC値上位200式を得た。 From the 4,109 logistic regression equations obtained above, 1,490 equations with ROC_AUC values of 0.679 or more in the MCI group and the healthy group were selected, and further, from the selected 1,490 equations. , ROC_AUC value top 200 equations were obtained.
 訓練データとは完全に独立した血中アミノ酸濃度データであって、MCIの確定診断が行われた60歳以上のMCI患者(MCI群:99名)、及び、認知機能が健常と考えられる60歳以上の健常高齢者(健常群:100名)の血漿サンプルから得られたもの(以下、検証データと記す)を用いて、上記で得られたロジスティック回帰式200式の性能を検証した。 Plasma amino acid concentration data completely independent of the training data, MCI patients aged 60 years or older (MCI group: 99) who had a definitive diagnosis of MCI, and 60 years old who are considered to have healthy cognitive function. The performance of the logistic regression equation 200 obtained above was verified using the plasma samples obtained from the above healthy elderly people (healthy group: 100 persons) (hereinafter referred to as verification data).
 検証データでのMCI群と健常群のROC_AUC値が0.600以上となる頑健性の高い128通りのロジスティック回帰式を、以下の[6変数の式]に示した。これらのロジスティック回帰式は、ROC_AUC値が高く、頑健性が高いことから、前記の評価において実臨床での要求基準を満たす有用なものであると考えられる。なお、以下の[6変数の式]には、式に含まれる6つのアミノ酸に対応する、ROC_AUC値と、ROC_AUC値の95%CIの下限の値と、ROC_AUC値の95%CIの上限の値とが示されている。 128 highly robust logistic regression equations in which the ROC_AUC value of the MCI group and the healthy group in the verification data is 0.600 or more are shown in the following [6-variable equation]. Since these logistic regression equations have a high ROC_AUC value and high robustness, they are considered to be useful in the above evaluation to meet the requirements in clinical practice. In the following [6-variable formula], the ROC_AUC value corresponding to the 6 amino acids contained in the formula, the lower limit value of 95% CI of ROC_AUC value, and the upper limit value of 95% CI of ROC_AUC value are shown. Is shown.
[6変数の式]
Ser, Gly, Thr, Cit, Lys, Trp, 0.707 (0.641 , 0.774); Ser, Thr, Cit, Arg, Lys, Leu, 0.707 (0.639 , 0.774); Ser, Thr, Arg, Lys, Leu, Trp, 0.706 (0.639 , 0.773); Ser, Thr, Arg, Val, Lys, Trp, 0.706 (0.64 , 0.773); Ser, Gly, Thr, Cit, Lys, Leu, 0.706 (0.639 , 0.773); Ser, Cit, Met, Lys, Leu, Trp, 0.706 (0.64 , 0.773); Ser, Thr, Cit, Arg, Lys, Trp, 0.705 (0.638 , 0.772); Ser, Gly, Thr, Arg, Lys, Trp, 0.705 (0.638 , 0.772); Ser, Gly, Thr, Cit, Val, Lys, 0.705 (0.638 , 0.772); Ser, Thr, Cit, Val, Lys, Trp, 0.705 (0.638 , 0.771); Ser, Cit, Arg, Met, Lys, Trp, 0.705 (0.638 , 0.771); Ser, Thr, Cit, Arg, Val, Lys, 0.704 (0.637 , 0.771); Ser, Thr, Cit, Met, Lys, Trp, 0.704 (0.637 , 0.771); Ser, Thr, Cit, Lys, Leu, Trp, 0.703 (0.636 , 0.77); Ser, Gly, Cit, Met, Lys, Trp, 0.703 (0.636 , 0.769); Ser, Thr, Cit, Lys, Phe, Trp, 0.703 (0.636 , 0.77); Ser, Cit, Arg, Val, Met, Lys, 0.703 (0.636 , 0.77); Ser, Thr, Cit, Lys, Ile, Trp, 0.702 (0.636 , 0.769); Ser, Cit, Tyr, Met, Lys, Leu, 0.702 (0.636 , 0.769); Ser, Gln, Thr, Cit, Lys, Trp, 0.702 (0.635 , 0.769); Ser, Cit, Val, Met, Lys, Trp, 0.702 (0.635 , 0.769); Ser, Asn, Thr, Cit, Lys, Trp, 0.702 (0.636 , 0.769); Ser, Thr, Arg, Met, Lys, Trp, 0.702 (0.635 , 0.769); Ser, Gly, Thr, Cit, Lys, Ile, 0.701 (0.634 , 0.769); Ser, Thr, Cit, Orn, Lys, Trp, 0.701 (0.634 , 0.768); Ser, Asn, Thr, Cit, Lys, Leu, 0.701 (0.634 , 0.768); Ser, Thr, Cit, Met, Lys, Leu, 0.701 (0.634 , 0.769); Ser, Gln, Cit, Met, Lys, Leu, 0.701 (0.634 , 0.768); Ser, Thr, Cit, Val, Met, Lys, 0.701 (0.633 , 0.768); Ser, Cit, Met, Lys, Ile, Trp, 0.701 (0.634 , 0.768); Ser, Thr, Arg, Lys, Ile, Trp, 0.701 (0.634 , 0.768); Ser, Asn, Cit, Arg, Val, Lys, 0.701 (0.634 , 0.767); Ser, Gly, Thr, Arg, Lys, Ile, 0.7 (0.634 , 0.767); Ser, Thr, Cit, Lys, Ile, Leu, 0.7 (0.633 , 0.768); Ser, Gln, Thr, Arg, Lys, Leu, 0.7 (0.633 , 0.768); Ser, Ala, Cit, Val, Met, Lys, 0.7 (0.633 , 0.767); Ser, Cit, Met, Orn, Lys, Trp, 0.7 (0.633 , 0.767); Ser, Thr, Cit, Orn, Lys, Leu, 0.7 (0.633 , 0.768); Ser, Thr, Cit, Lys, Leu, Phe, 0.7 (0.633 , 0.768); Ser, Asn, Cit, Lys, Leu, Trp, 0.7 (0.634 , 0.767); Ser, Thr, Cit, Val, Orn, Lys, 0.7 (0.633 , 0.768); Ser, Thr, Arg, Orn, Lys, Leu, 0.7 (0.632 , 0.768); Ser, Thr, Arg, Lys, Phe, Trp, 0.7 (0.633 , 0.767); Ser, Thr, Ala, Cit, Lys, Leu, 0.7 (0.633 , 0.767); Ser, Thr, Cit, Val, Lys, Phe, 0.7 (0.633 , 0.767); Ser, Cit, Val, Met, Lys, Ile, 0.7 (0.633 , 0.767); Ser, Gln, Cit, Arg, Lys, Leu, 0.7 (0.633 , 0.767); Ser, Thr, Cit, Tyr, Lys, Trp, 0.7 (0.633 , 0.767); Ser, Cit, Val, Met, Orn, Lys, 0.7 (0.633 , 0.767); Ser, Cit, Met, Orn, Lys, Ile, 0.7 (0.632 , 0.767); Ser, Asn, Cit, Val, Met, Lys, 0.7 (0.633 , 0.767); Ser, His, Thr, Cit, Lys, Trp, 0.7 (0.633 , 0.766); Ser, Thr, Cit, Pro, Lys, Trp, 0.7 (0.632 , 0.767); Ser, Thr, Ala, Cit, Lys, Trp, 0.7 (0.632 , 0.767); Ser, Cit, Arg, Met, Lys, Ile, 0.7 (0.632 , 0.767); Ser, Thr, Cit, Pro, Val, Lys, 0.7 (0.632 , 0.767); Ser, Thr, Ala, Cit, Val, Lys, 0.7 (0.632 , 0.767); Ser, Asn, Gly, Cit, Lys, Trp, 0.7 (0.633 , 0.766); Ser, Thr, Cit, Pro, Lys, Leu, 0.699 (0.632 , 0.767); Ser, Thr, Arg, Tyr, Lys, Leu, 0.699 (0.632 , 0.767); Ser, Gln, Cit, Lys, Leu, Trp, 0.699 (0.632 , 0.767); Ser, Gly, Thr, Pro, Lys, Trp, 0.699 (0.632 , 0.766); Ser, Thr, Cit, Val, Lys, Leu, 0.699 (0.632 , 0.767); Ser, Thr, Arg, Val, Met, Lys, 0.699 (0.632 , 0.767); Ser, His, Cit, Met, Lys, Leu, 0.699 (0.632 , 0.766); Ser, Asn, Cit, Tyr, Lys, Leu, 0.699 (0.632 , 0.766); Ser, Gln, Cit, Met, Lys, Trp, 0.699 (0.632 , 0.766); Ser, Asn, Cit, Met, Lys, Trp, 0.699 (0.632 , 0.766); Ser, Cit, Tyr, Met, Lys, Trp, 0.699 (0.632 , 0.766); Ser, Asn, Thr, Cit, Val, Lys, 0.699 (0.632 , 0.766); Ser, Thr, Arg, Orn, Lys, Trp, 0.699 (0.632 , 0.766); Ser, Arg, Met, Lys, Ile, Trp, 0.699 (0.632 , 0.766); Ser, Asn, Gln, Cit, Lys, Trp, 0.699 (0.632 , 0.765); Ser, Gly, Thr, Lys, Ile, Trp, 0.699 (0.632 , 0.766); Ser, Gln, Thr, Cit, Lys, Leu, 0.699 (0.631 , 0.766); Ser, Asn, Thr, Arg, Lys, Trp, 0.699 (0.632 , 0.766); Ser, Cit, Pro, Val, Met, Lys, 0.699 (0.632 , 0.766); Ser, Gln, Cit, Orn, Lys, Leu, 0.699 (0.631 , 0.766); Ser, Thr, Cit, Val, Lys, Ile, 0.699 (0.631 , 0.766); Ser, Thr, Arg, Tyr, Lys, Trp, 0.699 (0.631 , 0.766); Ser, Gln, Thr, Cit, Val, Lys, 0.699 (0.631 , 0.766); Ser, Thr, Ala, Arg, Lys, Trp, 0.699 (0.631 , 0.766); Ser, Cit, Tyr, Val, Met, Lys, 0.698 (0.632 , 0.765); Ser, Cit, Val, Met, Lys, Phe, 0.698 (0.631 , 0.766); Ser, Thr, Arg, Val, Orn, Lys, 0.698 (0.631 , 0.766); Ser, Gln, Cit, Lys, Ile, Leu, 0.698 (0.631 , 0.766); Ser, Thr, Cit, Tyr, Lys, Leu, 0.698 (0.631 , 0.766); Ser, Asn, Cit, Val, Orn, Lys, 0.698 (0.631 , 0.765); Ser, Gln, Cit, Pro, Lys, Leu, 0.698 (0.631 , 0.766); Ser, His, Thr, Cit, Lys, Leu, 0.698 (0.631 , 0.765); Ser, Asn, Gln, Cit, Lys, Leu, 0.698 (0.631 , 0.765); Ser, Gly, Cit, Met, Lys, Ile, 0.698 (0.631 , 0.765); Ser, Asn, Thr, Arg, Val, Lys, 0.698 (0.631 , 0.765); Ser, Thr, Cit, Arg, Lys, Ile, 0.698 (0.63 , 0.766); Ser, Gln, Cit, Tyr, Lys, Leu, 0.698 (0.63 , 0.765); Ser, His, Cit, Met, Lys, Trp, 0.698 (0.631 , 0.765); Ser, Ala, Cit, Met, Lys, Trp, 0.698 (0.631 , 0.765); Ser, His, Thr, Arg, Lys, Leu, 0.698 (0.63 , 0.765); Ser, Gly, Gln, Cit, Lys, Trp, 0.698 (0.631 , 0.765); Ser, Asn, Cit, Val, Lys, Ile, 0.698 (0.631 , 0.765); Ser, Gln, Thr, Arg, Val, Lys, 0.698 (0.63 , 0.765); Ser, Asn, Cit, Pro, Val, Lys, 0.698 (0.631 , 0.765); Ser, Gly, Thr, Ala, Lys, Trp, 0.698 (0.63 , 0.765); Ser, Gln, Thr, Arg, Lys, Trp, 0.698 (0.63 , 0.765); Ser, Thr, Arg, Pro, Lys, Trp, 0.698 (0.63 , 0.765); Ser, Gln, Cit, Val, Lys, Trp, 0.698 (0.631 , 0.764); Ser, Asn, Cit, Tyr, Val, Lys, 0.697 (0.63 , 0.764); Ser, Thr, Arg, Val, Lys, Ile, 0.697 (0.63 , 0.765); Ser, Thr, Arg, Pro, Lys, Leu, 0.697 (0.63 , 0.765); Ser, Thr, Cit, Tyr, Val, Lys, 0.697 (0.63 , 0.765); Ser, Asn, Gly, Cit, Lys, Ile, 0.697 (0.63 , 0.764); Ser, Asn, Cit, Val, Lys, Phe, 0.697 (0.63 , 0.764); Ser, His, Thr, Arg, Lys, Trp, 0.697 (0.63 , 0.765); Ser, Thr, Arg, Pro, Val, Lys, 0.697 (0.63 , 0.765); Ser, Thr, Arg, Tyr, Val, Lys, 0.697 (0.63 , 0.764); Ser, Cit, Pro, Met, Lys, Trp, 0.697 (0.63 , 0.764); Ser, Asn, Cit, Lys, Phe, Trp, 0.697 (0.63 , 0.764); Ser, Gln, Cit, Arg, Val, Lys, 0.697 (0.63 , 0.764); Ser, Cit, Val, Lys, Ile, Phe, 0.697 (0.63 , 0.764); Ser, Cit, Met, Lys, Phe, Trp, 0.697 (0.63 , 0.764); Ser, Thr, Cit, Met, Lys, Ile, 0.697 (0.629 , 0.764); Ser, Asn, Cit, Arg, Lys, Trp, 0.697 (0.63 , 0.763); Ser, Thr, Ala, Arg, Val, Lys, 0.697 (0.629 , 0.764); Ser, Gln, Cit, Val, Met, Lys, 0.697 (0.629 , 0.764); Ser, Cit, Pro, Val, Lys, Ile, 0.697 (0.629 , 0.764); Ser, Asn, Cit, Val, Lys, Trp, 0.697 (0.63 , 0.763); Ser, Asn, Arg, Val, Lys, Trp, 0.697 (0.63 , 0.763); Ser, Asn, Cit, Met, Lys, Ile, 0.696 (0.629 , 0.764)
[Expression of 6 variables]
Ser, Gly, Thr, Cit, Lys, Trp, 0.707 (0.641, 0.774); Ser, Thr, Cit, Arg, Lys, Leu, 0.707 (0.639, 0.774); Ser, Thr, Arg, Lys, Leu, Trp, 0.706 (0.639, 0.773); Ser, Thr, Arg, Val, Lys, Trp, 0.706 (0.64, 0.773); Ser, Gly, Thr, Cit, Lys, Leu, 0.706 (0.639, 0.773); Ser, Cit, Met , Lys, Leu, Trp, 0.706 (0.64, 0.773); Ser, Thr, Cit, Arg, Lys, Trp, 0.705 (0.638, 0.772); Ser, Gly, Thr, Arg, Lys, Trp, 0.705 (0.638, 0.772) ); Ser, Gly, Thr, Cit, Val, Lys, 0.705 (0.638, 0.772); Ser, Thr, Cit, Val, Lys, Trp, 0.705 (0.638, 0.771); Ser, Cit, Arg, Met, Lys, Trp, 0.705 (0.638, 0.771); Ser, Thr, Cit, Arg, Val, Lys, 0.704 (0.637, 0.771); Ser, Thr, Cit, Met, Lys, Trp, 0.704 (0.637, 0.771); Ser, Thr , Cit, Lys, Leu, Trp, 0.703 (0.636, 0.77); Ser, Gly, Cit, Met, Lys, Trp, 0.703 (0.636, 0.769); Ser, Thr, Cit, Lys, Phe, Trp, 0.703 (0.636) , 0.77); Ser, Cit, Arg, Val, Met, Lys, 0.703 (0.636, 0.77); Ser, Thr, Cit, Lys, Ile, Trp, 0.702 (0.636, 0.769); Ser, Cit, Tyr, Met, Lys, Leu, 0.702 (0.636, 0.769) Ser, Gln, Thr, Cit, Lys, Trp, 0.702 (0.635, 0.769); Ser, Cit, Val, Met, Lys, Trp, 0.702 (0.635, 0.769); Ser, Asn, Thr, Cit, Lys, Trp , 0.702 (0.636, 0.769); Ser, Thr, Arg, Met, Lys, Trp, 0.702 (0.635, 0.769); Ser, Gly, Thr, Cit, Lys, Ile, 0.701 (0.634, 0.769); Ser, Thr, Cit, Orn, Lys, Trp, 0.701 (0.634, 0.768); Ser, Asn, Thr, Cit, Lys, Leu, 0.701 (0.634, 0.768); Ser, Thr, Cit, Met, Lys, Leu, 0.701 (0.634, 0.769); Ser, Gln, Cit, Met, Lys, Leu, 0.701 (0.634, 0.768); Ser, Thr, Cit, Val, Met, Lys, 0.701 (0.633, 0.768); Ser, Cit, Met, Lys, Ile , Trp, 0.701 (0.634, 0.768); Ser, Thr, Arg, Lys, Ile, Trp, 0.701 (0.634, 0.768); Ser, Asn, Cit, Arg, Val, Lys, 0.701 (0.634, 0.767); Ser, Gly, Thr, Arg, Lys, Ile, 0.7 (0.634, 0.767); Ser, Thr, Cit, Lys, Ile, Leu, 0.7 (0.633, 0.768); Ser, Gln, Thr, Arg, Lys, Leu, 0.7 ( 0.633, 0.768); Ser, Ala, Cit, Val, Met, Lys, 0.7 (0.633, 0.767); Ser, Cit, Met, Orn, Lys, Trp, 0.7 (0.633, 0.767); Ser, Thr, Cit, Orn , Lys, Leu, 0.7 (0.633, 0.768); Ser , Thr, Cit, Lys, Leu, Phe, 0.7 (0.633, 0.768); Ser, Asn, Cit, Lys, Leu, Trp, 0.7 (0.634, 0.767); Ser, Thr, Cit, Val, Orn, Lys, 0.7 (0.633, 0.768); Ser, Thr, Arg, Orn, Lys, Leu, 0.7 (0.632, 0.768); Ser, Thr, Arg, Lys, Phe, Trp, 0.7 (0.633, 0.767); Ser, Thr, Ala, Cit, Lys, Leu, 0.7 (0.633, 0.767); Ser, Thr, Cit, Val, Lys, Phe, 0.7 (0.633, 0.767); Ser, Cit, Val, Met, Lys, Ile, 0.7 (0.633, 0.767) Ser, Gln, Cit, Arg, Lys, Leu, 0.7 (0.633, 0.767); Ser, Thr, Cit, Tyr, Lys, Trp, 0.7 (0.633, 0.767); Ser, Cit, Val, Met, Orn, Lys , 0.7 (0.633, 0.767); Ser, Cit, Met, Orn, Lys, Ile, 0.7 (0.632, 0.767); Ser, Asn, Cit, Val, Met, Lys, 0.7 (0.633, 0.767); Ser, His, Thr, Cit, Lys, Trp, 0.7 (0.633, 0.766); Ser, Thr, Cit, Pro, Lys, Trp, 0.7 (0.632, 0.767); Ser, Thr, Ala, Cit, Lys, Trp, 0.7 (0.632, 0.767); Ser, Cit, Arg, Met, Lys, Ile, 0.7 (0.632, 0.767); Ser, Thr, Cit, Pro, Val, Lys, 0.7 (0.632, 0.767); Ser, Thr, Ala, Cit, Val , Lys, 0.7 (0.632, 0.767); Ser, Asn, Gly, Cit, Lys, Trp, 0.7 (0.633, 0.766); Ser, Thr, Cit, Pro, Lys, Leu, 0.699 (0.632, 0.767); Ser, Thr, Arg, Tyr, Lys, Leu, 0.699 (0.632, 0.767); Ser, Gln, Cit, Lys, Leu, Trp, 0.699 (0.632, 0.767); Ser, Gly, Thr, Pro, Lys, Trp, 0.699 (0.632, 0.766); Ser, Thr, Cit, Val, Lys, Leu, 0.699 (0.632, 0.767) Ser, Thr, Arg, Val, Met, Lys, 0.699 (0.632, 0.767); Ser, His, Cit, Met, Lys, Leu, 0.699 (0.632, 0.766); Ser, Asn, Cit, Tyr, Lys, Leu , 0.699 (0.632, 0.766); Ser, Gln, Cit, Met, Lys, Trp, 0.699 (0.632, 0.766); Ser, Asn, Cit, Met, Lys, Trp, 0.699 (0.632, 0.766); Ser, Cit, Tyr, Met, Lys, Trp, 0.699 (0.632, 0.766); Ser, Asn, Thr, Cit, Val, Lys, 0.699 (0.632, 0.766); Ser, Thr, Arg, Orn, Lys, Trp, 0.699 (0.632, 0.766); Ser, Arg, Met, Lys, Ile, Trp, 0.699 (0.632, 0.766); Ser, Asn, Gln, Cit, Lys, Trp, 0.699 (0.632, 0.765); Ser, Gly, Thr, Lys, Ile , Trp, 0.699 (0.632, 0.766); Ser, Gln, Thr, Cit, Lys, Leu, 0.699 (0.631, 0.766); Ser, Asn, Thr, Arg, Lys, Trp, 0.699 (0.632, 0.766); Ser, Cit, Pro, Val, Met, Lys, 0.699 (0.632, 0.766); Ser, Gln, Cit, Orn, Lys, Leu, 0.699 (0.631, 0.766); Ser, Thr, Cit, Val, Lys, Ile, 0.699 (0.631, 0.766); Ser, Thr, Arg , Tyr, Lys, Trp, 0.699 (0.631, 0.766); Ser, Gln, Thr, Cit, Val, Lys, 0.699 (0.631, 0.766); Ser, Thr, Ala, Arg, Lys, Trp, 0.699 (0.631, 0.766) ); Ser, Cit, Tyr, Val, Met, Lys, 0.698 (0.632, 0.765); Ser, Cit, Val, Met, Lys, Phe, 0.698 (0.631, 0.766); Ser, Thr, Arg, Val, Orn, Lys, 0.698 (0.631, 0.766); Ser, Gln, Cit, Lys, Ile, Leu, 0.698 (0.631, 0.766); Ser, Thr, Cit, Tyr, Lys, Leu, 0.698 (0.631, 0.766); Ser, Asn , Cit, Val, Orn, Lys, 0.698 (0.631, 0.765); Ser, Gln, Cit, Pro, Lys, Leu, 0.698 (0.631, 0.766); Ser, His, Thr, Cit, Lys, Leu, 0.698 (0.631) , 0.765); Ser, Asn, Gln, Cit, Lys, Leu, 0.698 (0.631, 0.765); Ser, Gly, Cit, Met, Lys, Ile, 0.698 (0.631, 0.765); Ser, Asn, Thr, Arg, Val, Lys, 0.698 (0.631, 0.765); Ser, Thr, Cit, Arg, Lys, Ile, 0.698 (0.63, 0.766); Ser, Gln, Cit, Tyr, Lys, Leu, 0.698 (0.63, 0.765); Ser , His, Cit, Met, Lys, Trp, 0.698 (0.631, 0.765); Ser, Ala, Cit, Met, Lys, Trp, 0.698 (0.631, 0.765); Ser, His, Thr, Arg, Lys, Leu, 0.698 (0.63, 0.765); Ser, Gly , Gln, Cit, Lys, Trp, 0.698 (0.631, 0.765); Ser, Asn, Cit, Val, Lys, Ile, 0.698 (0.631, 0.765); Ser, Gln, Thr, Arg, Val, Lys, 0.698 (0.63) , 0.765); Ser, Asn, Cit, Pro, Val, Lys, 0.698 (0.631, 0.765); Ser, Gly, Thr, Ala, Lys, Trp, 0.698 (0.63, 0.765); Ser, Gln, Thr, Arg, Lys, Trp, 0.698 (0.63, 0.765); Ser, Thr, Arg, Pro, Lys, Trp, 0.698 (0.63, 0.765); Ser, Gln, Cit, Val, Lys, Trp, 0.698 (0.631, 0.764); Ser , Asn, Cit, Tyr, Val, Lys, 0.697 (0.63, 0.764); Ser, Thr, Arg, Val, Lys, Ile, 0.697 (0.63, 0.765); Ser, Thr, Arg, Pro, Lys, Leu, 0.697 (0.63, 0.765); Ser, Thr, Cit, Tyr, Val, Lys, 0.697 (0.63, 0.765); Ser, Asn, Gly, Cit, Lys, Ile, 0.697 (0.63, 0.764); Ser, Asn, Cit, Val, Lys, Phe, 0.697 (0.63, 0.764); Ser, His, Thr, Arg, Lys, Trp, 0.697 (0.63, 0.765); Ser, Thr, Arg, Pro, Val, Lys, 0.697 (0.63, 0.765) Ser, Thr, Arg, Tyr, Val, Lys, 0.697 (0.63, 0.764); Ser, Cit, Pro, Met, Lys, Trp, 0.697 (0.63, 0.764); Ser, Asn, Cit, Lys, Phe, Trp, 0.697 (0.63, 0.764); Ser, Gln, Cit , Arg, Val, Lys, 0.697 (0.63, 0.764); Ser, Cit, Val, Lys, Ile, Phe, 0.697 (0.63, 0.764); Ser, Cit, Met, Lys, Phe, Trp, 0.697 (0.63, 0.764) ); Ser, Thr, Cit, Met, Lys, Ile, 0.697 (0.629, 0.764); Ser, Asn, Cit, Arg, Lys, Trp, 0.697 (0.63, 0.763); Ser, Thr, Ala, Arg, Val, Lys, 0.697 (0.629, 0.764); Ser, Gln, Cit, Val, Met, Lys, 0.697 (0.629, 0.764); Ser, Cit, Pro, Val, Lys, Ile, 0.697 (0.629, 0.764); Ser, Asn , Cit, Val, Lys, Trp, 0.697 (0.63, 0.763); Ser, Asn, Arg, Val, Lys, Trp, 0.697 (0.63, 0.763); Ser, Asn, Cit, Met, Lys, Ile, 0.696 (0.629) , 0.764)
 実施例5で得られた、訓練データでのMCI群と健常群のROC_AUC値上位200式のうち、検証データでのMCI群と健常群のROC_AUC値が0.600以上となる頑健性の高い128通りのロジスティック回帰式を用いた。 Of the top 200 formulas of ROC_AUC values of the MCI group and the healthy group obtained in Example 5, the ROC_AUC values of the MCI group and the healthy group in the verification data are 0.600 or more, which is highly robust 128. The street logistic regression equation was used.
 訓練データと検証データを含む血中アミノ酸濃度データ(以下、全データと記す)を用いた。つまり、実施例1に記載した120名のMCI群と実施例5に記載した99名のMCI群を組み合わせた219名のMCI群、及び、実施例1に記載した120名の健常群と実施例5に記載した100名の健常群を組み合わせた220名の健常群の血漿サンプルから得られた血中アミノ酸濃度データを用いた。 Blood amino acid concentration data (hereinafter referred to as all data) including training data and verification data was used. That is, the 219 MCI group, which is a combination of the 120 MCI group described in Example 1 and the 99 MCI group described in Example 5, and the 120 healthy group and Example described in Example 1. Blood amino acid concentration data obtained from plasma samples of 220 healthy groups in which the 100 healthy groups described in 5 were combined was used.
 第一のカットオフ値として特異度60%のときの式の値を設定し、第二のカットオフ値として特異度90%のときの式の値を設定した。また、式の値が第一のカットオフ値より低い場合はランクA(MCIである可能性(確率、リスク)が低いことを意味する区分)で、式の値が第一のカットオフ値より高く第二のカットオフ値より低い場合はランクB(MCIである可能性が中程度であることを意味する区分)で、式の値が第二のカットオフ値より高い場合はランクC(MCIである可能性が高いことを意味する区分)と定義した。 The value of the formula when the specificity was 60% was set as the first cutoff value, and the value of the formula when the specificity was 90% was set as the second cutoff value. If the value of the formula is lower than the first cutoff value, it is ranked A (classification meaning that the possibility of MCI (probability, risk) is low), and the value of the formula is lower than the first cutoff value. If it is high and lower than the second cutoff value, it is rank B (a division that means that the probability of MCI is medium), and if the value of the expression is higher than the second cutoff value, it is rank C (MCI). It is defined as a category that means that there is a high possibility that it is.
 そして、前記設定および前記定義の下、全データと前記128通りのロジスティック回帰式を用いて、人別かつ式別にランクを算出した。さらに、この算出結果を用いて、ランクA、Bを陰性としランクCを陽性とした場合の、「陽性尤度比=感度※1/(1-特異度※2)」で定義される陽性尤度比を、式別に計算した。つまり、健常高齢者の中で陽性と算出される者の割合に対する、MCI患者の中で陽性と算出される者の割合の比を、式別に計算した。
※1:感度=b/(a+b)
 a=MCI患者の中で陰性(ランクAまたはランクB)と算出された者の人数
 b=MCI患者の中で陽性(ランクC)と算出された者の人数
※2:特異度=c/(c+d)
 c=健常高齢者の中で陰性(ランクAまたはランクB)と算出された者の人数
 d=健常高齢者の中で陽性(ランクC)と算出された者の人数
Then, under the above-mentioned setting and the above-mentioned definition, the rank was calculated for each person and each formula by using all the data and the 128 kinds of logistic regression equations. Furthermore, using this calculation result, when ranks A and B are negative and rank C is positive, the positive probability defined by "positive probability ratio = sensitivity * 1 / (1-specificity * 2)" The degree ratio was calculated for each formula. That is, the ratio of the ratio of those who are calculated to be positive among MCI patients to the ratio of those who are calculated to be positive among healthy elderly people was calculated by formula.
* 1: Sensitivity = b / (a + b)
a = Number of MCI patients calculated to be negative (Rank A or Rank B) b = Number of MCI patients calculated to be positive (Rank C) * 2: Specificity = c / ( c + d)
c = Number of healthy elderly people calculated as negative (Rank A or Rank B) d = Number of healthy elderly people calculated as positive (Rank C)
 陽性尤度比が3.0以上となる7通りのロジスティック回帰式を、以下の表3に示した。これらのロジスティック回帰式は、陽性尤度比が高く、他の式よりも受診者の行動変容に繋がりやすいことが期待できる。 Table 3 below shows seven logistic regression equations with a positive likelihood ratio of 3.0 or higher. These logistic regression equations have a high positive likelihood ratio, and it can be expected that they are more likely to lead to behavior change of the examinee than other equations.
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003
 前記7通りのロジスティック回帰式のうち、変数の組「Ser,Thr,Ala,Cit,Lys,Trp」を持つロジスティック回帰式、変数の組「Ser,Thr,Cit,Met,Lys,Trp」を持つロジスティック回帰式、変数の組「Ser,Thr,Cit,Tyr,Lys,Trp」を持つロジスティック回帰式および変数の組「Ser,Thr,Cit,Orn,Lys,Trp」を持つロジスティック回帰式は、訓練データでのMCI群と健常群のROC_AUC値が0.70以上と高く、かつ検証データでのMCI群と健常群のROC_AUC値も0.65以上と高いことから、判別性能が高く、特に頑健性の高い式である。 Of the above seven logistic regression equations, it has a logistic regression equation having a variable set "Ser, Thr, Ala, Cit, Lys, Trp" and a variable set "Ser, Thr, Cit, Met, Lys, Trp". Logistic regression equation, logistic regression equation with variable set "Ser, Thr, Cit, Tyr, Lys, Trp" and logistic regression equation with variable set "Ser, Thr, Cit, Orn, Lys, Trp" are trained. The ROC_AUC value of the MCI group and the healthy group in the data is as high as 0.70 or more, and the ROC_AUC value of the MCI group and the healthy group in the verification data is also as high as 0.65 or more. Is a high expression.
 以上のように、本発明は、産業上の多くの分野、特に医薬品や食品、医療などの分野で広く実施することができ、特に、MCIの状態の進行予測や疾病リスク予測やプロテオームやメタボローム解析などを行うバイオインフォマティクス分野において極めて有用である。 As described above, the present invention can be widely implemented in many industrial fields, especially in fields such as pharmaceuticals, foods, and medical treatments, and in particular, MCI status progression prediction, disease risk prediction, proteome, and metabolome analysis. It is extremely useful in the field of bioinformatics.
 100 評価装置(算出装置を含む)
 102 制御部
 102a 取得部
 102b 指定部
 102c 式作成部
 102d 評価部
 102d1 算出部
 102d2 変換部
 102d3 生成部
 102d4 分類部
 102e 結果出力部
 102f 送信部
 104 通信インターフェース部
 106 記憶部
 106a 濃度データファイル
 106b 指標状態情報ファイル
 106c 指定指標状態情報ファイル
 106d 式関連情報データベース
 106d1 式ファイル
 106e 評価結果ファイル
 108 入出力インターフェース部
 112 入力装置
 114 出力装置
 200 クライアント装置(端末装置(情報通信端末装置))
 300 ネットワーク
 400 データベース装置
100 Evaluation device (including calculation device)
102 Control unit 102a Acquisition unit 102b Designation unit 102c Expression creation unit 102d Evaluation unit 102d1 Calculation unit 102d2 Conversion unit 102d3 Generation unit 102d4 Classification unit 102e Result output unit 102f Transmission unit 104 Communication interface unit 106 Storage unit 106a Concentration data file 106b Index status information File 106c Designated index status information file 106d Expression-related information database 106d1 Expression file 106e Evaluation result file 108 Input / output interface unit 112 Input device 114 Output device 200 Client device (terminal device (information and communication terminal device))
300 network 400 database device

Claims (15)

  1.  評価対象の血液中のCit、Lys、Ser、ThrおよびTrpのうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を用いて、前記評価対象について、軽度認知障害の状態を評価する評価ステップを含むこと、
     を特徴とする評価方法。
    The concentration value of at least two amino acids of Cit, Lys, Ser, Thr and Trp in the blood to be evaluated, or the above calculated using the formula including the variable to which the concentration value is substituted and the concentration value. Including an evaluation step for evaluating the state of mild cognitive impairment for the evaluation target using the value of the formula.
    An evaluation method characterized by.
  2.  前記濃度値は、少なくとも3つのアミノ酸の濃度値であり、
     前記少なくとも3つのアミノ酸は、Ser、LysおよびTrp、Ser、CitおよびLys、Cit、LysおよびTrp、Ser、ThrおよびLys、Thr、LysおよびTrp、Thr、CitおよびLys、Ser、ThrおよびCit、Ser、ThrおよびTrp、Thr、CitおよびTrp、または、Ser、CitおよびTrpを含むこと、
     を特徴とする請求項1に記載の評価方法。
    The concentration value is a concentration value of at least three amino acids.
    The at least three amino acids are Ser, Lys and Trp, Ser, Cit and Lys, Cit, Lys and Trp, Ser, Thr and Lys, Thr, Lys and Trp, Thr, Cit and Lys, Ser, Thr and Cit, Ser. , Thr and Trp, Thr, Cit and Trp, or Ser, Cit and Trp,
    The evaluation method according to claim 1.
  3.  前記濃度値は、少なくとも6つのアミノ酸の濃度値であり、
     前記少なくとも6つのアミノ酸は、Ser、Thr、Ala、Cit、LysおよびTrp、Ser、Thr、Cit、Met、LysおよびTrp、Ser、Gln、Cit、Val、MetおよびLys、Ser、Gln、Cit、Met、LysおよびLeu、Ser、Thr、Cit、Tyr、LysおよびTrp、Ser、Cit、Tyr、Met、LysおよびTrp、または、Ser、Thr、Cit、Orn、LysおよびTrpを含むこと、
     を特徴とする請求項2に記載の評価方法。
    The concentration value is a concentration value of at least 6 amino acids.
    The at least 6 amino acids are Ser, Thr, Ala, Cit, Lys and Trp, Ser, Thr, Cit, Met, Lys and Trp, Ser, Gln, Cit, Val, Met and Lys, Ser, Gln, Cit, Met. , Lys and Leu, Ser, Thr, Cit, Tyr, Lys and Trp, Ser, Cit, Tyr, Met, Lys and Trp, or Ser, Thr, Cit, Orn, Lys and Trp.
    2. The evaluation method according to claim 2.
  4.  前記評価ステップは、制御部を備えた情報処理装置の前記制御部において実行されること、
     を特徴とする請求項1から3のいずれか1つに記載の評価方法。
    The evaluation step is executed in the control unit of the information processing apparatus including the control unit.
    The evaluation method according to any one of claims 1 to 3.
  5.  評価対象の血液中のCit、Lys、Ser、ThrおよびTrpのうちの少なくとも2つのアミノ酸の濃度値、および、前記濃度値が代入される変数を含む軽度認知障害の状態を評価するための式を用いて、前記式の値を算出する算出ステップを含むこと、
     を特徴とする算出方法。
    An expression for evaluating the state of mild cognitive impairment including the concentration value of at least two amino acids of Cit, Lys, Ser, Thr and Trp in the blood to be evaluated and the variable to which the concentration value is substituted Including a calculation step to calculate the value of the equation using
    A calculation method characterized by.
  6.  前記算出ステップは、制御部を備えた情報処理装置の前記制御部において実行されること、
     を特徴とする請求項5に記載の算出方法。
    The calculation step is executed in the control unit of the information processing apparatus including the control unit.
    5. The calculation method according to claim 5.
  7.  制御部を備える評価装置であって、
     前記制御部は、
     評価対象の血液中のCit、Lys、Ser、ThrおよびTrpのうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を用いて、前記評価対象について、軽度認知障害の状態を評価する評価手段
     を備えること、
     を特徴とする評価装置。
    An evaluation device equipped with a control unit
    The control unit
    The concentration value of at least two amino acids of Cit, Lys, Ser, Thr and Trp in the blood to be evaluated, or the above calculated using the formula including the variable to which the concentration value is substituted and the concentration value. To provide an evaluation means for evaluating the state of mild cognitive impairment for the evaluation target using the value of the formula.
    An evaluation device characterized by.
  8.  前記濃度値または前記式の前記値を提供する端末装置とネットワークを介して通信可能に接続され、
     前記制御部は、
     前記端末装置から送信された前記濃度値または前記式の前記値を受信するデータ受信手段と、
     前記評価手段で得られた評価結果を前記端末装置へ送信する結果送信手段と、
     をさらに備え、
     前記評価手段は、前記データ受信手段で受信した前記濃度値または前記式の前記値を用いること、
     を特徴とする請求項7に記載の評価装置。
    Communicatably connected via a network to the terminal device providing the concentration value or the value of the equation.
    The control unit
    A data receiving means for receiving the concentration value or the value of the formula transmitted from the terminal device, and
    A result transmission means for transmitting the evaluation result obtained by the evaluation means to the terminal device, and a result transmission means.
    Further prepare
    The evaluation means uses the concentration value received by the data receiving means or the value of the formula.
    7. The evaluation device according to claim 7.
  9.  制御部を備える算出装置であって、
     前記制御部は、
     評価対象の血液中のCit、Lys、Ser、ThrおよびTrpのうちの少なくとも2つのアミノ酸の濃度値、および、前記濃度値が代入される変数を含む軽度認知障害の状態を評価するための式を用いて、前記式の値を算出する算出手段
     を備えること、
     を特徴とする算出装置。
    It is a calculation device equipped with a control unit.
    The control unit
    An expression for evaluating the state of mild cognitive impairment including the concentration value of at least two amino acids of Cit, Lys, Ser, Thr and Trp in the blood to be evaluated and the variable to which the concentration value is substituted To provide a calculation means for calculating the value of the above formula by using.
    A calculation device characterized by.
  10.  制御部を備える情報処理装置において実行させるための評価プログラムであって、
     前記制御部において実行させるための、
     評価対象の血液中のCit、Lys、Ser、ThrおよびTrpのうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を用いて、前記評価対象について、軽度認知障害の状態を評価する評価ステップ
     を含むこと、
     を特徴とする評価プログラム。
    It is an evaluation program to be executed in an information processing device equipped with a control unit.
    To be executed in the control unit
    The concentration value of at least two amino acids of Cit, Lys, Ser, Thr and Trp in the blood to be evaluated, or the above calculated using the formula including the variable to which the concentration value is substituted and the concentration value. Including an evaluation step for evaluating the state of mild cognitive impairment for the evaluation target using the value of the formula.
    An evaluation program featuring.
  11.  制御部を備える情報処理装置において実行させるための算出プログラムであって、
     前記制御部において実行させるための、
     評価対象の血液中のCit、Lys、Ser、ThrおよびTrpのうちの少なくとも2つのアミノ酸の濃度値、および、前記濃度値が代入される変数を含む軽度認知障害の状態を評価するための式を用いて、前記式の値を算出する算出ステップ
     を含むこと、
     を特徴とする算出プログラム。
    It is a calculation program to be executed in an information processing device equipped with a control unit.
    To be executed in the control unit
    An expression for evaluating the state of mild cognitive impairment including the concentration value of at least two amino acids of Cit, Lys, Ser, Thr and Trp in the blood to be evaluated and the variable to which the concentration value is substituted Including a calculation step to calculate the value of the equation using
    A calculation program featuring.
  12.  請求項10または11に記載のプログラムを記録したコンピュータ読み取り可能な記録媒体。 A computer-readable recording medium on which the program according to claim 10 or 11 is recorded.
  13.  制御部を備える評価装置と、制御部を備える端末装置とを、ネットワークを介して通信可能に接続して構成される評価システムであって、
     前記端末装置の前記制御部は、
     評価対象の血液中のCit、Lys、Ser、ThrおよびTrpのうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を、前記評価装置へ送信するデータ送信手段と、
     前記評価装置から送信された、前記評価対象についての軽度認知障害の状態に関する評価結果を受信する結果受信手段と、
     を備え、
     前記評価装置の前記制御部は、
     前記端末装置から送信された前記濃度値または前記式の前記値を受信するデータ受信手段と、
     前記データ受信手段で受信した前記濃度値または前記式の前記値を用いて、前記評価対象について、軽度認知障害の状態を評価する評価手段と、
     前記評価手段で得られた前記評価結果を前記端末装置へ送信する結果送信手段と、
     を備えること、
     を特徴とする評価システム。
    It is an evaluation system configured by connecting an evaluation device having a control unit and a terminal device having a control unit so as to be able to communicate with each other via a network.
    The control unit of the terminal device
    The concentration value of at least two amino acids of Cit, Lys, Ser, Thr and Trp in the blood to be evaluated, or the above calculated using the formula including the variable to which the concentration value is substituted and the concentration value. A data transmission means for transmitting the value of the expression to the evaluation device,
    A result receiving means for receiving the evaluation result regarding the state of mild cognitive impairment for the evaluation target transmitted from the evaluation device.
    Equipped with
    The control unit of the evaluation device
    A data receiving means for receiving the concentration value or the value of the formula transmitted from the terminal device, and
    An evaluation means for evaluating the state of mild cognitive impairment with respect to the evaluation target using the concentration value received by the data receiving means or the value of the formula.
    A result transmission means for transmitting the evaluation result obtained by the evaluation means to the terminal device, and a result transmission means.
    To prepare for
    An evaluation system featuring.
  14.  制御部を備えた端末装置であって、
     前記制御部は、
     評価対象についての軽度認知障害の状態に関する評価結果を取得する結果取得手段
     を備え、
     前記評価結果は、前記評価対象の血液中のCit、Lys、Ser、ThrおよびTrpのうちの少なくとも2つのアミノ酸の濃度値、または、前記濃度値が代入される変数を含む式と前記濃度値を用いて算出された前記式の値を用いて、前記評価対象について、軽度認知障害の状態を評価した結果であること、
     を特徴とする端末装置。
    It is a terminal device equipped with a control unit.
    The control unit
    Equipped with a result acquisition means to acquire evaluation results regarding the state of mild cognitive impairment for the evaluation target
    The evaluation result is a concentration value of at least two amino acids of Cit, Lys, Ser, Thr and Trp in the blood to be evaluated, or an expression including a variable to which the concentration value is substituted and the concentration value. It is the result of evaluating the state of mild cognitive impairment for the evaluation target using the value of the above formula calculated using the above.
    A terminal device characterized by.
  15.  前記評価対象について軽度認知障害の状態を評価する評価装置とネットワークを介して通信可能に接続されており、
     前記制御部は、前記濃度値または前記式の前記値を前記評価装置へ送信するデータ送信手段を備え、
     前記結果取得手段は、前記評価装置から送信された前記評価結果を受信すること、
     を特徴とする請求項14に記載の端末装置。
    The evaluation target is connected to an evaluation device that evaluates the state of mild cognitive impairment via a network so as to be communicable.
    The control unit includes data transmission means for transmitting the concentration value or the value of the formula to the evaluation device.
    The result acquisition means receives the evaluation result transmitted from the evaluation device.
    14. The terminal device according to claim 14.
PCT/JP2021/026034 2020-07-09 2021-07-09 Method for evaluating mild cognitive impairment, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device WO2022009991A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022535407A JPWO2022009991A1 (en) 2020-07-09 2021-07-09
KR1020237000211A KR20230037533A (en) 2020-07-09 2021-07-09 Evaluation method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device for mild cognitive impairment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-118782 2020-07-09
JP2020118782 2020-07-09

Publications (1)

Publication Number Publication Date
WO2022009991A1 true WO2022009991A1 (en) 2022-01-13

Family

ID=79552566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/026034 WO2022009991A1 (en) 2020-07-09 2021-07-09 Method for evaluating mild cognitive impairment, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device

Country Status (3)

Country Link
JP (1) JPWO2022009991A1 (en)
KR (1) KR20230037533A (en)
WO (1) WO2022009991A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016017801A (en) * 2014-07-07 2016-02-01 公立大学法人大阪市立大学 Method for detecting mild cognitive impairment at risk of shifting to alzheimer-type dementia and kit for the same
JP2017197571A (en) * 2017-07-25 2017-11-02 株式会社Mcbi Biomarker for cognitive function disorder disease and method for detecting cognitive function disorder disease by using biomarker
WO2018008764A1 (en) * 2016-07-08 2018-01-11 味の素株式会社 Method for evaluating mild cognitive impairment or alzheimer's type dementia
WO2019012671A1 (en) * 2017-07-13 2019-01-17 株式会社Mcbi Biomarker for cognitive impairment disorders and detection method for cognitive impairment disorders using said biomarker
WO2020067386A1 (en) * 2018-09-26 2020-04-02 味の素株式会社 Mild-cognitive-impairment evaluation method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200067386A (en) 2018-12-04 2020-06-12 이은호 Karaoke machine with phone charger

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016017801A (en) * 2014-07-07 2016-02-01 公立大学法人大阪市立大学 Method for detecting mild cognitive impairment at risk of shifting to alzheimer-type dementia and kit for the same
WO2018008764A1 (en) * 2016-07-08 2018-01-11 味の素株式会社 Method for evaluating mild cognitive impairment or alzheimer's type dementia
WO2019012671A1 (en) * 2017-07-13 2019-01-17 株式会社Mcbi Biomarker for cognitive impairment disorders and detection method for cognitive impairment disorders using said biomarker
JP2017197571A (en) * 2017-07-25 2017-11-02 株式会社Mcbi Biomarker for cognitive function disorder disease and method for detecting cognitive function disorder disease by using biomarker
WO2020067386A1 (en) * 2018-09-26 2020-04-02 味の素株式会社 Mild-cognitive-impairment evaluation method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device

Also Published As

Publication number Publication date
JPWO2022009991A1 (en) 2022-01-13
KR20230037533A (en) 2023-03-16

Similar Documents

Publication Publication Date Title
JP7173240B2 (en) Acquisition method, calculation method, evaluation device, calculation device, evaluation program, calculation program, and evaluation system
WO2016056631A1 (en) Evaluation method, evaluation device, evaluation program, evaluation system, and terminal device
WO2014168125A1 (en) Method for evaluating life style-related disease index, life style-related disease index evaluation device, life style-related disease index evaluation method, life style-related disease index evaluation program, life style-related disease index evaluation system and information communication terminal device
JP2022066387A (en) Acquisition method, computation method, evaluation device, computation device, evaluation program, computation program, and evaluation system
JP2024038394A (en) Method for acquisition, method for calculation, evaluation device, calculation device, evaluation program, calculation program, recording medium, and evaluation system
JP7311119B2 (en) Acquisition method, calculation method, evaluation device, calculation device, evaluation program, calculation program, and evaluation system
WO2020203878A1 (en) Evaluating method, calculating method, evaluating device, calculating device, evaluating program, calculating program, storage medium, evaluating system, and terminal device of amyloid beta accumulation in brain
WO2022009991A1 (en) Method for evaluating mild cognitive impairment, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device
JP2022010154A (en) Acquisition method, computation method, evaluation device, computation device, evaluation program, computation program, and evaluation system
JP7093163B2 (en) Acquisition method, calculation method, evaluation device, calculation device, evaluation program, calculation program, and evaluation system
WO2019194144A1 (en) Breast cancer evaluation method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal unit
JP7435856B2 (en) Acquisition method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, and evaluation system
WO2020184660A1 (en) Method for evaluating sarcopenia, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device
JP7120027B2 (en) Acquisition method, calculation method, evaluation device, calculation device, evaluation program, calculation program, and evaluation system
JP7435855B2 (en) Acquisition method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, and evaluation system
JP7093162B2 (en) Acquisition method, calculation method, evaluation device, calculation device, evaluation program, calculation program, and evaluation system
WO2020158828A1 (en) Method for evaluating future risk of occurrence of cerebral and cardiovascular event, calculation method, evaluation device, calculation device, evaluation program, calculation program, storage medium, evaluation system, and terminal device
WO2024143402A1 (en) Dietary diversity evaluation method
WO2022210606A1 (en) Method for evaluating future risk of developing dementia
JP6886241B2 (en) Evaluation method of skeletal muscle area
JP2022090070A (en) Cancer monitoring method, computation method, evaluation device, computation device, evaluation program, computation program, and evaluation system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21838633

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022535407

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21838633

Country of ref document: EP

Kind code of ref document: A1